ANNUAL REPORT
FY2022 — Annual report (Form 10-K)
FY2022PDF · 137 pages1.4 MB
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-K
(Mark one)
[x] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 TRUE
For the Fiscal Year Ended June 30, 2022
OR
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 False
For the transition period from to
Commission File No. 1-434
Cincinnati THE PROCTER & GAMBLE COMPANY OH
One
Procter &
Gamble
Plaza One Procter & Gamble Plaza, Cincinnati, Ohio 45202 45202
513 Telephone (513) 983-1100
983-
1100
IRS Employer Identification No. 31-0411980
31-
0411980
State of Incorporation: Ohio OH
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol Name of each exchange on which registered
Common Stock, without Par Value PG New York Stock Exchange
2.000% Notes due 2022 PG22B New York Stock Exchange
1.125% Notes due 2023 PG23A New York Stock Exchange
0.500% Notes due 2024 PG24A New York Stock Exchange
0.625% Notes due 2024 PG24B New York Stock Exchange
1.375% Notes due 2025 PG25 New York Stock Exchange
0.110% Notes due 2026 PG26D New York Stock Exchange
4.875% EUR Notes due May 2027 PG27A New York Stock Exchange
1.200% Notes due 2028 PG28 New York Stock Exchange
1.250% Notes due 2029 PG29B New York Stock Exchange
1.800% Notes due 2029 PG29A New York Stock Exchange
6.250% GBP Notes due January 2030 PG30 New York Stock Exchange
0.350% Notes due 2030 PG30C New York Stock Exchange
0.230% Notes due 2031 PG31A New York Stock Exchange
5.250% GBP Notes due January 2033 PG33 New York Stock Exchange
1.875% Notes due 2038 PG38 New York Stock Exchange
0.900% Notes due 2041 PG41 New York Stock Exchange
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes þ No o
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes o No þ
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such
shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þ No o
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter)
during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes þ No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of
"large accelerated filed," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer þ Accelerated filer ¨
Non-accelerated filer ¨ Smaller reporting company ¨ FALSE
Emerging growth company ¨ FALSE
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ¨
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No þ False
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section
404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. Yes þ No o TRUE
The aggregate market value of the voting stock held by non-affiliates amounted to $392 billion on December 31, 2021.
There were 2,389,553,883 shares of Common Stock outstanding as of July 31, 2022.
Documents Incorporated by Reference
Portions of the Proxy Statement for the 2022 Annual Meeting of Shareholders, which will be filed within one hundred and twenty days of the fiscal year ended June 30, 2022 (2022 Proxy Statement),
are incorporated by reference into Part III of this report to the extent described herein.
-- 1 of 137 --
FORM 10-K TABLE OF CONTENTS Page
PART I Item 1. Business 1
Item 1A. Risk Factors 3
Item 1B. Unresolved Staff Comments 9
Item 2. Properties 9
Item 3. Legal Proceedings 9
Item 4. Mine Safety Disclosure 9
Information about our Executive Officers 10
PART II Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 11
Item 6. Intentionally Omitted 12
Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations 12
Item 7A. Quantitative and Qualitative Disclosures about Market Risk 32
Item 8. Financial Statements and Supplementary Data 32
Management's Report and Reports of Independent Registered Public Accounting Firm 33
Consolidated Statements of Earnings 37
Consolidated Statements of Comprehensive Income 38
Consolidated Balance Sheets 39
Consolidated Statements of Shareholders' Equity 40
Consolidated Statements of Cash Flows 41
Notes to Consolidated Financial Statements 42
Note 1: Summary of Significant Accounting Policies 42
Note 2: Segment Information 44
Note 3: Supplemental Financial Information 45
Note 4: Goodwill and Intangible Assets 47
Note 5: Income Taxes 48
Note 6: Earnings Per Share 49
Note 7: Stock-based Compensation 50
Note 8: Postretirement Benefits and Employee Stock Ownership Plan 51
Note 9: Risk Management Activities and Fair Value Measurements 57
Note 10: Short-term and Long-term Debt 60
Note 11: Accumulated Other Comprehensive Income/(Loss) 60
Note 12: Leases 62
Note 13: Commitments and Contingencies 62
Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 63
Item 9A. Controls and Procedures 63
Item 9B. Other Information 63
Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 63
PART III Item 10. Directors, Executive Officers and Corporate Governance 64
Item 11. Executive Compensation 64
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 64
Item 13. Certain Relationships and Related Transactions and Director Independence 64
Item 14. Principal Accountant Fees and Services 64
PART IV Item 15. Exhibits and Financial Statement Schedules 65
Item 16. Form 10-K Summary 67
Signatures 68
Exhibit Index 69
-- 2 of 137 --
The Procter & Gamble Company 1
PART I
Item 1. Business.
The Procter & Gamble Company (the Company) is focused on providing
branded products of superior quality and value to improve the lives of the
world's consumers, now and for generations to come. The Company was
incorporated in Ohio in 1905, having first been established as a New Jersey
corporation in 1890, and was built from a business founded in Cincinnati in
1837 by William Procter and James Gamble. Today, our products are sold in
approximately 180 countries and territories.
Additional information required by this item is incorporated herein by
reference to Management's Discussion and Analysis (MD&A); and Notes 1
and 2 to our Consolidated Financial Statements. Unless the context
indicates otherwise, the terms the "Company," "P&G," "we," "our" or "us"
as used herein refer to The Procter & Gamble Company (the registrant) and
its subsidiaries.
Throughout this Form 10-K, we incorporate by reference information from
other documents filed with the Securities and Exchange Commission
(SEC).
The Company's Annual Report on Form 10-K, quarterly reports on Form
10-Q and current reports on Form 8-K, and amendments thereto, are filed
electronically with the SEC. The SEC maintains an internet site that
contains these reports at: www.sec.gov. Reports can also be accessed
through links from our website at: www.pginvestor.com. P&G includes the
website link solely as a textual reference. The information contained on our
website is not incorporated by reference into this report.
Copies of these reports are also available, without charge, by contacting EQ
Shareowner Services, 1100 Centre Pointe Curve, Suite 101, Mendota, MN
55120-4100.
Financial Information about Segments
Information about our reportable segments can be found in the MD&A and
Note 2 to our Consolidated Financial Statements.
Narrative Description of Business
Business Model. Our business model relies on the continued growth and
success of existing brands and products, as well as the creation of new
innovative products and brands. The markets and industry segments in
which we offer our products are highly competitive. Our products are sold
in approximately 180 countries and territories through numerous channels
as well as direct-to-consumer. Our growth strategy is to deliver meaningful
and noticeable superiority across five key vectors of our consumer
proposition - product performance, packaging, brand communication, retail
execution and consumer and customer value. We use our research and
development (R&D) and consumer insights to provide superior products
and packaging. We utilize our marketing and online presence to deliver
superior brand messaging to our consumers. We work collaboratively with
our customers to deliver superior retail execution, both in-store and online.
In conjunction with the above vectors, we provide superior value to
consumers and our retail customers in each price tier in which we compete.
Productivity improvement is also critical to delivering our objectives of
balanced top and bottom-line growth and value creation.
Key Product Categories. Information on key product categories can be
found in the MD&A and Note 2 to our Consolidated Financial Statements.
Key Customers. Our customers include mass merchandisers, e-commerce
(including social commerce) channels, grocery stores, membership club
stores, drug stores, department stores, distributors, wholesalers, specialty
beauty stores (including airport duty-free stores), high-frequency stores,
pharmacies, electronics stores and professional channels. We also sell direct
to consumers. Sales to Walmart Inc. and its affiliates represent
approximately 15% of our total sales in 2022, 2021 and 2020. No other
customer represents more than 10% of our total sales. Our top ten customers
accounted for approximately 39% of our total sales in 2022, 39% in 2021
and 38% in 2020.
Sources and Availability of Materials. Almost all of the raw and
packaging materials used by the Company are purchased from third parties,
some of whom are single-source suppliers. We produce certain raw
materials, primarily chemicals, for further use in the manufacturing process.
In addition, fuel, natural gas and derivative products are important
commodities consumed in our manufacturing processes and in the
transportation of input materials and finished products. The prices we pay
for materials and other commodities are subject to fluctuation. When prices
for these items change, we may or may not pass the change to our
customers. The Company purchases a substantial variety of other raw and
packaging materials, none of which are material to our business taken as a
whole.
Trademarks and Patents. We own or have licenses under patents and
registered trademarks, which are used in connection with our activity in all
businesses. Some of these patents or licenses cover significant product
formulation and processes used to manufacture our products. The
trademarks are important to the overall marketing and branding of our
products. All major trademarks in each business are registered. In part, our
success can be attributed to the existence and continued protection of these
trademarks, patents and licenses.
Competitive Condition. The markets in which our products are sold are
highly competitive. Our products compete against similar products of many
large and small companies, including well-known global competitors. In
many of the markets and industry segments in which we sell our products,
we compete against other branded products as well as retailers' private-label
brands. We are well positioned in the industry segments and markets in
which we operate, often holding a leadership or significant market share
position. We support our products with advertising, promotions and other
marketing vehicles to build awareness
-- 3 of 137 --
2 The Procter & Gamble Company
and trial of our brands and products in conjunction with our sales force. We
believe this combination provides the most efficient method of marketing
for these types of products. Product quality, performance, value and
packaging are also important differentiating factors.
Government Regulation. Our Company is subject to a wide variety of
laws and regulations across the countries in which we do business. In the
United States, many of our products and manufacturing operations are
subject to one or more federal or state regulatory agencies, including the
U.S. Food and Drug Administration (FDA), the Environmental Protection
Agency (EPA), the Occupational Safety and Health Administration
(OSHA), the Federal Trade Commission (FTC) and the Consumer Product
Safety Commission (CPSC). We are also subject to anti-corruption laws and
regulations, such as the U.S. Foreign Corrupt Practices Act, and antitrust
and competition laws and regulations that govern our dealings with
suppliers, customers, competitors and government officials.
In addition, many foreign jurisdictions in which we do business have
regulations and regulatory bodies that govern similar aspects of our
operations and products, in some cases to an even more significant degree.
We are also subject to expanding laws and regulations related to
environmental protection and other sustainability-related matters, non-
financial reporting and diligence, labor and employment, trade, taxation and
data privacy and protection, including the European Union’s General Data
Protection Regulation (GDPR) and similar regulations in states within the
United States and in countries around the world. For additional information
on the potential impacts of global legal and regulatory requirements on our
business, see “Item 1A. Risk Factors” herein.
The Company has in place compliance programs and internal and external
experts to help guide our business in complying with these and other
existing laws and regulations that apply to us around the globe; and we have
made, and plan to continue making, necessary expenditures for compliance
with these laws and regulations. We also expect that our many suppliers,
consultants and other third parties working on our behalf share our
commitment to compliance, and we have policies and procedures in place to
manage these relationships, though they inherently involve a lesser degree
of control over operations and governance. We do not expect that the
Company’s expenditures for compliance with current government
regulations, including current environmental regulations, will have a
material effect on our total capital expenditures, earnings or competitive
position in fiscal year 2023 as compared to prior periods.
Human Capital. Our employees are a key source of competitive advantage.
Their actions, guided by our Purpose, Values and Principles (PVPs), are
critical to the long-term success of our business. We aim to retain our
talented employees by offering competitive compensation and benefits,
strong career development and a respectful and inclusive culture that
provides equal opportunity for all.
Our Board of Directors, through the Compensation and Leadership
Development Committee (C&LD Committee), provides oversight of the
Company’s policies and strategies relating to talent including diversity,
equality and inclusion as well as the Company’s compensation principles
and practices. The C&LD Committee also evaluates and approves the
Company’s compensation plans, policies and programs applicable to our
senior executives.
Employees
As of June 30, 2022, the Company had approximately 106,000 employees,
an increase of five percent versus the prior year due primarily to business
growth. The total number of employees is an estimate of total Company
employees excluding interns, co-ops, contractors and employees of joint
ventures. 49% of our employees are in manufacturing roles and 26% of our
employees are located in the United States. 41% of our global employees
are women. As of June 30, 2022, 28% of our U.S. employees identify as
multicultural.
Training and Development
We focus on attracting, developing and retaining skilled and diverse talent,
both from universities and the broader market. We recruit from among the
best universities across markets in which we compete and are generally able
to select from the top talent. We focus on developing our employees by
providing a variety of job experiences, training programs and skill
development opportunities. Given our develop-from-within model for
staffing most of our senior leadership positions, it is particularly important
for us to ensure holistic growth and full engagement of our employees.
Diversity, Equality and Inclusion
As a consumer products company, we believe that it is important for our
workforce to reflect the diversity of our consumers worldwide. We also seek
to foster an inclusive work environment where each individual can bring
their authentic self, which helps drive innovation and enables us to better
serve our consumers. We aspire to achieve equal gender representation
globally and at key management and leadership levels. Within the U.S.
workforce, our aspiration is to achieve 40% multicultural representation
overall as well as at management and leadership levels.
Compensation and Benefits
Our compensation plans are based on the principles of paying for
performance, paying competitively versus peer companies that we compete
with for talent and in the marketplace and focusing on long-term success
through a combination of short-term and long-term incentive programs. We
also offer competitive benefit programs, including retirement plans and
health insurance in line with local country practices with flexibility to
accommodate the needs of a diverse workforce.
Sustainability. Environmental sustainability is a key focus area and
integrated into P&G’s business strategies. The Company has declared its
focus on developing irresistibly superior products and packages that are
sustainable. The Company announced an ambition to reduce greenhouse gas
emissions, purchase renewable electricity for our operations, reduce our use
of virgin petroleum-based plastic in our packaging, increase the
recyclability or reusability of our packaging and increase responsible
sourcing of key forest-based commodities such as wood pulp and palm oil.
-- 4 of 137 --
The Procter & Gamble Company 3
Additional detailed information on our sustainability efforts including our
TCFD (Task Force on Climate-Related Financial Disclosures), SASB
(Sustainability Accounting Standards Board) and CDP (Carbon Disclosure
Project) reports can be found on our website at https://pginvestor.com/esg.
References to our sustainability reports and website are for informational
purposes only and neither the sustainability reports nor the other
information on our website is incorporated by reference into this Annual
Report on Form 10-K.
Item 1A. Risk Factors.
We discuss our expectations regarding future performance, events and
outcomes, such as our business outlook and objectives in this Form 10-K, as
well as in our quarterly and annual reports, current reports on Form 8-K,
press releases and other written and oral communications. All statements,
except for historical and present factual information, are “forward-looking
statements” and are based on financial data and business plans available
only as of the time the statements are made, which may become outdated or
incomplete. We assume no obligation to update any forward-looking
statements as a result of new information, future events or other factors,
except to the extent required by law. Forward-looking statements are
inherently uncertain, and investors must recognize that events could
significantly differ from our expectations.
The following discussion of “risk factors” identifies significant factors that
may adversely affect our business, operations, financial position or future
financial performance. This information should be read in conjunction with
Management's Discussion and Analysis and the Consolidated Financial
Statements and related Notes incorporated in this report. The following
discussion of risks is not all inclusive but is designed to highlight what we
believe are important factors to consider when evaluating our expectations.
These and other factors could cause our future results to differ from those in
the forward-looking statements and from historical trends, perhaps
materially.
MACROECONOMIC CONDITIONS AND RELATED FINANCIAL
RISKS
Our business is subject to numerous risks as a result of having
significant operations and sales in international markets, including
foreign currency fluctuations, currency exchange or pricing controls
and localized volatility.
We are a global company, with operations in approximately 70 countries
and products sold in approximately 180 countries and territories around the
world. We hold assets, incur liabilities, generate sales and pay expenses in a
variety of currencies other than the U.S. dollar, and our operations outside
the U.S. generate more than fifty percent of our annual net sales.
Fluctuations in exchange rates for foreign currencies have and could
continue to reduce the U.S. dollar value of sales, earnings and cash flows
we receive from non-U.S. markets, increase our supply costs (as measured
in U.S. dollars) in those markets, negatively impact our competitiveness in
those markets or otherwise adversely
impact our business results or financial condition. Further, we have a
significant amount of foreign currency debt and derivatives as part of our
capital markets activities. The maturity cash outflows of these instruments
could be adversely impacted by significant appreciation of foreign currency
exchange rates (particularly the Euro), which could adversely impact our
overall cash flows. Moreover, discriminatory or conflicting fiscal or trade
policies in different countries, including changes to tariffs and existing trade
policies and agreements, could adversely affect our results. See also the
Results of Operations and Cash Flow, Financial Condition and Liquidity
sections of the MD&A and the Consolidated Financial Statements and
related Notes.
We also have businesses and maintain local currency cash balances in a
number of countries with currency exchange, import authorization, pricing
or other controls or restrictions, such as Nigeria, Turkey, Argentina and
Egypt. Our results of operations, financial condition and cash flows could
be adversely impacted if we are unable to successfully manage such
controls and restrictions, continue existing business operations and
repatriate earnings from overseas, or if new or increased tariffs, quotas,
exchange or price controls, trade barriers or similar restrictions are imposed
on our business.
Additionally, our business, operations or employees have been and could
continue to be adversely affected (including by the need to de-consolidate
or even exit certain businesses in particular countries) by political volatility,
labor market disruptions or other crises or vulnerabilities in individual
countries or regions, including political instability or upheaval or acts of
war (such as the Russia-Ukraine War) and the related government and other
entity responses, broad economic instability or sovereign risk related to a
default by or deterioration in the creditworthiness of local governments,
particularly in emerging markets.
Uncertain economic or social conditions may adversely impact demand
for our products or cause our customers and other business partners to
suffer financial hardship, which could adversely impact our business.
Our business could be negatively impacted by reduced demand for our
products related to one or more significant local, regional or global
economic or social disruptions. These disruptions have included and may in
the future include: a slow-down, recession or inflationary pressures in the
general economy; reduced market growth rates; tighter credit markets for
our suppliers, vendors or customers; a significant shift in government
policies; significant social unrest; the deterioration of economic relations
between countries or regions, including potential negative consumer
sentiment toward non-local products or sources; or the inability to conduct
day-to-day transactions through our financial intermediaries to pay funds to
or collect funds from our customers, vendors and suppliers. Additionally,
these and other economic conditions may cause our suppliers, distributors,
contractors or other third-party partners to suffer financial or operational
difficulties that they cannot overcome, resulting in their inability to provide
us with the materials and services we need, in which case our business and
results of operations could be adversely affected.
-- 5 of 137 --
4 The Procter & Gamble Company
Customers may also suffer financial hardships due to economic conditions
such that their accounts become uncollectible or are subject to longer
collection cycles. In addition, if we are unable to generate sufficient sales,
income and cash flow, it could affect the Company’s ability to achieve
expected share repurchase and dividend payments.
Disruptions in credit markets or to our banking partners or changes to
our credit ratings may reduce our access to credit or overall liquidity.
A disruption in the credit markets or a downgrade of our current credit
rating could increase our future borrowing costs and impair our ability to
access capital and credit markets on terms commercially acceptable to us,
which could adversely affect our liquidity and capital resources or
significantly increase our cost of capital. In addition, we rely on top-tier
banking partners in key markets around the world, who themselves face
economic, societal, political and other risks, for access to credit and to
facilitate collection, payment and supply chain finance programs. A
disruption to one or more of these top-tier partners could impact our ability
to draw on existing credit facilities or otherwise adversely affect our cash
flows or the cash flows of our customers and vendors.
Changing political conditions could adversely impact our business and
financial results.
Changes in the political conditions in markets in which we manufacture,
sell or distribute our products may be difficult to predict and may adversely
affect our business and financial results. Results of elections, referendums,
sanctions or other political processes in certain markets in which our
products are manufactured, sold or distributed could create uncertainty
regarding how existing governmental policies, laws and regulations may
change, including with respect to sanctions, taxes, tariffs, import and export
controls and the general movement of goods, services, capital and people
between countries and other matters. The potential implications of such
uncertainty, which include, among others, exchange rate fluctuations, new
or increased tariffs, trade barriers and market contraction, could adversely
affect the Company’s results of operations and cash flows.
The war between Russia and Ukraine has adversely impacted and
could continue to adversely impact our business and financial results.
The war between Russia and Ukraine has negatively impacted, and the
situation it generates may continue to negatively impact, our operations.
Beginning in March 2022, the Company reduced its product portfolio,
discontinued new capital investments and suspended media, advertising and
promotional activity in Russia. Future impacts to the Company are difficult
to predict due to the high level of uncertainty as to how the overall situation
will evolve. Within Ukraine, there is a possibility of physical damage and
destruction of our two manufacturing facilities, our distribution centers or
those of our customers. We may not be able to operate our manufacturing
sites and source raw materials from our suppliers or ship finished products
to
our customers. Within Russia, we may reduce further or discontinue our
operations due to sanctions and export controls and counter-sanctions,
monetary, currency or payment controls, restrictions on access to financial
institutions, supply and transportation challenges or other circumstances and
considerations. Ultimately, these could result in loss of assets or
impairments of our manufacturing plants and fixed assets or write-downs of
other operating assets and working capital.
The war between Russia and Ukraine could also amplify or affect the other
risk factors set forth in this Part I, Item 1A, including, but not limited to,
foreign exchange volatility, disruptions to the financial and credit markets,
energy supply and supply chain disruptions, increased risks of an
information security or operational technology incident, cost fluctuations
and commodity cost increases and increased costs to ensure compliance
with global and local laws and regulations. The occurrence of any of these
risks, combined with the increased impact from the war between Russia and
Ukraine, could adversely impact our business and financial results.
More broadly, there could be additional negative impacts to our net sales,
earnings and cash flows should the situation worsen, including, among
other potential impacts, economic recessions in certain neighboring
countries or globally due to inflationary pressures, energy and supply chain
cost increases or the geographic proximity of the war relative to the rest of
Europe.
BUSINESS OPERATIONS RISKS
Our business results depend on our ability to manage disruptions in our
global supply chain.
Our ability to meet our customers’ needs and achieve cost targets depends
on our ability to maintain key manufacturing and supply arrangements,
including execution of supply chain optimizations and certain sole supplier
or sole manufacturing plant arrangements. The loss or disruption of such
manufacturing and supply arrangements, including for issues such as labor
disputes or controversies, loss or impairment of key manufacturing sites,
discontinuity or disruptions in our internal information and data systems or
those of our suppliers, inability to procure sufficient raw or input materials
(including water, recycled materials and materials that meet our labor
standards), significant changes in trade policy, natural disasters, increasing
severity or frequency of extreme weather events due to climate change or
otherwise, acts of war or terrorism, disease outbreaks or other external
factors over which we have no control, have at times interrupted and could,
in the future, interrupt product supply and, if not effectively managed and
remedied, could have an adverse impact on our business, financial
condition, results of operations or cash flows.
Our businesses face cost fluctuations and pressures that could affect
our business results.
Our costs are subject to fluctuations, particularly due to changes in the
prices of commodities (including certain petroleum-derived materials like
resins and paper-based
-- 6 of 137 --
The Procter & Gamble Company 5
materials like pulp) and raw and packaging materials and the costs of labor,
transportation (including trucks and containers), energy, pension and
healthcare. Inflation pressures could also result in increases in these input
costs. Therefore, our business results depend, in part, on our continued
ability to manage these fluctuations through pricing actions, cost saving
projects and sourcing decisions, while maintaining and improving margins
and market share. Failure to manage these fluctuations could adversely
impact our results of operations or cash flows.
The ability to achieve our business objectives depends on how well we
can compete with our local and global competitors in new and existing
markets and channels.
The consumer products industry is highly competitive. Across all of our
categories, we compete against a wide variety of global and local
competitors. As a result, we experience ongoing competitive pressures in
the environments in which we operate, which may result in challenges in
maintaining sales and profit margins. To address these challenges, we must
be able to successfully respond to competitive factors and emerging retail
trends, including pricing, promotional incentives, product delivery windows
and trade terms. In addition, evolving sales channels and business models
may affect customer and consumer preferences as well as market dynamics,
which, for example, may be seen in the growing consumer preference for
shopping online, ease of competitive entry into certain categories and
growth in hard discounter channels. Failure to successfully respond to
competitive factors and emerging retail trends and effectively compete in
growing sales channels and business models, particularly e-commerce and
mobile or social commerce applications, could negatively impact our results
of operations or cash flows.
A significant change in customer relationships or in customer demand
for our products could have a significant impact on our business.
We sell most of our products via retail customers, which include mass
merchandisers, e-commerce (including social commerce) channels, grocery
stores, membership club stores, drug stores, department stores, distributors,
wholesalers, specialty beauty stores (including airport duty-free stores),
high-frequency stores, pharmacies, electronics stores and professional
channels. Our success depends on our ability to successfully manage
relationships with our retail trade customers, which includes our ability to
offer trade terms that are mutually acceptable and are aligned with our
pricing and profitability targets. Continued concentration among our retail
customers could create significant cost and margin pressure on our business,
and our business performance could suffer if we cannot reach agreement
with a key customer on trade terms and principles. Our business could also
be negatively impacted if a key customer were to significantly reduce the
inventory level of or shelf space allocated to our products as a result of
increased offerings of other branded manufacturers, private label brands and
generic non-branded products or for other
reasons, significantly tighten product delivery windows or experience a
significant business disruption.
If the reputation of the Company or one or more of our brands erodes
significantly, it could have a material impact on our financial results.
The Company's reputation, and the reputation of our brands, form the
foundation of our relationships with key stakeholders and other
constituencies, including consumers, customers and suppliers. The quality
and safety of our products are critical to our business. Many of our brands
have worldwide recognition and our financial success directly depends on
the success of our brands. The success of our brands can suffer if our
marketing plans or product initiatives do not have the desired impact on a
brand's image or its ability to attract consumers. Our results of operations or
cash flows could also be negatively impacted if the Company or one of our
brands suffers substantial harm to its reputation due to a significant product
recall, product-related litigation, defects or impurities in our products,
product misuse, changing consumer perceptions of certain ingredients,
negative perceptions of packaging (such as plastic and other petroleum-
based materials), lack of recyclability or other environmental impacts,
concerns about actual or alleged labor or equality and inclusion practices,
privacy lapses or data breaches, allegations of product tampering or the
distribution and sale of counterfeit products. Additionally, negative or
inaccurate postings or comments on social media or networking websites
about the Company or one of its brands could generate adverse publicity
that could damage the reputation of our brands or the Company. If we are
unable to effectively manage real or perceived issues, including concerns
about safety, quality, ingredients, efficacy, environmental or social impacts
or similar matters, sentiments toward the Company or our products could be
negatively impacted, and our results of operations or cash flows could
suffer. Our Company also devotes time and resources to citizenship efforts
that are consistent with our corporate values and are designed to strengthen
our business and protect and preserve our reputation, including programs
driving ethics and corporate responsibility, strong communities, equality
and inclusion and environmental sustainability. While the Company has
many programs and initiatives to further these goals, our ability to achieve
these goals is impacted in part by the actions and efforts of third parties
including local and other governmental authorities, suppliers, vendors and
customers. If these programs are not executed as planned or suffer negative
publicity, the Company's reputation and results of operations or cash flows
could be adversely impacted.
We rely on third parties in many aspects of our business, which creates
additional risk.
Due to the scale and scope of our business, we must rely on relationships
with third parties, including our suppliers, contract manufacturers,
distributors, contractors, commercial banks, joint venture partners and
external business partners, for certain functions. If we are unable to
effectively manage our third-party relationships and the agreements under
which our third-party partners operate, our results of operations and cash
flows could be adversely impacted. Further, failure of these third parties to
meet their obligations to the Company or substantial disruptions in the
relationships between the
-- 7 of 137 --
6 The Procter & Gamble Company
Company and these third parties could adversely impact our operations and
financial results. Additionally, while we have policies and procedures for
managing these relationships, they inherently involve a lesser degree of
control over business operations, governance and compliance, thereby
potentially increasing our financial, legal, reputational and operational risk.
A significant information security or operational technology incident,
including a cybersecurity breach, or the failure of one or more key
information or operations technology systems, networks, hardware,
processes and/or associated sites owned or operated by the Company or
one of its service providers could have a material adverse impact on our
business or reputation.
We rely extensively on information and operational technology (IT/OT)
systems, networks and services, including internet and intranet sites, data
hosting and processing facilities and technologies, physical security systems
and other hardware, software and technical applications and platforms,
many of which are managed, hosted, provided and/or used by third parties
or their vendors, to assist in conducting our business. The various uses of
these IT/OT systems, networks and services include, but are not limited to:
• ordering and managing materials from suppliers;
• converting materials to finished products;
• shipping products to customers;
• marketing and selling products to consumers;
• collecting, transferring, storing and/or processing customer, consumer,
employee, vendor, investor and other stakeholder information and
personal data, including such data from persons covered by an
expanding landscape of privacy and data regulations, such as citizens
of the European Union who are covered by the General Data Protection
Regulation (GDPR), residents of California covered by the California
Consumer Privacy Act (CCPA), citizens of China covered by the
Personal Information Protection Law (PIPL) and citizens of Brazil
covered by the General Personal Data Protection Law (LGPD);
• summarizing and reporting results of operations, including financial
reporting;
• managing our banking and other cash liquidity systems and platforms;
• hosting, processing and sharing, as appropriate, confidential and
proprietary research, business plans and financial information;
• collaborating via an online and efficient means of global business
communications;
• complying with regulatory, legal and tax requirements;
• providing data security; and
• handling other processes necessary to manage our business.
Numerous and evolving information security threats, including advanced
persistent cybersecurity threats, pose a
risk to the security of our services, systems, networks and supply chain, as
well as to the confidentiality, availability and integrity of our data and of our
critical business operations. In addition, because the techniques, tools and
tactics used in cyber-attacks frequently change and may be difficult to
detect for periods of time, we may face difficulties in anticipating and
implementing adequate preventative measures or fully mitigating harms
after such an attack.
Our IT/OT databases and systems and our third-party providers’ databases
and systems have been, and will likely continue to be, subject to advanced
computer viruses or other malicious codes, ransomware, unauthorized
access attempts, denial of service attacks, phishing, social engineering,
hacking and other cyber-attacks. Such attacks may originate from outside
parties, hackers, criminal organizations or other threat actors, including
nation states. In addition, insider actors-malicious or otherwise-could cause
technical disruptions and/or confidential data leakage. We cannot guarantee
that our security efforts or the security efforts of our third-party providers
will prevent material breaches, operational incidents or other breakdowns to
our or our third-party providers’ IT/OT databases or systems.
A breach of our data security systems or failure of our IT/OT databases and
systems may have a material adverse impact on our business operations and
financial results. If the IT/OT systems, networks or service providers we
rely upon fail to function properly or cause operational outages or
aberrations, or if we or one of our third-party providers suffer significant
unavailability of key operations, or inadvertent disclosure of, lack of
integrity of, or loss of our sensitive business or stakeholder information, due
to any number of causes, including catastrophic events, natural disasters,
power outages, computer and telecommunications failures, improper data
handling, viruses, phishing attempts, cyber-attacks, malware and
ransomware attacks, security breaches, security incidents or employee error
or malfeasance, and our business continuity plans do not effectively address
these failures on a timely basis, we may suffer interruptions in our ability to
manage operations and be exposed to reputational, competitive, operational,
financial and business harm as well as litigation and regulatory action. If
our critical IT systems or back-up systems or those of our third-party
vendors are damaged or cease to function properly, we may have to make a
significant investment to repair or replace them.
In addition, if a ransomware attack or other cybersecurity incident occurs,
either internally or at our third-party technology service providers, we could
be prevented from accessing our data or systems, which may cause
interruptions or delays in our business operations, cause us to incur
remediation costs, subject us to demands to pay a ransom or damage our
reputation. In addition, such events could result in unauthorized disclosure
of confidential information, and we may suffer financial and reputational
damage because of lost or misappropriated confidential information
belonging to us or to our partners, our employees, customers and suppliers.
Additionally, we could
-- 8 of 137 --
The Procter & Gamble Company 7
be exposed to potential liability, litigation, governmental inquiries,
investigations or regulatory enforcement actions; and we could be subject to
payment of fines or other penalties, legal claims by our suppliers, customers
or employees and significant remediation costs.
Periodically, we also upgrade our IT/OT systems or adopt new technologies.
If such a new system or technology does not function properly or otherwise
exposes us to increased cybersecurity breaches and failures, it could affect
our ability to order materials, make and ship orders and process payments in
addition to other operational and information integrity and loss issues. The
costs and operational consequences of responding to the above items and
implementing remediation measures could be significant and could
adversely impact our results of operations and cash flows.
We must successfully manage the demand, supply and operational
challenges associated with the effects of a disease outbreak, including
epidemics, pandemics or similar widespread public health concerns.
Our business may be negatively impacted by the fear of exposure to or
actual effects of a disease outbreak, epidemic, pandemic or similar
widespread public health concern, such as travel restrictions or
recommendations or mandates from governmental authorities as a result of
the COVID-19 virus, the threat of the virus or the emergence of any
variants. These impacts include, but are not limited to:
• Significant reductions in demand or significant volatility in demand for
one or more of our products, which may be caused by, among other
things: the temporary inability of consumers to purchase our products
due to illness, quarantine or other travel restrictions or financial
hardship, shifts in demand away from one or more of our more
discretionary or higher priced products to lower priced products, or
stockpiling or similar pantry-loading activity. If prolonged, such
impacts can further increase the difficulty of business or operations
planning and may adversely impact our results of operations and cash
flows;
• Inability to meet our customers’ needs and achieve cost targets due to
disruptions in our manufacturing and supply arrangements caused by
constrained workforce capacity or the loss or disruption of other
essential manufacturing and supply elements such as raw materials or
other finished product components, transportation, or other
manufacturing and distribution capability;
• Failure of third parties on which we rely, including our suppliers,
contract manufacturers, distributors, contractors, commercial banks,
joint venture partners and external business partners, to meet their
obligations to the Company, or significant disruptions in their ability to
do so, which may be caused by their own financial or operational
difficulties and may adversely impact our operations;
• Periods of disruption that limit the ability to access the financial
markets or which increase the cost of liquidity; or
• Significant changes in the political conditions in markets in which we
manufacture, sell or distribute our products, including quarantines,
import/export restrictions, price controls, or governmental or regulatory
actions, closures or other restrictions that limit or close our operating
and manufacturing facilities, restrict our employees’ ability to travel or
perform necessary business functions, or otherwise prevent our third-
party partners, suppliers or customers from sufficiently staffing
operations, including operations necessary for the production,
distribution, sale and support of our products, which could adversely
impact our results of operations and cash flows.
Despite our efforts to manage and remedy these impacts to the Company,
their ultimate impact also depends on factors beyond our knowledge or
control, including the duration and severity of any such outbreak as well as
third-party actions taken to contain its spread and mitigate its public health
effects. In the case of COVID-19, the emergence of variants may continue
to occur across regions and countries where we operate, leading to varied
government responses and the potential for decreased vaccine effectiveness,
resulting in further volatility and disparity in our results and operations
across geographies.
BUSINESS STRATEGY & ORGANIZATIONAL RISKS
Our ability to meet our growth targets depends on successful product,
marketing and operations innovation and successful responses to
competitive innovation, evolving digital marketing and selling
platforms and changing consumer habits.
We are a consumer products company that relies on continued global
demand for our brands and products. Achieving our business results
depends, in part, on successfully developing, introducing and marketing
new products and on making significant improvements to our equipment
and manufacturing processes. The success of such innovation depends on
our ability to correctly anticipate customer and consumer acceptance and
trends, to obtain, maintain and enforce necessary intellectual property
protections and to avoid infringing upon the intellectual property rights of
others and to continue to deliver efficient and effective marketing across
evolving media and mobile platforms with dynamic and increasingly more
restrictive privacy requirements. We must also successfully respond to
technological advances made by, and intellectual property rights granted to,
competitors, customers and vendors. Failure to continually innovate,
improve and respond to competitive moves, platform evolution and
changing consumer habits could compromise our competitive position and
adversely impact our financial condition, results of operations or cash
flows.
We must successfully manage ongoing acquisition, joint venture and
divestiture activities.
-- 9 of 137 --
8 The Procter & Gamble Company
As a company that manages a portfolio of consumer brands, our ongoing
business model includes a certain level of acquisition, joint venture and
divestiture activities. We must be able to successfully manage the impacts
of these activities, while at the same time delivering against our business
objectives. Specifically, our financial results have been, and in the future
could be, adversely impacted by the dilutive impacts from the loss of
earnings associated with divested brands or dissolution of joint ventures.
Our results of operations and cash flows have been, and in the future could
also be, impacted by acquisitions or joint venture activities, if: 1) changes in
the cash flows or other market-based assumptions cause the value of
acquired assets to fall below book value, or 2) we are not able to deliver the
expected cost and growth synergies associated with such acquisitions and
joint ventures, including as a result of integration and collaboration
challenges, which could also result in an impairment of goodwill and
intangible assets.
Our business results depend on our ability to successfully manage
productivity improvements and ongoing organizational change,
including attracting and retaining key talent as part of our overall
succession planning.
Our financial projections assume certain ongoing productivity
improvements and cost savings, including staffing adjustments and
employee departures. Failure to deliver these planned productivity
improvements and cost savings, while continuing to invest in business
growth, could adversely impact our results of operations and cash flows.
Additionally, successfully executing organizational change, management
transitions at leadership levels of the Company and motivation and retention
of key employees, is critical to our business success. Factors that may affect
our ability to attract and retain sufficient numbers of qualified employees
include employee morale, our reputation, competition from other employers
and availability of qualified individuals. Our success depends on
identifying, developing and retaining key employees to provide
uninterrupted leadership and direction for our business. This includes
developing and retaining organizational capabilities in key growth markets
where the depth of skilled or experienced employees may be limited and
competition for these resources is intense as well as continuing the
development and execution of robust leadership succession plans.
LEGAL & REGULATORY RISKS
We must successfully manage compliance with current and expanding
laws and regulations, as well as manage new and pending legal and
regulatory matters in the U.S. and abroad.
Our business is subject to a wide variety of laws and regulations across the
countries in which we do business, including those laws and regulations
involving intellectual property, product liability, product composition or
formulation, packaging content or corporate responsibility after consumer
purchase, marketing, antitrust and competition, privacy, data protection,
environmental (including increasing focus on the climate, water and waste
impacts of consumer packaged goods companies' operations
and products), employment, healthcare, anti-bribery, anti-corruption, trade
(including tariffs, sanctions and export controls), tax, accounting and
financial reporting or other matters. In addition, increasing governmental
and societal attention to environmental, social and governance (ESG)
matters, including expanding mandatory and voluntary reporting, diligence
and disclosure on topics such as climate change, waste production, water
usage, human capital, labor and risk oversight, could expand the nature,
scope and complexity of matters that we are required to control, assess and
report. These and other rapidly changing laws, regulations, policies and
related interpretations as well as increased enforcement actions by various
governmental and regulatory agencies, create challenges for the Company,
including our compliance and ethics programs, may alter the environment in
which we do business and may increase the ongoing costs of compliance,
which could adversely impact our results of operations and cash flows. If
we are unable to continue to meet these challenges and comply with all
laws, regulations, policies and related interpretations, it could negatively
impact our reputation and our business results. Additionally, we are
currently, and in the future may be, subject to a number of inquiries,
investigations, claims, proceedings and requests for information from
governmental agencies or private parties, the adverse outcomes of which
could harm our business. Failure to successfully manage these new or
pending regulatory and legal matters and resolve such matters without
significant liability or damage to our reputation may materially adversely
impact our financial condition, results of operations and cash flows.
Furthermore, if new or pending legal or regulatory matters result in fines or
costs in excess of the amounts accrued to date, that may also materially
impact our results of operations and financial position.
Changes in applicable tax laws and regulations and resolutions of tax
disputes could negatively affect our financial results.
The Company is subject to taxation in the U.S. and numerous foreign
jurisdictions. Changes in the various tax laws can and do occur. For
example, in December 2017, the U.S. government enacted comprehensive
tax legislation commonly referred to as the Tax Cuts and Jobs Act (the U.S.
Tax Act). The changes included in the U.S. Tax Act were broad and
complex. Under the current U.S. presidential administration, comprehensive
federal income tax reform has been proposed, including an increase in the
U.S. Federal corporate income tax rate, elimination of certain investment
incentives and a more than doubling of U.S. residual taxation of non-U.S.
earnings. While these proposals are controversial, likely to change during
the legislative process and may prove difficult to enact as proposed in the
current closely divided U.S. Congress, their impact could nonetheless be
significant.
Additionally, longstanding international tax norms that determine each
country’s jurisdiction to tax cross-border international trade are subject to
potential evolution. An outgrowth of the original Base Erosion and Profit
Shifting (BEPS) project is a project undertaken by the approximately
-- 10 of 137 --
The Procter & Gamble Company 9
140 member countries of the expanded Organisation for Economic Co-
operation and Development (OECD) Inclusive Framework focused on
"Addressing the Challenges of the Digitalization of the Economy." The
breadth of this project extends beyond pure digital businesses and, as
proposed, would likely impact a large portion of multinational businesses
by potentially redefining jurisdictional taxation rights in market countries
and establishing a global minimum tax. Recent pronouncements related to
this project suggest an implementation of the proposed 15% global
minimum tax in the near to mid-term. Continued negotiations on important
details of this project are ongoing, and ultimate enactment and timing in the
EU, US and other jurisdictions remains uncertain.
While it is too early to assess the overall impact of these potential changes,
as these and other tax laws and related regulations are revised, enacted and
implemented, our financial condition, results of operations and cash flows
could be materially impacted.
Furthermore, we are subject to regular review and audit by both foreign and
domestic tax authorities. While we believe our tax positions will be
sustained, the final outcome of tax audits and related litigation, including
maintaining our intended tax treatment of divestiture transactions such as
the fiscal 2017 Beauty Brands transaction with Coty, may differ materially
from the tax amounts recorded in our Consolidated Financial Statements,
which could adversely impact our results of operations and cash flows.
Item 1B. Unresolved Staff Comments.
None.
Item 2. Properties.
In the U.S., we own and operate 23 manufacturing sites located in 17
different states. In addition, we own and operate 81 manufacturing sites in
35 other countries. Many of the domestic and international sites
manufacture products for multiple businesses. Beauty products are
manufactured at 22 of these locations; Grooming products at 17; Health
Care products at 20; Fabric & Home Care products at 38; and Baby,
Feminine & Family Care products at 37. We own our Corporate
headquarters in Cincinnati, Ohio. We own or lease our principal regional
general offices in Switzerland, Panama, Singapore, China and Dubai. We
own or lease our principal regional shared service centers in Costa Rica, the
United Kingdom and the Philippines. Management believes that the
Company's sites are adequate to support the business and that the properties
and equipment have been well maintained.
Item 3. Legal Proceedings.
The Company is subject, from time to time, to certain legal proceedings and
claims arising out of our business, which cover a wide range of matters,
including antitrust and trade regulation, product liability, advertising,
contracts, environmental issues, patent and trademark matters, labor and
employment matters and tax. In addition, SEC regulations require that we
disclose certain environmental proceedings arising under Federal, State or
local law when a governmental authority is a party and such proceeding
involves potential monetary sanctions that the Company reasonably
believes will exceed a certain threshold ($1 million or more). There are no
relevant matters to disclose under this Item for this period. See Note 13 to
our Consolidated Financial Statements for information on certain legal
proceedings for which there are contingencies.
This item should be read in conjunction with the Company's Risk Factors in
Part I, Item 1A for additional information.
Item 4. Mine Safety Disclosure.
Not applicable.
-- 11 of 137 --
10 The Procter & Gamble Company
INFORMATION ABOUT OUR EXECUTIVE OFFICERS
The names, ages and positions held by the Executive Officers of the Company on August 5, 2022, are:
Name Position Age
First Elected to
Officer Position
Jon R. Moeller Chairman of the Board, President and Chief Executive Officer 58 2009
Shailesh Jejurikar Chief Operating Officer 55 2018
Andre Schulten Chief Financial Officer 51 2021
Gary A. Coombe Chief Executive Officer - Grooming 58 2014
Jennifer L. Davis Chief Executive Officer - Health Care 51 2022
Ma. Fatima D. Francisco Chief Executive Officer - Baby, Feminine and Family Care and Executive
Sponsor for Gender Equality 54 2018
R. Alexandra Keith Chief Executive Officer - Beauty and Executive Sponsor for Corporate
Sustainability 54 2017
Sundar Raman Chief Executive Officer - Fabric and Home Care 47 2021
Victor Aguilar Chief Research, Development and Innovation Officer 55 2020
M. Tracey Grabowski Chief Human Resources Officer 54 2018
Marc S. Pritchard Chief Brand Officer 62 2008
Susan Street Whaley Chief Legal Officer and Secretary 48 2022
All the Executive Officers named above have been employed by the Company for more than the past five years.
Mr. Moeller previously served as President and Chief Executive Officer (2021 - 2022), Vice Chairman, Chief Operating Officer and Chief Financial Officer (2019 - 2021), Vice Chairman and
Chief Financial Officer (2017 - 2019) and as Chief Financial Officer (2009 - 2017).
Mr. Jejurikar previously served as Chief Executive Officer - Fabric and Home Care (2019 - 2021), President - Global Fabric, Home Care and P&G Professional (2018 - 2019), and President -
Global Fabric Care and Brand-Building Officer Global Fabric & Home Care (2015 - 2018).
Mr. Schulten previously served as Senior Vice President - Baby Care, North America (2018 - 2021) and Senior Vice President - Finance & Accounting, Global Baby, Feminine and Family Care
(2014 - 2018).
Mr. Coombe previously served as President - Europe Selling & Market Operations (2014 - 2018).
Ms. Davis previously served as President - Feminine Care (2019 - 2022), President - Global Feminine Care (2018 - 2019), and Vice President - Feminine Care, North America and Brand
Franchise Leader, Tampax (2016 - 2018).
Ms. Francisco previously served as Chief Executive Officer - Baby and Feminine Care (2019 - 2021), President - Global Baby Care and Baby & Feminine Care Sector (2018 - 2019), and
President - Global Feminine Care (2015 - 2018).
Ms. Keith previously served as Chief Executive Officer - Beauty (2017 - 2022).
Mr. Raman previously served as President–Home Care and P&G Professional (2020 - 2021), President - Fabric Care, North America and P&G Professional (2019 - 2020), and Vice President -
Fabric Care, North America (2015 - 2019).
Mr. Aguilar previously served as Senior Vice President - Research & Development, Corporate Function Research & Development (2020), Senior Vice President - Research & Development,
Corporate Function Research & Development and Global Fabric Care (2019), and Senior Vice President - Research & Development Global Fabric Care; and Sector Leader, Research &
Development Global Fabric and Home Care (2014 - 2019).
Ms. Grabowski previously served as Senior Vice President - Human Resources, North America Selling and Market Operations (2015 - 2018).
Ms. Whaley previously served as Senior Vice President and General Counsel - North America, Practice Groups and Sector Business Units (2019 - 2022), and Vice President and General Counsel
- North America, Global Go-To-Market and Practice Groups, and Global Business Units (2016 - 2019).
(1)
(2)
(3)
(4)
(5)
(6)
(7)
(8)
(9)
(10)
( )
(11)
(1)
(2)
(3)
(4)
(5)
(6)
(7)
(8)
(9)
(10)
(11)
-- 12 of 137 --
The Procter & Gamble Company 11
PART II
Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.
ISSUER PURCHASES OF EQUITY SECURITIES
Period Total Number of
Shares Purchased Average Price Paid per
Share
Total Number of
Shares Purchased as
Part of Publicly
Announced Plans or
Programs
Approximate Dollar Value of Shares that
May Yet Be Purchased Under Our Share
Repurchase Program
4/1/2022 - 4/30/2022 3,772,818 $159.03 3,772,818
5/1/2022 - 5/31/2022 — — —
6/1/2022 - 6/30/2022 5,319,017 140.93 4,620,153
Total 9,091,835 $148.44 8,392,971
All transactions are reported on a trade date basis and were made in the open market with large financial institutions. This table excludes shares withheld from employees to
satisfy minimum tax withholding requirements on option exercises and other equity-based transactions. The Company administers cashless exercises through an
independent third party and does not repurchase stock in connection with cashless exercises.
Average price paid per share for open market transactions excludes commission.
On April 20, 2022, the Company stated that in fiscal year 2022 the Company expected to reduce outstanding shares through direct share repurchases at a value of
approximately $10 billion, notwithstanding any purchases under the Company's compensation and benefit plans. The share repurchases were authorized pursuant to a
resolution issued by the Company's Board of Directors and were financed through a combination of operating cash flows and issuance of debt. The total value of the shares
purchased under the share repurchase plan was $10 billion. The share repurchase plan ended on June 30, 2022.
Additional information required by this item can be found in Part III, Item 12 of this Form 10-K.
SHAREHOLDER RETURN PERFORMANCE GRAPHS
Market and Dividend Information
P&G has been paying a dividend for 132 consecutive years since its incorporation in 1890 and has increased its dividend for 66 consecutive years since 1956.
Over the past ten years, the dividend has increased at an annual compound average rate of 5%. Nevertheless, as in the past, further dividends will be considered
after reviewing dividend yields, profitability and cash flow expectations and financing needs and will be declared at the discretion of the Company's Board of
Directors.
(in dollars; split-adjusted) 1956 1962 1972 1982 1992 2002 2012 2022
Dividends per share $ 0.01 $ 0.02 $ 0.05 $ 0.13 $ 0.26 $ 0.76 $ 2.14 $ 3.52
(1) (2) (3)
(3)
(3)
(3)
(3)
(1)
(2)
(3)
-- 13 of 137 --
12 The Procter & Gamble Company
Common Stock Information
P&G trades on the New York Stock Exchange under the stock symbol PG. As of June 30, 2022, there were approximately 5 million common stock
shareowners, including shareowners of record, participants in P&G stock ownership plans and beneficial owners with accounts at banks and brokerage firms.
Shareholder Return
The following graph compares the cumulative total return of P&G’s common stock for the five-year period ended June 30, 2022, against the cumulative total
return of the S&P 500 Stock Index (broad market comparison) and the S&P 500 Consumer Staples Index (line of business comparison). The graph and table
assume $100 was invested on June 30, 2017, and that all dividends were reinvested.
Cumulative Value of $100 Investment, through June 30
Company Name/Index 2017 2018 2019 2020 2021 2022
P&G $ 100 $ 93 $ 134 $ 150 $ 174 $ 189
S&P 500 Stock Index 100 114 126 136 191 171
S&P 500 Consumer Staples Index 100 96 112 116 143 152
Item 6. Intentionally Omitted.
-- 14 of 137 --
The Procter & Gamble Company 13
Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations.
Forward-Looking Statements
Certain statements in this report, other than purely historical information,
including estimates, projections, statements relating to our business plans,
objectives and expected operating results, and the assumptions upon which
those statements are based, are “forward-looking statements” within the
meaning of the Private Securities Litigation Reform Act of 1995,
Section 27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934. Forward-looking statements may appear throughout
this report, including without limitation, the following sections:
“Management's Discussion and Analysis,” “Risk Factors” and "Notes 4, 8
and 13 to the Consolidated Financial Statements." These forward-looking
statements generally are identified by the words “believe,” “project,”
“expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,”
“opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will
continue,” “will likely result” and similar expressions. Forward-looking
statements are based on current expectations and assumptions, which are
subject to risks and uncertainties that may cause results to differ materially
from those expressed or implied in the forward-looking statements. We
undertake no obligation to update or revise publicly any forward-looking
statements, whether because of new information, future events or otherwise,
except to the extent required by law.
Risks and uncertainties to which our forward-looking statements are subject
include, without limitation: (1) the ability to successfully manage global
financial risks, including foreign currency fluctuations, currency exchange
or pricing controls and localized volatility; (2) the ability to successfully
manage local, regional or global economic volatility, including reduced
market growth rates, and to generate sufficient income and cash flow to
allow the Company to effect the expected share repurchases and dividend
payments; (3) the ability to manage disruptions in credit markets or to our
banking partners or changes to our credit rating; (4) the ability to maintain
key manufacturing and supply arrangements (including execution of supply
chain optimizations and sole supplier and sole manufacturing plant
arrangements) and to manage disruption of business due to various factors,
including ones outside of our control, such as natural disasters, acts of war
(including the Russia-Ukraine War) or terrorism or disease outbreaks; (5)
the ability to successfully manage cost fluctuations and pressures, including
prices of commodities and raw materials and costs of labor, transportation,
energy, pension and healthcare; (6) the ability to stay on the leading edge of
innovation, obtain necessary intellectual property protections and
successfully respond to changing consumer habits, evolving digital
marketing and selling platform requirements and technological advances
attained by, and patents granted to, competitors; (7) the ability to compete
with our local and global competitors in new and existing sales channels,
including by successfully responding to competitive factors such as prices,
promotional incentives and trade terms for products; (8) the ability to
manage and maintain key
customer relationships; (9) the ability to protect our reputation and brand
equity by successfully managing real or perceived issues, including
concerns about safety, quality, ingredients, efficacy, packaging content,
supply chain practices or similar matters that may arise; (10) the ability to
successfully manage the financial, legal, reputational and operational risk
associated with third-party relationships, such as our suppliers, contract
manufacturers, distributors, contractors and external business partners; (11)
the ability to rely on and maintain key company and third-party information
and operational technology systems, networks and services and maintain the
security and functionality of such systems, networks and services and the
data contained therein; (12) the ability to successfully manage uncertainties
related to changing political conditions and potential implications such as
exchange rate fluctuations and market contraction; (13) the ability to
successfully manage current and expanding regulatory and legal
requirements and matters (including, without limitation, those laws and
regulations involving product liability, product and packaging composition,
intellectual property, labor and employment, antitrust, privacy and data
protection, tax, the environment, due diligence, risk oversight, accounting
and financial reporting) and to resolve new and pending matters within
current estimates; (14) the ability to manage changes in applicable tax laws
and regulations; (15) the ability to successfully manage our ongoing
acquisition, divestiture and joint venture activities, in each case to achieve
the Company’s overall business strategy and financial objectives, without
impacting the delivery of base business objectives; (16) the ability to
successfully achieve productivity improvements and cost savings and
manage ongoing organizational changes while successfully identifying,
developing and retaining key employees, including in key growth markets
where the availability of skilled or experienced employees may be limited;
(17) the ability to successfully manage the demand, supply and operational
challenges, as well as governmental responses or mandates, associated with
a disease outbreak, including epidemics, pandemics or similar widespread
public health concerns (including COVID-19); (18) the ability to manage
the uncertainties, sanctions and economic effects from the war between
Russia and Ukraine; and (19) the ability to successfully achieve our
ambition of reducing our greenhouse gas emissions and delivering progress
towards our environmental sustainability priorities. A detailed discussion of
risks and uncertainties that could cause actual results and events to differ
materially from those projected herein is included in the section titled
"Economic Conditions and Uncertainties" and the section titled "Risk
Factors" (Part I, Item 1A) of this Form 10-K.
Purpose, Approach and Non-GAAP Measures
The purpose of Management's Discussion and Analysis (MD&A) is to
provide an understanding of Procter & Gamble's financial condition, results
of operations and cash flows by focusing on changes in certain key
measures from year to year. The MD&A is provided as a supplement to,
-- 15 of 137 --
14 The Procter & Gamble Company
and should be read in conjunction with, our Consolidated Financial
Statements and accompanying Notes. The MD&A is organized in the
following sections:
• Overview
• Summary of 2022 Results
• Economic Conditions and Uncertainties
• Results of Operations
• Segment Results
• Cash Flow, Financial Condition and Liquidity
• Significant Accounting Policies and Estimates
• Other Information
Throughout the MD&A we refer to measures used by management to
evaluate performance, including unit volume growth, net sales, net earnings,
diluted net earnings per share and operating cash flow. We also refer to a
number of financial measures that are not defined under accounting
principles generally accepted in the United States of America (U.S. GAAP),
consisting of organic sales growth, core earnings per share (Core EPS),
adjusted free cash flow and adjusted free cash flow productivity. Organic
sales growth is net sales growth excluding the impacts of acquisitions,
divestitures and foreign exchange from year-over-year comparisons. Core
EPS is diluted net earnings per share from continuing operations excluding
certain items that are not judged to be part of the Company's sustainable
results or trends. Adjusted free cash flow is operating cash flow less capital
spending and transitional tax payments related to the U.S. Tax Act. Adjusted
free cash flow productivity is the
ratio of adjusted free cash flow to net earnings excluding certain one-time
items. We believe these measures provide our investors with additional
information about our underlying results and trends as well as insight to
some of the metrics used to evaluate management. The explanation at the
end of the MD&A provides more details on the use and the derivation of
these measures as well as reconciliations to the most directly comparable
U.S. GAAP measures.
Management also uses certain market share and market consumption
estimates to evaluate performance relative to competition despite some
limitations on the availability and comparability of share and consumption
information. References to market share and consumption in the MD&A are
based on a combination of vendor-purchased traditional brick-and-mortar
and online data in key markets as well as internal estimates. All market
share references represent the percentage of sales of our products in dollar
terms on a constant currency basis relative to all product sales in the
category. The Company measures quarter and fiscal year-to-date market
shares through the most recent period for which market share data is
available, which typically reflects a lag time of one or two months as
compared to the end of the reporting period. Management also uses unit
volume growth to evaluate and explain drivers of changes in net sales.
Organic volume growth reflects year-over-year changes in unit volume
excluding the impacts of acquisitions, divestitures and certain one-time
items, if applicable, and is used to explain changes in organic sales.
OVERVIEW
Procter & Gamble is a global leader in the fast-moving consumer goods industry, focused on providing branded consumer packaged goods of superior quality
and value to our consumers around the world. Our products are sold in approximately 180 countries and territories primarily through mass merchandisers, e-
commerce (including social commerce) channels, grocery stores, membership club stores, drug stores, department stores, distributors, wholesalers, specialty
beauty stores (including airport duty-free stores), high-frequency stores, pharmacies, electronics stores and professional channels. We also sell direct to
individual consumers. We have on-the-ground operations in approximately 70 countries.
Our market environment is highly competitive with global, regional and local competitors. In many of the markets and industry segments in which we sell our
products, we compete against other branded products, as well as retailers' private-label brands. Additionally, many of the product segments in which we
compete are differentiated by price tiers (referred to as super-premium, premium, mid-tier and value-tier products). We believe we are well positioned in the
industry segments and markets in which we operate, often holding a leadership or significant market share position.
Organizational Structure
Our organizational structure is comprised of Sector Business Units (SBUs), Enterprise Markets (EMs), Corporate Functions (CF) and Global Business Services
(GBS).
Sector Business Units
The Company's ten product categories are organized into five SBUs and five reportable segments (under U.S. GAAP): Beauty; Grooming; Health Care; Fabric
& Home Care; and Baby, Feminine & Family Care. The SBUs are responsible for global brand strategy, new product upgrades and innovation, marketing plans
and supply chain. They have direct profit responsibility for markets representing the large majority of the Company's sales and earnings (referred to as Focus
Markets) and are also responsible for innovation plans, supply plans and operating frameworks to drive growth and value creation in the remaining markets
(referred to as Enterprise Markets). Throughout the MD&A, we reference business results by region, which are comprised of North America, Europe, Greater
China, Latin America, Asia Pacific and India, Middle East and Africa (IMEA).
-- 16 of 137 --
The Procter & Gamble Company 15
The following provides additional detail on our reportable segments and the ten product categories and brand composition within each segment.
Reportable Segments
% of
Net Sales
% of Net
Earnings Product Categories (Sub-Categories) Major Brands
Beauty 18% 22%
Hair Care (Conditioner, Shampoo, Styling Aids, Treatments) Head & Shoulders, Herbal Essences,
Pantene, Rejoice
Skin and Personal Care (Antiperspirant and Deodorant, Personal
Cleansing, Skin Care) Olay, Old Spice, Safeguard, Secret,
SK-II
Grooming 8% 10%
Grooming (Shave Care - Female Blades & Razors, Male Blades
& Razors, Pre- and Post-Shave Products, Other Shave Care;
Appliances) Braun, Gillette, Venus
Health Care 14% 14%
Oral Care (Toothbrushes, Toothpaste, Other Oral Care) Crest, Oral-B
Personal Health Care (Gastrointestinal, Rapid Diagnostics,
Respiratory,
Vitamins/Minerals/Supplements, Pain Relief, Other Personal Health
Care)
Metamucil, Neurobion, Pepto-
Bismol, Vicks
Fabric & Home Care 35% 31%
Fabric Care (Fabric Enhancers, Laundry Additives, Laundry
Detergents) Ariel, Downy, Gain, Tide
Home Care (Air Care, Dish Care, P&G Professional, Surface Care) Cascade, Dawn, Fairy, Febreze, Mr.
Clean, Swiffer
Baby, Feminine &
Family Care 25% 23%
Baby Care (Baby Wipes, Taped Diapers and Pants) Luvs, Pampers
Feminine Care (Adult Incontinence, Feminine Care) Always, Always Discreet, Tampax
Family Care (Paper Towels, Tissues, Toilet Paper) Bounty, Charmin, Puffs
Percent of Net sales and Net earnings for the year ended June 30, 2022 (excluding results held in Corporate).
The Grooming product category is comprised of the Shave Care and Appliances operating segments.
Organization Design:
Sector Business Units
Beauty: We are a global market leader amongst the beauty categories in
which we compete, including hair care and skin and personal care. We are a
global market leader in the retail hair care market with more than 20%
global market share primarily behind our Pantene and Head & Shoulders
brands. In skin and personal care, we offer a wide variety of products,
ranging from deodorants to personal cleansing to skin care, such as our
Olay brand, which is one of the top facial skin care brands in the world with
approximately 6% global market share.
Grooming: We compete in shave care and appliances. In shave care, we are
the global market leader in the blades and razors market. Our global blades
and razors market share is more than 60%, primarily behind our Gillette and
Venus brands. Our appliances, such as electric shavers and epilators, are
sold primarily under the Braun brand in a number of markets around the
world where we compete against both global and regional competitors. We
hold over 25% of the male electric shavers market and over 65% of the
female epilators market.
Health Care: We compete in oral care and personal health care. In oral care,
there are several global competitors in the market and we have the number
two market share position with nearly 20% global market share behind our
Crest and Oral-B brands. In personal health care, we are a global market
leader among the categories in which we compete, including respiratory
treatments, digestive wellness, vitamins
and analgesics behind our Vicks, Metamucil, Pepto-Bismol and Neurobion
brands.
Fabric & Home Care: This segment is comprised of a variety of fabric care
products, including laundry detergents, additives and fabric enhancers; and
home care products, including dishwashing liquids and detergents, surface
cleaners and air fresheners. In fabric care, we generally have the number
one or number two market share position in the markets in which we
compete and are the global market leader with over 35% global market
share, primarily behind our Tide, Ariel and Downy brands. Our global home
care market share is nearly 25% across the categories in which we compete,
primarily behind our Cascade, Dawn, Febreze and Swiffer brands.
Baby, Feminine & Family Care: In baby care, we are a global market
leader and compete mainly in taped diapers, pants and baby wipes with
more than 20% global market share. We have the number one or number
two market share position in most of the key markets in which we compete,
primarily behind Pampers, the Company's largest brand, with annual net
sales of over $7 billion. We are a global market leader in the feminine care
category with over 20% global market share, primarily behind our Always
and Tampax brands. We also compete in the adult incontinence category in
certain markets behind Always Discreet, with over 10% market share in the
key markets in which we compete. Our family care business is
predominantly a North American business comprised primarily of the
Bounty paper towel and
(1) (1)
(2)
(1)
(2)
-- 17 of 137 --
16 The Procter & Gamble Company
Charmin toilet paper brands. North America market shares are over 40% for
Bounty and over 25% for Charmin.
Enterprise Markets
Enterprise Markets are responsible for sales and profit delivery in specific
countries, supported by SBU-agreed innovation and supply chain plans,
along with scaled services like planning, distribution and customer
management.
Corporate Functions
Corporate Functions provides company-level strategy and portfolio
analysis, corporate accounting, treasury, tax, external relations, governance,
human resources, information technology and legal services.
Global Business Services
Global Business Services provides scaled services in technology, process
and data tools to enable the SBUs, the EMs and CF to better serve
consumers and customers. The GBS organization is responsible for
providing world-class services and solutions that drive value for P&G.
Strategic Focus
Procter & Gamble aspires to serve the world’s consumers better than our
best competitors in every category and in every country in which we
compete and, as a result, deliver total shareholder return in the top one-third
of our peer group. Delivering and sustaining leadership levels of
shareholder value creation requires balanced top- and bottom-line growth
and strong cash generation.
The Company competes in daily-use product categories where performance
plays a significant role in the consumer's choice of brands, and therefore,
play to P&G's strengths. Our focused portfolio of businesses consists of ten
product categories where P&G has leading market positions, strong brands
and consumer-meaningful product technologies.
Within these categories, our strategic choices are focused on delighting and
winning with consumers. Our consumers are at the center of everything we
do. We win with consumers by delivering irresistible superiority across five
key vectors - product performance, packaging, brand communication, retail
execution and value. Winning with consumers around the world and against
our best competitors requires superior innovation. Innovation has always
been, and continues to be, P&G’s lifeblood. Superior products delivered
with superior execution drive market growth, value creation for retailers and
build share growth for P&G.
Ongoing productivity improvement is crucial to delivering our balanced
top- and bottom-line growth, cash generation and value creation objectives.
Productivity improvement enables investments to strengthen the superiority
of our brands via product and packaging innovation, more efficient
and effective supply chains, equity and awareness-building brand
advertising and other programs and expansion of sales coverage and R&D
programs. Productivity improvements also enable us to mitigate challenging
cost environments (including periods of increasing commodity and negative
foreign exchange impacts). Our objective is to drive productivity
improvements across all elements of the statement of earnings and balance
sheet, including cost of goods sold, marketing and promotional spending,
overhead costs and capital spending.
We act with agility and are constructively disrupting our highly competitive
industry and the way we do business, including how we innovate,
communicate and leverage new technologies, to create more value.
We are improving operational effectiveness and organizational culture
through enhanced clarity of roles and responsibilities, accountability and
incentive compensation programs.
Additionally, within these strategies of superiority, productivity,
constructive disruption and organization, we have declared four focus areas
to strengthen our performance going forward. These are 1) leveraging
environmental sustainability as an additional driver of superior performing
products and packaging innovations, 2) increasing digital acumen to drive
consumer and customer preference, reduce cost and enable rapid and
efficient decision making, 3) developing next-level supply chain capabilities
to enable flexibility, agility, resilience and a new level of productivity
adapting to a new reality and 4) delivering employee value equation for all
gender identities, races, ethnicities, sexual orientations, ages and abilities
for all roles to ensure we continue to attract, retain and develop the best
talent.
We believe these strategies are right for the long-term health of the
Company and our objective of delivering total shareholder return in the top
one-third of our peer group.
The Company expects the delivery of the following long-term growth
algorithm will result in total shareholder returns in the top third of the
competitive, fast-moving consumer goods peer group:
• Organic sales growth above market growth rates in the categories and
geographies in which we compete;
• Core earnings per share (EPS) growth of mid-to-high single digits; and
• Adjusted free cash flow productivity of 90% or greater.
During periods of significant macroeconomic pressures, we intend to
maintain a disciplined approach to investing in our business, which may
cause short-term results to deviate from the long-term growth algorithm.
-- 18 of 137 --
The Procter & Gamble Company 17
SUMMARY OF 2022 RESULTS
Amounts in millions, except per share amounts 2022 2021 Change vs. Prior Year
Net sales $ 80,187 $ 76,118 5 %
Operating income 17,813 17,986 (1)%
Net earnings 14,793 14,352 3 %
Net earnings attributable to Procter & Gamble 14,742 14,306 3 %
Diluted net earnings per common share 5.81 5.50 6 %
Core earnings per share 5.81 5.66 3 %
Cash flow from operating activities 16,723 18,371 (9)%
• Net sales increased 5% to $80.2 billion on a 2% increase in unit
volume. Unfavorable foreign exchange had a negative 2% impact on
net sales. Net sales growth was driven by a high single digit increase in
Health Care, mid-single digit increases in Fabric & Home Care and
Baby, Feminine & Family Care and low single digit increases in Beauty
and Grooming. Excluding the impact of acquisitions and divestitures
and foreign exchange, Organic sales increased 7% on a 2% increase in
organic volume. Organic sales increased double digits in Health Care,
increased high single digits in Fabric & Home Care, increased mid-
single digits in Baby, Feminine & Family Care and in Grooming and
increased low single digits in Beauty.
• Operating income decreased $0.2 billion, or 1% versus year ago to
$17.8 billion, as the increase in net sales was more than offset by a
decrease in operating margin.
• Net earnings increased $0.4 billion or 3% versus year ago to $14.8
billion, due to a prior year loss on early debt extinguishment, lower
taxes and interest expense in the current year. Foreign exchange
impacts negatively affected net earnings by approximately $274
million.
• Net earnings attributable to Procter & Gamble were $14.7 billion, an
increase of $0.4 billion or 3% versus the prior year primarily due to the
increase in net earnings.
• Diluted net earnings per share (EPS) increased 6% to $5.81 due to the
increase in net earnings, a reduction in shares outstanding and due to
the prior year loss on early debt extinguishment. Net earnings per share
increased 3% versus the prior year core net earnings per share due to
the increase in net earnings and a reduction in shares outstanding.
• Cash flow from operating activities was $16.7 billion.
◦ Adjusted free cash flow, which is operating cash flow less capital
expenditures and certain other impacts, was $13.8 billion.
◦ Adjusted free cash flow productivity, which is the ratio of adjusted
free cash flow to net earnings, was 93%.
ECONOMIC CONDITIONS AND UNCERTAINTIES
We discuss expectations regarding future performance, events and
outcomes, such as our business outlook and objectives, in annual and
quarterly reports, press releases and
other written and oral communications. All such statements, except for
historical and present factual information, are "forward-looking statements"
and are based on financial data and our business plans available only as of
the time the statements are made, which may become out-of-date or
incomplete. We assume no obligation to update any forward-looking
statements as a result of new information, future events or other factors,
except as required by law. Forward-looking statements are inherently
uncertain and investors must recognize that events could be significantly
different from our expectations. For more information on risk factors that
could impact our results, please refer to “Risk Factors” in Part I, Item 1A of
this Form 10-K.
Global Economic Conditions. Our products are sold in numerous countries
across North America, Europe, Latin America, Asia and Africa, with more
than half our sales generated outside the United States. As such, we are
exposed to and impacted by global macroeconomic factors, U.S. and
foreign government policies and foreign exchange fluctuations. Global
economic conditions continue to be volatile due to the COVID-19
pandemic, resulting in market size contractions in certain countries due to
economic slowdowns and government restrictions on movement. Other
macroeconomic factors also remain dynamic, and any causes of market size
contraction, such as greater political unrest or instability in the Middle East,
Central and Eastern Europe (including the ongoing Russia-Ukraine War),
certain Latin American markets, the Hong Kong market in Greater China
and the Korean peninsula could reduce our sales or erode our operating
margin and consequently reduce our net earnings and cash flows.
Changes in Costs. Our costs are subject to fluctuations, particularly due to
changes in commodity prices, transportation costs, other broader
inflationary impacts and our own productivity efforts. We have significant
exposures to certain commodities, in particular certain oil-derived materials
like resins and paper-based materials like pulp. Volatility in the market price
of these commodity input materials has a direct impact on our costs.
Disruptions in our manufacturing, supply and distribution operations,
including energy shortages, port congestions, labor constraints and freight
container and truck shortages have impacted our costs and could do so in
the future. If we are unable to manage these impacts through pricing
actions, cost savings projects and sourcing decisions, as well as through
-- 19 of 137 --
18 The Procter & Gamble Company
consistent productivity improvements, it may adversely impact our gross
margin, operating margin, net earnings and cash flows. Net sales could also
be adversely impacted following pricing actions if there is a negative impact
on the consumption of our products. We strive to implement, achieve and
sustain cost improvement plans, including supply chain optimization and
general overhead and workforce optimization. If we are not successful in
executing and sustaining these changes, there could be a negative impact on
our gross margin, operating margin, net earnings and cash flows.
Foreign Exchange. We have both translation and transaction exposure to
the fluctuation of exchange rates. Translation exposures relate to exchange
rate impacts of measuring income statements of foreign subsidiaries that do
not use the U.S. dollar as their functional currency. Transaction exposures
relate to 1) the impact from input costs that are denominated in a currency
other than the local reporting currency and 2) the revaluation of transaction-
related working capital balances denominated in currencies other than the
functional currency. In the past three years, a number of foreign currencies
have weakened versus the U.S. dollar, leading to lower sales and earnings
from these foreign exchange impacts. Certain countries that recently had
and are currently experiencing significant exchange rate fluctuations
include Argentina, Turkey, Brazil and Russia. These fluctuations have
significantly impacted our historical net sales, costs and net earnings and
could do so in the future. Increased pricing in response to certain
fluctuations in foreign currency exchange rates may offset portions of the
currency impacts but could also have a negative impact on the consumption
of our products, which would negatively affect our net sales, gross margin,
operating margin, net earnings and cash flows.
Government Policies. Our net earnings and cash flows could be affected by
changes in U.S. or foreign government legislative, regulatory or
enforcement policies. For example, our net earnings and cash flows could
be affected by any future legislative or regulatory changes in U.S. or non-
U.S. tax policy, or any significant change in global tax policy adopted under
the current work being led by the OECD for the G20 focused on
"Addressing the Challenges of the Digitalization of the Economy." The
breadth of the OECD project extends beyond pure digital businesses, and if
agreed and enacted by most countries, is likely to impact most large
multinational businesses by both redefining jurisdictional taxation rights
and broadly establishing a 15% minimum tax on their foreign operations.
Our net sales, gross margin, operating margin, net earnings and cash flows
may also be impacted by changes in U.S. and foreign government policies
related to environmental and climate change matters. Additionally, we
attempt to carefully manage our debt, currency and other exposures in
certain countries with currency exchange, import authorization and pricing
controls, such as Nigeria, Turkey, Argentina and Egypt. Further, our net
sales, gross margin, operating margin, net earnings and cash flows could be
affected by changes to
international trade agreements in North America and elsewhere. Changes in
government policies in these areas might cause an increase or decrease in
our net sales, gross margin, operating margin, net earnings and cash flows.
COVID-19 Pandemic. Because we sell products that are essential to the
daily lives of consumers, the pandemic has not had a materially negative
impact to our consolidated net sales, net earnings and cash flows.
However, the continued evolution of the pandemic may result in economic
recessions or a slowdown of economic growth in certain countries or
regions. It could also lead to volatility in consumer access to our products
(due to governmental actions or key material, transportation and labor
shortages impacting our ability to produce and ship products) or could
impact consumers’ movements and access to our products. There could also
be reduced demand due to consumption decreases and consumer pantry
destocking (particularly, in home cleaning, health and hygiene products) as
economic activity resumes following slowdowns or relaxation of
governmental restrictions. Net, the uncertainty in the timing and extent of
demand volatility, the relaxation and reimplementation of movement
restrictions, the timing and impact of potential consumer pantry destocking,
the future economic trends due to a resurgence of positive cases and
governmental actions in response to the pandemic may result in heightened
volatility and negative impacts to net sales, net earnings and cash flows
during and subsequent to the pandemic.
While we have been able to broadly maintain our operations, we
experienced some disruption in our supply chain in certain markets due
primarily to the restriction of employee movements, key material and labor
shortages and transportation constraints. We intend to continue to work with
our suppliers and government authorities to implement employee safety
measures to minimize disruption to the manufacturing and distribution of
our products. The continued evolution of the pandemic and uncertainty with
regards to the disruptions caused either by resurgence of positive cases or
governmental actions in response to the pandemic could result in an
unforeseen disruption to our supply chain and impact our operations (for
example, the closure of a key manufacturing or distribution facility or the
inability of a key material or transportation supplier to source and transport
materials).
The pandemic has not had a material negative impact on the Company’s
liquidity position. We continue to generate operating cash flows to meet our
short-term liquidity needs and continue to maintain access to capital
markets enabled by our strong short- and long-term credit ratings.
Russia-Ukraine War. The war between Russia and Ukraine has negatively
impacted our operations in both countries. Our Ukraine business includes
two manufacturing sites. We have approximately 500 employees including
both manufacturing and non-manufacturing personnel. Our operations in
Ukraine accounted for less than 1% of consolidated net sales and net
earnings in fiscal 2022. Additionally, net assets of our Ukraine subsidiary,
along
-- 20 of 137 --
The Procter & Gamble Company 19
with Ukraine related assets held by other subsidiaries, account for less than
1% of net assets as of June 30, 2022.
Our Russia business includes two manufacturing sites with a net book value
of approximately $350 million as of June 30, 2022. We have approximately
2,400 employees, including both manufacturing and non-manufacturing
personnel. In fiscal 2022, our operations in Russia accounted for less than
2% of consolidated net sales and less than 1% of net earnings. Additionally,
net assets of our Russia subsidiaries, along with Russia related assets held
by other subsidiaries, account for less than 2% of net assets as of June 30,
2022. Beginning in March 2022, the Company has reduced its product
portfolio, discontinued new capital investments and suspended media,
advertising and promotional activity in Russia.
Future impacts to the Company are difficult to predict due to the high level
of uncertainty as to how the war will evolve, what its duration will be and
its ultimate resolution. Within Ukraine, there is a possibility of physical
damage and destruction of our two manufacturing facilities. We may not be
able to operate our manufacturing sites and source raw materials from our
suppliers or ship finished products to our customers. Ultimately, these could
result in impairments of our manufacturing plants and fixed assets or write-
downs of other operating assets and working capital.
Within Russia, we may not be able to continue our reduced operations at
current levels due to sanctions and counter-sanctions, monetary, currency or
payment controls, restrictions on access to financial institutions and supply
and transportation challenges. Our suppliers, distributors and retail
customers are also impacted by the war and their ability to successfully
maintain their operations could also impact our operations or negatively
impact the sales of our products.
More broadly, there could be additional negative impacts to our net sales,
earnings and cash flows should the situation escalate beyond its current
scope, including, among other potential impacts, economic recessions in
certain neighboring countries or globally due to inflationary pressures and
supply chain cost increases or the geographic proximity of the war relative
to the rest of Europe.
For additional information on risk factors that could impact our results,
please refer to “Risk Factors” in Part I, Item 1A of this Form 10-K.
RESULTS OF OPERATIONS
The key metrics included in the discussion of our consolidated results of
operations include net sales, gross margin, selling, general and
administrative costs (SG&A), operating margin, other non-operating items,
income taxes and net earnings. The primary factors driving year-over-year
changes in net sales include overall market growth in the categories in
which we compete, product initiatives, competitive activities (the level of
initiatives, pricing and other activities by competitors), marketing spending,
retail executions (both in-store and online) and acquisition and divestiture
activity, all of which drive changes in our underlying unit volume, as well
as our pricing actions (which can also impact volume), changes in product
and
geographic mix and foreign exchange impacts on sales outside the U.S.
For most of our categories, our cost of products sold and SG&A are variable
in nature to some extent. Accordingly, our discussion of these operating
costs focuses primarily on relative margins rather than the absolute year-
over-year changes in total costs. The primary drivers of changes in gross
margin are input costs (energy and other commodities), pricing impacts,
geographic mix (for example, gross margins in North America are generally
higher than the Company average for similar products), product mix (for
example, the Beauty segment has higher gross margins than the Company
average), foreign exchange rate fluctuations (in situations where certain
input costs may be tied to a different functional currency than the
underlying sales), the impacts of manufacturing savings projects and
reinvestments (for example, product or package improvements) and, to a
lesser extent, scale impacts (for costs that are fixed or less variable in
nature). The primary components of SG&A are marketing-related costs and
non-manufacturing overhead costs. Marketing-related costs are primarily
variable in nature, although we may achieve some level of scale benefit
over time due to overall growth and other marketing efficiencies. While
overhead costs are variable to some extent, we generally experience more
scale-related impacts for these costs due to our ability to leverage our
organization and systems' infrastructures to support business growth. The
main drivers of changes in SG&A as a percentage of net sales are overhead
and marketing cost savings, reinvestments (for example, increased
advertising), inflation, foreign exchange fluctuations and scale impacts.
For a detailed discussion of the fiscal 2021 year-over-year changes, please
refer to the MD&A in Part II, Item 7 of the Company's Form 10-K for the
fiscal year ended June 30, 2021.
Net Sales
Net sales increased 5% to $80.2 billion in fiscal 2022 on a 2% increase in
unit volume versus the prior year. Unfavorable foreign exchange decreased
net sales by 2%. Favorable pricing had a 4% positive impact on net sales.
Mix increased net sales by 1% due to positive geographic mix from the
disproportionate growth of the North America region and positive category
mix from the disproportionate growth of the Personal Health Care category,
both of which have higher than Company-average selling prices. This was
partially offset by the disproportionate growth of the Fabric Care business,
which has lower than Company-average selling prices. Excluding the net
impacts of foreign exchange and acquisitions and divestitures, organic sales
grew 7% on a 2% increase in organic volume. Net sales increased high
single digits in Health Care, increased mid-single digits in Fabric & Home
Care and in Baby, Feminine & Family Care and increased low single digits
in Beauty and Grooming.
On a regional basis, volume increased mid-single digits in North America
and Latin America, increased low single digits in Asia Pacific and IMEA.
Volume in Europe was unchanged and decreased mid-single digits in
Greater China.
-- 21 of 137 --
20 The Procter & Gamble Company
Operating Costs
Comparisons as a percentage of net sales; Years ended June 30 2022 2021 Basis Point
Change
Gross margin 47.4 % 51.2 % (380)
Selling, general and administrative expense 25.2 % 27.6 % (240)
Operating margin 22.2 % 23.6 % (140)
Earnings before income taxes 22.4 % 23.1 % (70)
Net earnings 18.4 % 18.9 % (50)
Net earnings attributable to Procter & Gamble 18.4 % 18.8 % (40)
Gross margin decreased 380 basis points to 47.4% of net sales in fiscal
2022. The decrease in gross margin was due to:
• 390 basis points of increased commodity costs,
• a 130 basis-point decline from unfavorable mix, due primarily to
negative product mix resulting from the launch and growth of
premium-priced products that are profit-accretive but have lower than
Company-average gross margin, and
• 40 basis points of net manufacturing cost increases, as 60 basis points
of increased transportation costs and 20 basis points of product and
packaging investments were partially offset by 40 basis points of
productivity savings net of inflation and other cost increases.
These impacts were partially offset by a 180 basis-point increase due to
higher pricing.
Total SG&A decreased 4% to $20.2 billion, due to decreased overhead
costs, marketing spending and other operating costs. SG&A as a percentage
of net sales decreased 240 basis points to 25.2% primarily due to the
positive scale impacts of the net sales increase and, to a lesser extent, a
decrease in overhead costs and marketing spending.
• Marketing spending as a percentage of net sales decreased 120 basis
points due primarily to the positive scale impacts of the net sales
increase and, to a lesser extent, due to increased media and production
cost savings and decreased media spending.
• Overhead costs as a percentage of net sales decreased 110 basis points
due to the positive scale impacts of the net sales increase and
productivity savings.
• Other net operating expenses as a percentage of net sales decreased
approximately 10 basis points due primarily to gains from the
divestiture of a minor business and sale of real estate, partially offset by
increased foreign exchange transactional charges.
Productivity-driven cost savings delivered 70 basis points of benefit to
SG&A as a percentage of net sales.
Operating margin decreased 140 basis points to 22.2% due to the decrease
in gross margin partially offset by the decrease in SG&A as a percentage of
net sales as discussed above.
Non-Operating Items
• Interest expense was $439 million in fiscal 2022, a decrease of $63
million versus the prior year driven primarily by lower average interest
rates on fixed rate debt.
• Interest income was $51 million in fiscal 2022, an increase of $6
million versus the prior year.
• Other non-operating income increased $484 million to $570 million,
due primarily to a prior year loss on early-debt extinguishment and a
current year increase in net non-operating benefits on post-retirement
benefit plans, partially offset by unrealized gains on equity investments
in the prior year and unrealized losses on equity investments in the
current year.
Income Taxes
The effective tax rate decreased 70 basis points to 17.8% in 2022 due to:
• a 45 basis-point decrease from higher excess tax benefits of share-
based compensation (a 200 basis-point benefit in the current year
versus a 155 basis-point benefit in the prior year),
• a 30 basis-point decrease from discrete impacts related to uncertain tax
positions (35 basis-point favorable impact in the current year versus a 5
basis-point favorable impact in the prior year), and
• a 15 basis-point decrease from higher current year deductions for
foreign-derived intangible income versus prior year.
These decreases were partially offset by a 20 basis-point increase due to
unfavorable geographic mix impacts of current year earnings.
Net Earnings
Operating income decreased 1% or $0.2 billion, to $17.8 billion as the
increase in net sales was more than fully offset by the decrease in operating
margin, both of which are discussed above.
Earnings before income taxes increased 2%, or $0.4 billion, to $18.0 billion,
as the decrease in operating income was more than fully offset by a prior
year loss on early-debt extinguishment and lower interest expense. Net
earnings increased 3%, or $0.4 billion, to $14.8 billion due to the increase in
earnings before income taxes and the decrease in the effective income tax
rate discussed above. Foreign
-- 22 of 137 --
The Procter & Gamble Company 21
exchange impacts reduced net earnings by approximately $274 million in
fiscal 2022 due to a weakening of certain currencies against the U.S. dollar.
This impact includes both transactional charges and translational impacts
from converting earnings from foreign subsidiaries to U.S. dollars.
Net earnings attributable to Procter & Gamble increased $0.4 billion, or 3%,
to $14.7 billion.
Diluted net EPS increased $0.31, or 6%, to $5.81 due primarily to the
increase in net earnings and, to a lesser extent, a reduction in shares
outstanding. Net earnings per share increased 3% versus the prior year core
EPS due to the prior year loss on early debt extinguishment.
SEGMENT RESULTS
Segment results reflect information on the same basis we use for internal management reporting and performance evaluation. The results of these reportable
segments do not include certain non-business unit specific costs which are reported in our Corporate segment and are included as part of our Corporate segment
discussion. Additionally, we apply blended statutory tax rates in the segments. Eliminations to adjust segment results to arrive at our consolidated effective tax
rate are included in Corporate. See Note 2 to the Consolidated Financial Statements for additional information on items included in the Corporate segment.
Net Sales Change Drivers 2022 vs. 2021
Volume with
Acquisitions &
Divestitures
Volume Excluding
Acquisitions &
Divestitures
Foreign
Exchange Price Mix Other
Net Sales
Growth
Beauty — % — % — % 3 % (1) % — % 2 %
Grooming — % — % (3) % 5 % — % — % 2 %
Health Care 4 % 4 % (1) % 3 % 3 % — % 9 %
Fabric & Home Care 3 % 3 % (2) % 5 % — % — % 6 %
Baby, Feminine & Family Care 1 % 1 % (1) % 4 % 1 % — % 5 %
TOTAL COMPANY 2 % 2 % (2)% 4 % 1 % — % 5 %
Net sales percentage changes are approximations based on quantitative formulas that are consistently applied.
Other includes the sales mix impact from acquisitions and divestitures and rounding impacts necessary to reconcile volume to net sales.
BEAUTY
($ millions) 2022 2021 Change vs. 2021
Volume N/A N/A —%
Net sales $14,740 $14,417 2%
Net earnings $3,160 $3,210 (2)%
% of net sales 21.4% 22.3% (90) bps
Beauty net sales increased 2% to $14.7 billion in fiscal 2022 on unit volume
that was unchanged. Higher pricing increased net sales by 3%. Foreign
exchange had no impact on net sales. Unfavorable mix decreased net sales
by 1% due to the disproportionate decline of SK-II, which has higher than
segment-average selling prices. Organic sales also increased 2%. Global
market share of the Beauty segment increased 0.1 points.
• Hair Care net sales increased low single digits. A negative impact of a
low single digit decrease in volume was more than offset by increased
pricing and favorable mix (due to a higher proportion of premium
products, which have higher than category-average selling prices).
Organic sales also increased low single digits. Volume decreased mid-
single digits in Greater China (due to pandemic-related lockdowns and
market slowdown in traditional retailers where our shares are
disproportionately higher versus social commerce) and IMEA (due to
competitive activity) and decreased low
single digits in Europe (as a result of portfolio reduction in Russia and
higher pricing in certain markets) and Asia Pacific (due to competitive
activity). This was offset by a low single digit volume increase in North
America (due to acquisitions). Excluding the impacts of acquisitions,
volume was unchanged in North America. Global market share of the
hair care category decreased less than a point.
• Skin and Personal Care net sales increased low single digits. Positive
impacts of a low single digit increase in volume and increased pricing
were partially offset by negative category mix due to the decline of SK-
II brand (which has higher than category-average selling prices).
Organic sales increased low single digits. Volume increased mid-teens
in Latin America (due to innovation) and increased mid-single digits in
North America (due to innovation in personal care and acquisitions)
and in Greater China (due to innovation and market growth). Global
market share of the skin and personal care category increased half a
point.
Net earnings decreased 2% to $3.2 billion in fiscal 2022 as the increase in
net sales was more than offset by a 90 basis-point decrease in net earnings
margin. Net earnings margin decreased due primarily to a reduction in gross
margin, partially offset by a reduction in SG&A as a percentage of sales.
The gross margin reduction was driven by increased commodity and
transportation costs and negative product mix caused by the decline of SK-
II (which has higher than
(1)
(2)
(1)
(2)
-- 23 of 137 --
22 The Procter & Gamble Company
segment-average gross margins), partially offset by increased pricing.
SG&A as a percentage of net sales decreased as the positive scale benefit of
the net sales increase and increased cost savings in marketing spending
were partially offset by an increase in overhead costs.
GROOMING
($ millions) 2022 2021 Change vs. 2021
Volume N/A N/A —%
Net sales $6,587 $6,440 2%
Net earnings $1,490 $1,427 4%
% of net sales 22.6% 22.2% 40 bps
Grooming net sales increased 2% to $6.6 billion in fiscal 2022 on unit
volume that was unchanged. Higher pricing increased net sales by 5%.
Unfavorable foreign exchange decreased net sales by 3%. Mix had a neutral
impact to net sales. Organic sales increased 5%. Global market share of the
Grooming segment increased 1.2 points.
• Shave Care net sales increased mid-single digits. Positive impacts of a
low single digit volume increase and increased pricing were partially
offset by unfavorable foreign exchange. Organic sales increased high
single digits. Volume increased low single digits in North America (due
to innovation), Europe (due to innovation and market growth versus the
prior year that was negatively impacted by the pandemic), IMEA (due
to market growth) and Latin America (due to innovation). This was
partially offset by a high teens decline in Greater China (due to
pandemic-related shutdowns and market slowdown in traditional
retailers where our shares are disproportionately higher versus social
commerce retailers). Global market share of the shave care category
increased nearly half a point.
• Appliances net sales decreased mid-single digits. Negative impacts of a
high single digit decline in volume and unfavorable foreign exchange
were partially offset by increased pricing (net of increased trade
spending) and positive mix (due to a higher proportion of premium
shavers and epilators, which have higher than category-average selling
prices). Organic sales decreased low single digits. Volume declined
double digits in Europe, mid-single digits in North America and low
single digits in Asia Pacific, all due to market declines versus the prior
year that benefited from pandemic-related consumption increases.
Excluding the impact of a divestiture, volume declined high single
digits in Europe. Global market share of the appliances category
increased less than a point.
Net earnings increased 4% to $1.5 billion in fiscal 2022 due to the increase
in net sales and a 40 basis-point increase in net earnings margin. The net
earnings margin increased due to a reduction in SG&A as a percentage of
net sales, partially offset by a decrease in gross margin and a higher
effective tax rate. The gross margin decrease was driven by negative
product mix (due to the launch and growth of premium-priced, profit-
accretive products that have lower than segment-average gross margins) and
increased commodity and transportation costs, partially offset by increased
pricing
and manufacturing cost savings. SG&A as a percentage of net sales
decreased due primarily to the positive scale impacts of the net sales
increase. The higher effective tax rate was driven by disproportionate
growth in North America, which has higher than segment-average tax rates.
HEALTH CARE
($ millions) 2022 2021 Change vs. 2021
Volume N/A N/A 4%
Net sales $10,824 $9,956 9%
Net earnings $2,006 $1,851 8%
% of net sales 18.5% 18.6% (10) bps
Health Care net sales increased 9% to $10.8 billion in fiscal 2022 on a 4%
increase in unit volume. Unfavorable foreign exchange impacts decreased
net sales by 1%. Favorable mix increased net sales by 3% due to the
disproportionate growth in North America and the Personal Health Care
category, both of which have higher than segment-average selling prices.
Higher pricing increased net sales by 3%. Organic sales increased 10%.
Global market share of the Health Care segment decreased 0.2 points.
• Oral Care net sales increased low single digits. A negative impact of a
low single digit volume decrease and unfavorable foreign exchange
were more than fully offset by the positive impacts from favorable mix
(due to growth in North America and a higher proportion of premium
tier products, both of which have higher than category-average selling
prices) and increased pricing. Organic sales increased mid-single digits.
Volume decreased low teens in Greater China (due to slowdown of the
power brush market and pandemic-related lockdowns) and mid-single
digits in Europe (as a result of supply constraints primarily due to the
global chip shortage). This was partially offset by a double digit
increase in Asia Pacific (due to distribution gains and market growth), a
mid-single digit increase in IMEA (due to market growth and
innovation) and low single digit increases in North America and Latin
America (both due to market growth and innovation). Global market
share of the oral care category increased half a point.
• Personal Health Care net sales increased high-teens. This was due
primarily to a low teens increase in volume, increased pricing,
increased trade spend efficiencies and positive mix (due to the
disproportionate growth in North America and respiratory products,
both of which have higher than category-average selling prices),
partially offset by unfavorable foreign exchange impacts. Organic sales
increased about 20%. Volume increased high teens in North America,
increased high single digits in Europe (both due to stronger respiratory
seasons and innovation) and increased mid-single digits in IMEA (due
to innovation, increased marketing spending and distribution gains).
Global market share of the personal health care category increased less
than half a point.
-- 24 of 137 --
The Procter & Gamble Company 23
Net earnings increased 8% to $2.0 billion in fiscal 2022 due primarily to the
increase in net sales. Net earnings margin decreased slightly as a decrease in
gross margin and a higher effective tax rate were mostly offset by a
decrease in SG&A as a percentage of net sales. The decrease in gross
margin was driven primarily by increased commodity and transportation
costs and other cost increases associated with the global chip shortage,
partially offset by increased pricing. SG&A as a percentage of net sales
decreased due to the positive scale impacts of the net sales increase and
overhead productivity, partially offset by an increase in media spending.
The higher effective tax rate was driven by disproportionate growth in
North America, which has higher than segment-average tax rates.
FABRIC & HOME CARE
($ millions) 2022 2021 Change vs. 2021
Volume N/A N/A 3%
Net sales $27,556 $26,014 6%
Net earnings $4,386 $4,622 (5)%
% of net sales 15.9% 17.8% (190) bps
Fabric & Home Care net sales increased 6% to $27.6 billion in fiscal 2022
on a 3% increase in unit volume. Unfavorable foreign exchange decreased
net sales by 2%. Higher pricing increased net sales by 5%. Mix had a
neutral impact to net sales. Organic sales increased 8%. Global market share
of the Fabric & Home Care segment increased 1.5 points.
• Fabric Care net sales increased high single digits. The positive impacts
of a mid-single digit increase in volume, increased pricing, increased
trade spend efficiencies and positive mix (due to the disproportionate
growth in North America and growth of fabric enhancers and premium
forms, all of which have higher than category-average selling prices)
were partially offset by unfavorable foreign exchange. Organic sales
increased double digits. Volume increased high single digits in North
America and increased low single digits in Asia Pacific, both due to
market growth and innovation. Global market share of the fabric care
category increased more than a point.
• Home Care net sales were unchanged. Negative impacts of a low single
digit decrease in volume, increased trade spending and unfavorable
foreign exchange were offset by increased pricing. Organic sales
increased low single digits. Volume decreased 20% in IMEA (due to
market contraction and competitive activity) and decreased low single
digits in North America (due to market contraction versus a prior year
that benefited from pandemic-related consumption increases). Global
market share of the home care category increased more than a point.
Net earnings decreased 5% to $4.4 billion in fiscal 2022 as the increase in
net sales was more than offset by a 190 basis-point reduction in net earnings
margin. Net earnings margin decreased due primarily to a reduction in gross
margin, partially offset by a reduction in SG&A as a percentage of net sales.
The gross margin decrease was primarily driven
by an increase in commodity and transportation costs, and unfavorable mix
caused by the growth of premium-priced, profit-accretive products that have
lower than segment-average gross margins, partially offset by increased
pricing. SG&A as a percentage of net sales declined due to the positive
scale benefits of the net sales increase and a reduction in marketing
spending.
BABY, FEMININE & FAMILY CARE
($ millions) 2022 2021 Change vs. 2021
Volume N/A N/A 1%
Net sales $19,736 $18,850 5%
Net earnings $3,266 $3,629 (10)%
% of net sales 16.5% 19.3% (280) bps
Baby, Feminine & Family Care net sales increased 5% to $19.7 billion in
fiscal 2022 on a 1% increase in unit volume. Higher pricing increased net
sales by 4%. Favorable mix increased net sales by 1% due to the
disproportionate growth in North America and growth of premium tier
products, both of which have higher than segment-average selling prices.
Unfavorable foreign exchange decreased net sales by 1%. Organic sales
increased 6%. Global market share of the Baby, Feminine & Family Care
segment increased 0.8 points.
• Baby Care net sales increased mid-single digits on unit volume that
was unchanged. Positive impacts of increased pricing and favorable
mix (due to a higher proportion of sales in North America and the
growth of premium pants and taped diaper products, all of which have
higher than category-average selling prices) were partially offset by
unfavorable foreign exchange. Organic sales increased high single
digits. Volume increased high single digits in Latin America (due to
innovation) and increased low single digits in North America (due to
market growth and better on-shelf availability versus competitors),
Europe (due to market growth) and IMEA (due to market growth
versus a prior year impacted by pandemic-related contraction). This
increase was fully offset by a mid-teens decline in Greater China (due
to competitive activity) and a mid-single digit decline in Asia Pacific
(due to market decline). Global market share of the baby care category
increased nearly half a point.
• Feminine Care net sales increased high single digits. Positive impacts
of a low single digit increase in volume, increased pricing and positive
mix (due to a higher proportion of sales in North America and the
growth of premium products, including adult incontinence, both of
which have higher than category-average selling prices) were partially
offset by unfavorable foreign exchange. Organic sales increased double
digits. The volume increase was driven by a high single digit increase
in North America (due to innovation, distribution gains and market
growth) partially offset by a low single digit decrease in IMEA (due to
market decline). Market share of the feminine care category increased
more than a point.
-- 25 of 137 --
24 The Procter & Gamble Company
• Net sales in Family Care, which is predominantly a North American
business, increased low single digits. Positive impacts of a low single
digit increase in volume (due to increased promotional activity and
innovation) and increased pricing were partially offset by increased
promotional spending (versus the prior year with low promotional
activity due to the pandemic) and unfavorable mix (due to
disproportionate growth in the club channel, which have lower than
category-average selling prices). Organic sales also increased low
single digits. North America's share of the family care category
increased nearly a point.
Net earnings in fiscal 2022 decreased 10% to $3.3 billion as the increase in
net sales was more than offset by a 280 basis-point decrease in net earnings
margin. Net earnings margin decreased primarily due to a decrease in gross
margin, partially offset by lower SG&A as a percentage of net sales. Gross
margin decreased primarily due to an increase in commodity and
transportation costs partially offset by increased pricing. SG&A as a
percentage of net sales decreased due to the positive scale benefits of the net
sales increase and reductions in both marketing and overhead costs.
CORPORATE
($ millions) 2022 2021 Change vs. 2021
Net sales $744 $441 69%
Net earnings/(loss) $485 $(387) N/A
Corporate includes certain operating and non-operating activities not
allocated to specific business segments. These include but are not limited to
incidental businesses managed at the corporate level, gains and losses
related to certain divested brands or businesses, impacts from various
financing and investing activities and other impacts related to employee
benefits, asset impairments and restructuring activities including
manufacturing and workforce optimization. Corporate also includes
reconciling items to adjust the accounting policies used within the
reportable segments to U.S. GAAP. The most notable ongoing reconciling
item is income taxes, which adjusts the blended statutory rates that are
reflected in the reportable segments to the overall Company effective tax
rate.
Corporate net sales increased 69% to $744 million in fiscal 2022 due to an
increase in the net sales of the incidental businesses managed at the
corporate level. Corporate net earnings improved by $872 million to $485
million in fiscal 2022 due primarily to the prior year loss on the early debt
extinguishment, a current year gain on the divestiture of a minor business,
net sales growth, current year tax benefits (primarily higher excess tax
benefits of share-based compensation) and lower restructuring charges,
partially offset by increased commodity costs tied to the aforementioned
incidental businesses.
Restructuring Program to Deliver Productivity and Cost Savings
The Company has historically had an ongoing restructuring program with
annual spending in the range of $250 to $500 million. Savings generated
from the Company's
restructuring program are difficult to estimate, given the nature of the
activities, the timing of the execution and the degree of reinvestment. In
fiscal 2022, the Company incurred before tax restructuring costs within the
range of our historical annual ongoing level of $250 to $500 million.
Restructuring accruals of $147 million as of June 30, 2022, are classified as
current liabilities. Approximately 65% of the restructuring charges incurred
in fiscal 2022 either have been or will be settled with cash. Consistent with
our historical policies for ongoing restructuring-type activities, the resulting
charges are funded by and included within Corporate for segment reporting.
In addition to our restructuring programs, we have additional ongoing
savings efforts in our supply chain, marketing and overhead areas that yield
additional benefits to our operating margins.
CASH FLOW, FINANCIAL CONDITION AND LIQUIDITY
We believe our financial condition continues to be of high quality, as
evidenced by our ability to generate substantial cash from operations and to
readily access capital markets at competitive rates.
Operating cash flow provides the primary source of cash to fund operating
needs and capital expenditures. Excess operating cash is used first to fund
shareholder dividends. Other discretionary uses include share repurchases
and acquisitions to complement our portfolio of businesses, brands and
geographies. As necessary, we may supplement operating cash flow with
debt to fund these activities. The overall cash position of the Company
reflects our strong business results and a global cash management strategy
that takes into account liquidity management, economic factors and tax
considerations.
Cash Flow Analysis
($ millions) 2022 2021
Net cash provided by operating
activities $ 16,723 $ 18,371
Net cash provided/(used) by investing
activities (4,424) (2,834)
Net cash used in financing activities (14,876) (21,531)
Adjusted Free Cash Flow 13,792 15,809
Adjusted Free Cash Flow Productivity 93 % 107 %
Operating Cash Flow
Operating cash flow was $16.7 billion in 2022, a 9% decrease versus the
prior year. Net earnings, adjusted for non-cash items (depreciation and
amortization, share-based compensation, deferred income taxes and gain on
sale of assets) generated approximately $17.6 billion of operating cash flow.
Working capital and other impacts used $918 million of operating cash flow
as summarized below.
• An increase in accounts receivable used $694 million of cash primarily
due to sales growth. The number of days
-- 26 of 137 --
The Procter & Gamble Company 25
sales outstanding increased approximately 1 day versus prior year.
• Higher inventory used $1.2 billion of cash, due to business growth and
increased safety stock levels to strengthen supply chain sufficiency
amidst business growth and commodity cost increases. Inventory days
on hand increased approximately 1 day primarily due to these same
factors.
• Accounts payable, accrued and other liabilities generated $1.4 billion
of cash. Accounts payable increased in line with the increase in
inventory and, to a lesser extent, the impact of extended payment terms
with suppliers (see Extended Payment Terms and Supply Chain
Financing below); partially offset by lower marketing spending. Days
payable outstanding increased approximately 1 day versus prior year
due to these same factors.
• Other net operating assets and liabilities used $406 million of cash
primarily driven by the current portion of transitional tax payments due
related to the U.S. Tax Act and pension related contributions, partially
offset by other impacts.
Adjusted Free Cash Flow. We view adjusted free cash flow as an important
non-GAAP measure because it is a factor impacting the amount of cash
available for dividends, share repurchases, acquisitions and other
discretionary investments. It is defined as operating cash flow less capital
expenditures and excluding payments for the transitional tax resulting from
the U.S. Tax Act. Adjusted free cash flow is one of the measures used to
evaluate senior management and determine their at-risk compensation.
Adjusted free cash flow was $13.8 billion in 2022, a decrease of 13% versus
the prior year. The decrease was primarily driven by the decrease in
operating cash flows as discussed above. Adjusted free cash flow
productivity, defined as the ratio of adjusted free cash flow to net earnings
was 93% in 2022.
Extended Payment Terms and Supply Chain Financing. Beginning in
fiscal 2014, in response to evolving market practices, the Company began a
program to negotiate extended payment terms with its suppliers. At the
same time, the Company initiated a Supply Chain Finance program (the
"SCF") with a number of global financial institutions (the "SCF Banks").
Under the SCF, qualifying suppliers may elect to sell their receivables from
the Company to a SCF Bank. These participating suppliers negotiate their
receivables sales arrangements directly with the respective SCF Bank.
While the Company is not party to those agreements, the SCF Banks allow
the participating suppliers to utilize the Company’s creditworthiness in
establishing credit spreads and associated costs. This generally provides the
suppliers with more favorable terms than they would be able to secure on
their own. The Company has no economic interest in a supplier’s decision
to sell a receivable. Once a qualifying supplier elects to participate in the
SCF and reaches an agreement with an SCF Bank, they elect which
individual Company invoices they sell to the SCF bank. However, all the
Company’s payments to participating suppliers are paid to the SCF Bank on
the
invoice due date, regardless of whether the individual invoice is sold by the
supplier to the SCF Bank. The SCF Bank pays the supplier on the invoice
due date for any invoices that were not previously sold to the SCF Bank
under the SCF.
The terms of the Company’s payment obligation are not impacted by a
supplier’s participation in the SCF. Our payment terms with our suppliers
for similar services and materials within individual markets are consistent
between suppliers that elect to participate in the SCF and those that do not
participate. Accordingly, our average days outstanding are not significantly
impacted by the portion of suppliers or related input costs that are included
in the SCF. In addition, the SCF is available to both material suppliers,
where the underlying costs are largely included in Cost of goods sold, and
to service suppliers, where the underlying costs are largely included in
SG&A. As of June 30, 2022, approximately 3% of our global suppliers have
elected to participate in the SCF. Payments to those suppliers during fiscal
year 2022 total approximately $15 billion, which equals approximately 25%
of our total Cost of goods sold and SG&A for the year. For participating
suppliers, we believe substantially all of their receivables with the Company
are sold to the SCF Banks. Accordingly, we would expect that at each
balance sheet date, a similar proportion of amounts originally due to
suppliers would instead be payable to SCF Banks. All outstanding amounts
related to suppliers participating in the SCF are recorded within Accounts
payable in our Consolidated Balance Sheets, and the associated payments
are included in operating activities within our Consolidated Statements of
Cash Flows. As of June 30, 2022 and 2021, the amount due to suppliers
participating in the SCF and included in Accounts payable were
approximately $6 billion and $5 billion, respectively.
Although difficult to project due to market and other dynamics, we
anticipate incremental cash flow benefits from the extended payment terms
with suppliers could increase at a slower rate in fiscal 2023. Future changes
in our suppliers’ financing policies or economic developments, such as
changes in interest rates, general market liquidity or the Company’s credit-
worthiness relative to participating suppliers, could impact suppliers’
participation in the SCF and/or our ability to negotiate extended payment
terms with our suppliers. However, any such impacts are difficult to predict.
Investing Cash Flow
Net investing activities used $4.4 billion of cash in 2022, primarily due to
capital spending and acquisitions. Net investing activities used $2.8 billion
in cash in 2021, mainly due to capital spending.
Capital Spending. Capital expenditures, primarily to support capacity
expansion, innovation and cost efficiencies, were $3.2 billion in 2022 and
$2.8 billion in 2021. Capital spending as a percentage of net sales increased
20 basis points to 3.9% in 2022.
-- 27 of 137 --
26 The Procter & Gamble Company
Acquisitions. Acquisition activity used cash of $1.4 billion in 2022,
primarily related to Beauty acquisitions of Farmacy Beauty, Ouai and
TULA. Acquisition activity used $34 million in 2021, primarily related to a
minor Health Care acquisition.
Proceeds from Divestitures and Other Asset Sales. Proceeds from asset
sales were $110 million in 2022 and $42 million in 2021, primarily from
fixed asset sales and minor brand divestitures.
Investment Securities. Investments provided net cash of $3 million in 2022
primarily from the sale of other investments and used cash of $55 million in
2021 primarily from the purchase of investment securities.
Financing Cash Flow
Net financing activities consumed $14.9 billion of cash in 2022, mainly due
to treasury stock purchases and dividends to shareholders, partially offset by
a net debt increase and the impact of proceeds received from stock option
exercises. Net financing activities consumed $21.5 billion in cash in 2021,
mainly due to treasury stock purchases, dividends to shareholders and a net
debt reduction, partially offset by the impact of stock options.
Dividend Payments. Our first discretionary use of cash is dividend
payments. Dividends per common share increased 9% to $3.5227 per share
in 2022. Total dividend payments to common and preferred shareholders
were $8.8 billion in 2022 and $8.3 billion in 2021. In April 2022, the Board
of Directors declared a 5% increase in our quarterly dividend from $0.8698
to $0.9133 per share on Common Stock and Series A and B Employee
Stock Ownership Plan (ESOP) Convertible Class A Preferred Stock. This is
the 66th consecutive year that our dividend has increased. We have paid a
dividend for 132 consecutive years, every year since our incorporation in
1890.
Long-Term and Short-Term Debt. We maintain debt levels we consider
appropriate after evaluating a number of factors, including cash flow
expectations, cash requirements for ongoing operations, investment and
financing plans (including acquisitions and share repurchase activities) and
the overall cost of capital. Total debt was $31.5 billion as of June 30, 2022,
and $32.0 billion as of June 30, 2021. We generated $1.9 billion from net
debt increases, primarily due to issuance of bonds. In 2021, we used $3.9
billion for net debt reductions, including $512 million for early debt
extinguishment costs related to the early retirement of $2.3 billion of debt.
Treasury Purchases. Total share repurchases were $10.0 billion in 2022
and $11.0 billion in 2021.
Impact of Stock Options and Other. The exercise of stock options and other
financing activities generated $2.0 billion and $1.6 billion of cash in 2022
and 2021, respectively.
Liquidity
At June 30, 2022, our current liabilities exceeded current assets by $11.4
billion, largely due to short-term borrowings under our commercial paper
program. We anticipate being able to support our short-term liquidity and
operating needs largely through cash generated from operations. The
Company regularly assesses its cash needs and the available sources to fund
these needs. As of June 30, 2022, the Company had $5.8 billion of cash and
cash equivalents related to foreign subsidiaries, primarily in various
Western European and Asian countries. We did not have material cash and
cash equivalents related to any country subject to exchange controls that
significantly restrict our ability to access or repatriate the funds. Under
current law, we do not expect restrictions or taxes on repatriation of cash
held outside of the U.S. to have a material effect on our overall liquidity,
financial condition or the results of operations for the foreseeable future.
We utilize short- and long-term debt to fund discretionary items, such as
acquisitions and share repurchases. We have strong short- and long-term
debt ratings, which have enabled, and should continue to enable, us to
refinance our debt as it becomes due at favorable rates in commercial paper
and bond markets. In addition, we have agreements with a diverse group of
financial institutions that, if needed, should provide sufficient funding to
meet short-term financing requirements.
On June 30, 2022, our short-term credit ratings were P-1 (Moody's) and A-
1+ (Standard & Poor's), while our long-term credit ratings were Aa3
(Moody's) and AA- (Standard & Poor's), all with a stable outlook.
We maintain bank credit facilities to support our ongoing commercial paper
program. The current facility is an $8.0 billion facility split between a $3.2
billion five-year facility and a $4.8 billion 364-day facility, which expire in
November 2026 and November 2022, respectively. Both facilities can be
extended for certain periods of time as specified in the terms of the credit
agreement. These facilities are currently undrawn and we anticipate that
they will remain undrawn. These credit facilities do not have cross-default
or ratings triggers, nor do they have material adverse events clauses, except
at the time of signing. In addition to these credit facilities, we have an
automatically effective registration statement on Form S-3 filed with the
SEC that is available for registered offerings of short- or long-term debt
securities. For additional details on debt, see Note 10 to the Consolidated
Financial Statements.
Guarantees and Other Off-Balance Sheet Arrangements
We do not have guarantees or other off-balance sheet financing
arrangements, including variable interest entities, which we believe could
have a material impact on our financial condition or liquidity.
-- 28 of 137 --
The Procter & Gamble Company 27
Contractual Commitments
The following table provides information on the amount and payable date of our contractual commitments as of June 30, 2022.
($ millions) Total Less Than 1 Year 1-3 Years 3-5 Years After 5 Years
RECORDED LIABILITIES
Total debt $ 31,925 $ 8,656 $ 4,190 $ 6,508 $ 12,571
Leases 885 206 314 156 209
U.S. Tax Act transitional charge 1,886 225 983 678 —
OTHER
Interest payments relating to long-term debt 4,813 568 988 868 2,389
Minimum pension funding 493 160 333 — —
Purchase obligations 2,785 1,082 826 452 425
TOTAL CONTRACTUAL COMMITMENTS $ 42,787 $ 10,897 $ 7,634 $ 8,662 $ 15,594
Represents the U.S. federal tax liability associated with the repatriation provisions of the U.S. Tax Act.
Represents future pension payments to comply with local funding requirements. These future pension payments assume the Company continues to meet its future statutory
funding requirements. Considering the current economic environment in which the Company operates, the Company believes its cash flows are adequate to meet the future
statutory funding requirements. The projected payments beyond fiscal year 2025 are not currently determinable.
Primarily reflects future contractual payments under various take-or-pay arrangements entered into as part of the normal course of business. Commitments made under take-
or-pay obligations represent minimum commitments with suppliers and are in line with expected usage. This includes service contracts for information technology, human
resources management and facilities management activities that have been outsourced. While the amounts listed represent contractual obligations, we do not believe it is
likely that the full contractual amount would be paid if the underlying contracts were canceled prior to maturity. In such cases, we generally are able to negotiate new
contracts or cancellation penalties, resulting in a reduced payment. The amounts do not include other contractual purchase obligations that are not take-or-pay arrangements.
Such contractual purchase obligations are primarily purchase orders at fair value that are part of normal operations and are reflected in historical operating cash flow trends.
We do not believe such purchase obligations will adversely affect our liquidity position.
SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES
In preparing our financial statements in accordance with U.S. GAAP, there
are certain accounting policies that may require a choice between
acceptable accounting methods or may require substantial judgment or
estimation in their application. These include revenue recognition, income
taxes, certain employee benefits and goodwill and intangible assets. We
believe these accounting policies, and others set forth in Note 1 to the
Consolidated Financial Statements, should be reviewed as they are integral
to understanding the results of operations and financial condition of the
Company.
The Company has discussed the selection of significant accounting policies
and the effect of estimates with the Audit Committee of the Company's
Board of Directors.
Revenue Recognition
Our revenue is primarily generated from the sale of finished product to
customers. Those sales predominantly contain a single performance
obligation and revenue is recognized at a single point in time when
ownership, risks and rewards transfer, which can be on the date of shipment
or the date of receipt by the customer. Trade promotions, consisting
primarily of customer pricing allowances, in-store merchandising funds,
advertising and other promotional activities and consumer coupons, are
offered through various programs to customers and consumers. Sales are
recorded net of trade promotion spending, which is recognized as incurred
at the time of the sale. Amounts accrued for trade promotions at the end of
a period require estimation, based
on contractual terms, sales volumes and historical utilization and
redemption rates. The actual amounts paid may be different from such
estimates. These differences, which have historically not been significant,
are recognized as a change in management estimate in a subsequent period.
Income Taxes
Our annual tax rate is determined based on our income, statutory tax rates
and the tax impacts of items treated differently for tax purposes than for
financial reporting purposes. Also inherent in determining our annual tax
rate are judgements and assumptions regarding the recoverability of certain
deferred tax balances, primarily net operating loss and other carryforwards,
and our ability to uphold certain tax positions.
Realization of net operating losses and other carryforwards is dependent
upon generating sufficient taxable income in the appropriate jurisdiction
prior to the expiration of the carryforward periods, which involves business
plans, planning opportunities and expectations about future outcomes.
Although realization is not assured, management believes it is more likely
than not that our deferred tax assets, net of valuation allowances, will be
realized.
We operate in multiple jurisdictions with complex tax policy and regulatory
environments. In certain of these jurisdictions, we may take tax positions
that management believes are supportable but are potentially subject to
successful challenge by the applicable taxing authority. These
interpretational differences with the respective
(1)
(2)
(3)
(1)
(2)
(3)
-- 29 of 137 --
28 The Procter & Gamble Company
governmental taxing authorities can be impacted by the local economic and
fiscal environment.
A core operating principle is that our tax structure is based on our business
operating model, such that profits are earned in line with the business
substance and functions of the various legal entities in the jurisdictions
where those functions are performed. However, because of the complexity
of transfer pricing concepts, we may have income tax uncertainty related to
the determination of intercompany transfer prices for our various cross-
border transactions. We have obtained and continue to prioritize the strategy
of seeking advance rulings with tax authorities to reduce this uncertainty.
We estimate that our current portfolio of advance rulings reduces this
uncertainty with respect to over 70% of our global earnings. We evaluate
our tax positions and establish liabilities in accordance with the applicable
accounting guidance on uncertainty in income taxes. We review these tax
uncertainties considering changing facts and circumstances, such as the
progress of tax audits, and adjust them accordingly. We have several audits
in process in various jurisdictions. Although the resolution of these tax
positions is uncertain, based on currently available information, we believe
that the ultimate outcomes will not have a material adverse effect on our
financial position, results of operations or cash flows.
Because there are several estimates and assumptions inherent in calculating
the various components of our tax provision, certain future events such as
changes in tax legislation, geographic mix of earnings, completion of tax
audits or earnings repatriation plans could have an impact on those
estimates and our effective tax rate. See Note 5 to the Consolidated
Financial Statements for additional details on the Company's income taxes.
Employee Benefits
We sponsor various postretirement benefits throughout the world. These
include pension plans, both defined contribution plans and defined benefit
plans, and other postretirement benefit (OPRB) plans, consisting primarily
of health care and life insurance for retirees. For accounting purposes, the
defined benefit pension and OPRB plans require assumptions to estimate
the net projected and accumulated benefit obligations, including the
following variables: discount rate; expected salary increases; certain
employee-related factors, such as turnover, retirement age and mortality;
expected return on assets; and health care cost trend rates. These and other
assumptions affect the annual expense and net obligations recognized for
the underlying plans. Our assumptions reflect our historical experiences and
management's best judgment regarding future expectations. As permitted by
U.S. GAAP, the net amount by which actual results differ from our
assumptions is deferred. If this net deferred amount exceeds 10% of the
greater of plan assets or liabilities, a portion of the deferred amount is
included in expense for the following year. The cost or benefit of plan
changes, such as increasing or decreasing benefits for prior employee
service (prior service cost), is deferred and included in expense on a
straight-line
basis over the average remaining service period of the employees expected
to receive benefits.
The expected return on plan assets assumption impacts our defined benefit
expense since many of our defined benefit pension plans and our primary
OPRB plan are partially funded. The process for setting the expected rates
of return is described in Note 8 to the Consolidated Financial Statements.
For 2022, the average return on assets assumptions for pension plan assets
and OPRB assets was 5.5% and 8.4%, respectively. A change in the rate of
return of 100 basis points for both pension and OPRB assets would impact
annual after-tax benefit/expense by approximately $125 million.
Since pension and OPRB liabilities are measured on a discounted basis, the
discount rate impacts our plan obligations and expenses. Discount rates
used for our U.S. defined benefit pension and OPRB plans are based on a
yield curve constructed from a portfolio of high quality bonds for which the
timing and amount of cash outflows approximate the estimated payouts of
the plan. For our international plans, the discount rates are set by
benchmarking against investment grade corporate bonds rated AA or better.
The average discount rate on the defined benefit pension plans of 3.7%
represents a weighted average of local rates in countries where such plans
exist. A 100 basis point change in the discount rate would impact annual
after-tax benefit expense by approximately $135 million. The average
discount rate on the OPRB plan of 5.0% reflects the higher interest rates
generally applicable in the U.S., which is where most of the plan
participants receive benefits. A 100 basis point change in the discount rate
would impact annual after-tax OPRB expense by approximately $10
million. See Note 8 to the Consolidated Financial Statements for additional
details on our defined benefit pension and OPRB plans.
Goodwill and Intangible Assets
Significant judgment is required to estimate the fair value of our goodwill
reporting units and intangible assets. Accordingly, we typically obtain the
assistance of third-party valuation specialists for significant goodwill
reporting units and intangible assets. The fair value estimates are based on
available historical information and on future expectations. We typically
estimate the fair value of these assets using the income method, which is
based on the present value of estimated future cash flows attributable to the
respective assets. The valuations used to establish and to test goodwill and
intangible assets for impairment are dependent on a number of significant
estimates and assumptions, including macroeconomic conditions, overall
category growth rates, competitive activities, cost containment and margin
progression, Company business plans and the discount rate applied to cash
flows.
Indefinite-lived intangible assets and goodwill are not amortized, but are
tested at least annually for impairment. Our ongoing annual impairment
testing for goodwill and indefinite-lived intangible assets occurs during the
3 months ended December 31. Assumptions used in our impairment
evaluations, such as forecasted growth rates and cost of
-- 30 of 137 --
The Procter & Gamble Company 29
capital, are consistent with internal projections and operating plans. We
believe these estimates and assumptions are reasonable and comparable to
those that would be used by other marketplace participants. Unanticipated
market or macroeconomic events and circumstances may occur, which
could affect the accuracy or validity of the estimates and assumptions. For
example, future changes in the judgments, assumptions and estimates that
are used in our impairment testing for goodwill and indefinite-lived
intangible assets, including discount and tax rates or future cash flow
projections, could result in significantly different estimates of the fair
values. In addition, changes to or a failure to achieve business plans or
deterioration of macroeconomic conditions could result in reduced cash
flows or higher discount rates, leading to a lower valuation that would
trigger an impairment of the goodwill and intangible assets of these
businesses.
We test individual indefinite-lived intangible assets by comparing the book
value of each asset to the estimated fair value. Our impairment testing for
goodwill is performed separately from our impairment testing of indefinite-
lived intangible assets. If the fair value of the reporting unit or indefinite-
lived intangible is less than its carrying value, that difference represents an
impairment.
Determining the useful life of an intangible asset also requires judgment.
Certain brand intangible assets are expected to have indefinite lives based
on their history and our plans to continue to support and build the acquired
brands. Other acquired intangible assets (e.g., certain brands, all customer
relationships, patents and technologies) are expected to have determinable
useful lives. Our assessment as to brands that have an indefinite life and
those that have a determinable life is based on a number of factors including
competitive environment, market share, brand history, underlying product
life cycles, operating plans and the macroeconomic environment of the
countries in which the brands are sold. Determinable-lived intangible assets
are amortized to expense over their estimated lives. An impairment
assessment for determinable-lived intangibles is only required when an
event or change in circumstances indicates that the carrying amount of the
asset may not be recoverable.
Most of our goodwill reporting units are comprised of a combination of
legacy and acquired businesses and as a result have fair value cushions that,
at a minimum, exceed three times their underlying carrying values. Certain
of our goodwill reporting units, in particular Shave Care and Appliances,
are comprised entirely of acquired businesses and as a result have fair value
cushions that are not as high as our legacy businesses. The Appliances
reporting unit has a fair value that significantly exceeds the underlying
carrying value.
Based on our annual impairment testing during the three months ended
December 31, 2021, the Shave Care reporting unit's fair value exceeded its
carrying value by more than 30% and the Gillette indefinite-lived intangible
asset's fair value exceeded its carrying value by approximately 5%.
The most significant assumptions utilized in the determination of the
estimated fair values of the Shave Care reporting unit and the Gillette
indefinite-lived intangible asset are the net sales and earnings growth rates
(including residual growth rates) and discount rate. The residual growth rate
represents the expected rate at which the reporting unit and Gillette brand
are expected to grow beyond the shorter-term business planning period. The
residual growth rate utilized in our fair value estimates is consistent with the
reporting unit and brand operating plans and approximates expected long-
term category market growth rates. The residual growth rate is dependent on
overall market growth rates, the competitive environment, inflation, relative
currency exchange rates and business activities that impact market share. As
a result, the residual growth rate could be adversely impacted by a sustained
deceleration in category growth, grooming habit changes, devaluation of
currencies against the U.S. dollar or an increased competitive environment.
The discount rate, which is consistent with a weighted average cost of
capital that is likely to be expected by a market participant, is based upon
industry required rates of return, including consideration of both debt and
equity components of the capital structure. Our discount rate may be
impacted by adverse changes in the macroeconomic environment, volatility
in the equity and debt markets or other country specific factors, such as
further devaluation of currencies against the U.S. dollar. Spot rates as of the
fair value measurement date are utilized in our fair value estimates for cash
flows outside the U.S. Another key assumption in our fair value
determination of the Gillette indefinite-lived intangible asset is the royalty
rate, which is driven by historical and estimated future profitability of the
underlying Gillette business. The royalty rate may be impacted by
significant adverse changes in long-term operating margins.
While management can and has implemented strategies to address these
events in the past, changes in operating plans or adverse changes in the
business or in the macroeconomic environment in the future could reduce
the underlying cash flows used to estimate fair values and could result in a
decline in fair value that would trigger future impairment charges of the
Shave Care reporting unit's goodwill and indefinite-lived intangible assets.
The duration and severity of the pandemic and the Russia-Ukraine War
could result in a slow-down or a recession or drive inflationary pressures or
foreign currency devaluations in the general economy. These could trigger
additional future impairment charges for the Shave Care reporting unit
goodwill and the Gillette indefinite-lived intangible asset. While we have
concluded that a triggering event did not occur during the quarter ended
June 30, 2022, the Gillette indefinite-lived intangible asset is most
susceptible to future impairment risk. Our assessment of the Gillette
intangible asset assumes the net sales growth rates will continue to recover
from the impact of the pandemic. There continues to be a high level of
uncertainty relating to geopolitical and macroeconomic factors as a result of
the Russia-Ukraine War and the COVID-19 pandemic. Accordingly, there
-- 31 of 137 --
30 The Procter & Gamble Company
continues to be risk related to this key assumption. The continued evolution
of the pandemic and the Russia-Ukraine War could impact the assumptions
utilized in the determination of the estimated fair values of Shave Care
reporting unit and the Gillette indefinite-lived intangible asset that are
significant enough to trigger an impairment. Net sales and earnings growth
rates could be negatively impacted by more prolonged reductions or
changes in demand for our shave care products, which may be caused by,
among other things: the temporary inability of consumers to purchase our
products due to illness, quarantine or other travel restrictions, financial
hardship, changes in the use and frequency of grooming products or by
shifts in demand away from one or more of our higher priced products to
lower priced products or by disruption in the supply chain or operations due
to the evolving Russia-Ukraine War. In addition, relative global and
country/regional macroeconomic factors including the Russia-Ukraine War
could result in additional and prolonged devaluation of other countries’
currencies relative to the U.S. dollar. Finally, the discount rate utilized in
our valuation model could be impacted by changes in the underlying
interest rates and risk premiums included in the determination of the cost of
capital. As of June 30, 2022, the carrying values of the Shave Care goodwill
and the Gillette indefinite-lived intangible asset were $12.3 billion and
$14.1 billion, respectively.
We performed a sensitivity analysis for the Shave Care reporting unit and
the Gillette indefinite-lived intangible asset during our annual impairment
testing, utilizing reasonably possible changes in the assumptions for the
shorter-term and residual growth rates, the discount rate and the royalty rate
to demonstrate the potential impacts to the estimated fair values. The table
below provides, in isolation, the estimated fair value impacts related to a 25
basis point increase in the discount rate, a 25 basis point decrease in our
shorter-term and residual growth rates, or a 50 basis point decrease in our
royalty rate, some of which would result in an impairment of the Gillette
indefinite-lived intangible asset.
Approximate Percent Change in Estimated Fair Value
+25 bps
Discount Rate
-25 bps
Growth Rate
-50 bps Royalty
Rate
Shave Care goodwill
reporting unit (6)% (6)% N/A
Gillette indefinite-lived
intangible asset (6)% (6)% (3)%
In light of the Russia-Ukraine War, we performed an additional sensitivity
analysis for the Shave Care reporting unit and the Gillette indefinite-lived
intangible asset for a range of outcomes, including reduced future cash
flows and no future cash flows in Ukraine and Russia. Under these
scenarios, the Shave Care reporting unit fair value continued to exceed its
carrying value by approximately 30% and the Gillette indefinite-lived
intangible asset’s fair value exceeded or approximated its carrying value.
However, if
the impact of the war were to extend beyond its current scope, there could
be a triggering event for the Gillette indefinite-lived intangible asset that
may cause us to perform an additional impairment assessment for that asset
in a future period that may result in an impairment charge.
See Note 4 to the Consolidated Financial Statements for additional
discussion on goodwill and intangible asset impairment testing results.
New Accounting Pronouncements
Refer to Note 1 to the Consolidated Financial Statements for recently
adopted accounting pronouncements and recently issued accounting
pronouncements not yet adopted as of June 30, 2022.
OTHER INFORMATION
Hedging and Derivative Financial Instruments
As a multinational company with diverse product offerings, we are exposed
to market risks, such as changes in interest rates, currency exchange rates
and commodity prices. We evaluate exposures on a centralized basis to take
advantage of natural exposure correlation and netting. We leverage the
Company's diversified portfolio of exposures as a natural hedge and
prioritize operational hedging activities over financial market instruments.
To the extent we choose to further manage volatility within our financing
operations, as discussed below, we enter into various financial transactions
which we account for using the applicable accounting guidance for
derivative instruments and hedging activities. These financial transactions
are governed by our policies covering acceptable counterparty exposure,
instrument types and other hedging practices. See Note 9 to the
Consolidated Financial Statements for a discussion of our accounting
policies for derivative instruments.
Derivative positions are monitored using techniques including market
valuation, sensitivity analysis and value-at-risk modeling. The tests for
interest rate, currency rate and commodity derivative positions discussed
below are based on the RiskManager™ value-at-risk model using a one-
year horizon and a 95% confidence level. The model incorporates the
impact of correlation (the degree to which exposures move together over
time) and diversification (from holding multiple currency, commodity and
interest rate instruments) and assumes that financial returns are normally
distributed. Estimates of volatility and correlations of market factors are
drawn from the RiskMetrics™ dataset as of June 30, 2022. In cases where
data is unavailable in RiskMetrics™, a reasonable proxy is included.
Our market risk exposures relative to interest rates, currency rates and
commodity prices, as discussed below, have not changed materially versus
the previous reporting period. In addition, we are not aware of any facts or
circumstances that would significantly impact such exposures in the near
term.
Interest Rate Exposure on Financial Instruments. Interest rate swaps are
used to hedge exposures to interest rate movement on underlying debt
obligations. Certain interest rate swaps denominated in foreign currencies
are designated to hedge exposures to currency exchange rate movements on
-- 32 of 137 --
The Procter & Gamble Company 31
our investments in foreign operations. These currency interest rate swaps
are designated as hedges of the Company's foreign net investments.
Based on our interest rate exposure as of and during the year ended June 30,
2022, including derivative and other instruments sensitive to interest rates,
we believe a near-term change in interest rates, at a 95% confidence level
based on historical interest rate movements, would not materially affect our
financial statements.
Currency Rate Exposure on Financial Instruments. Because we
manufacture and sell products and finance operations in a number of
countries throughout the world, we are exposed to the impact on revenue
and expenses of movements in currency exchange rates. Corporate policy
prescribes the range of allowable hedging activity. To manage the exchange
rate risk associated with the financing of our operations, we primarily use
forward contracts and currency swaps with maturities of less than 18
months.
Based on our currency rate exposure on derivative and other instruments as
of and during the year ended June 30, 2022, we believe, at a 95%
confidence level based on historical currency rate movements, the impact
on such instruments of a near-term change in currency rates would not
materially affect our financial statements.
Commodity Price Exposure on Financial Instruments. We use raw
materials that are subject to price volatility caused by weather, supply
conditions, political and economic variables and other unpredictable factors.
We may use futures, options and swap contracts to manage the volatility
related to the above exposures.
As of and during the years ended June 30, 2022, and June 30, 2021, we did
not have any financial commodity hedging activity.
Measures Not Defined By U.S. GAAP
In accordance with the SEC's Regulation S-K Item 10(e), the following
provides definitions of the non-GAAP measures and the reconciliation to
the most closely related GAAP measure. We believe that these measures
provide useful perspective of underlying business trends (i.e., trends
excluding non-recurring or unusual items) and results and provide a
supplemental measure of year-on-year results. The non-GAAP measures
described below are used by management in making operating decisions,
allocating financial resources and for business strategy purposes. These
measures may be useful to investors as they provide supplemental
information about business performance and provide investors a view of our
business results through the eyes of management. These measures are also
used to evaluate senior management and are a factor in determining their at-
risk compensation. These non-GAAP measures are not intended to be
considered by the user in place of the related GAAP measures, but rather as
supplemental information to our business results. These non-GAAP
measures may not be the same as similar measures used by other companies
due to possible differences in method and in the items or events being
adjusted. These measures include:
Organic Sales Growth. Organic sales growth is a non-GAAP measure of
sales growth excluding the impacts of acquisitions, divestitures and foreign
exchange from year-over-year comparisons. We believe this measure
provides investors with a supplemental understanding of underlying sales
trends by providing sales growth on a consistent basis. This measure is used
in assessing achievement of management goals for at-risk compensation.
The following tables provide a numerical reconciliation of organic sales
growth to reported net sales growth:
Year ended June 30,
2022
Net Sales
Growth
Foreign
Exchange
Impact
Acquisition &
Divestiture
Impact/Other Organic Sales
Growth
Beauty 2 % — % — % 2 %
Grooming 2 % 3 % — % 5 %
Health Care 9 % 1 % — % 10 %
Fabric & Home
Care 6 % 2 % — % 8 %
Baby, Feminine &
Family Care 5 % 1 % — % 6 %
TOTAL
COMPANY 5 % 2 % — % 7 %
Acquisition & Divestiture Impact/Other includes the volume and mix impact of
acquisitions and divestitures and rounding impacts necessary to reconcile net
sales to organic sales.
Adjusted Free Cash Flow. Adjusted free cash flow is defined as operating
cash flow less capital spending and transitional tax payments resulting from
the U.S. Tax Act beginning in 2019. Adjusted free cash flow represents the
cash that the Company is able to generate after taking into account planned
maintenance and asset expansion. We view adjusted free cash flow as an
important measure because it is one factor used in determining the amount
of cash available for dividends, share repurchases, acquisitions and other
discretionary investments.
The following table provides a numerical reconciliation of adjusted free
cash flow ($ millions):
Operating
Cash Flow
Capital
Spending
Adjustments to
Operating
Cash Flow
Adjusted Free
Cash Flow
2022 $ 16,723 $ (3,156) $ 225 $ 13,792
2021 $ 18,371 $ (2,787) $ 225 $ 15,809
Adjustments to Operating Cash Flow include transitional tax payments resulting
from the U.S. Tax Act of $225 in 2022 and 2021.
(1)
(1)
(1)
(1)
-- 33 of 137 --
32 The Procter & Gamble Company
Adjusted Free Cash Flow Productivity. Adjusted free cash flow
productivity is defined as the ratio of adjusted free cash flow to net earnings
excluding the charges for early debt extinguishment (which are not
considered part of our ongoing operations). We view adjusted free cash flow
productivity as a useful measure to help investors understand P&G’s ability
to generate cash. Adjusted free cash flow productivity is used by
management in making operating decisions, in allocating financial
resources and for budget planning purposes. This measure is used in
assessing the achievement of management goals for at-risk compensation.
The Company's long-term target is to generate annual adjusted free cash
flow productivity at or above 90 percent.
The following table provides a numerical reconciliation of adjusted free
cash flow productivity ($ millions):
Adjusted
Free Cash
Flow Net
Earnings
Early Debt
Extinguishment
Charges
Net Earnings
Excluding
Adjustments
Adjusted Free
Cash Flow
Productivity
2022 $ 13,792 $ 14,793 $ — $ 14,793 93 %
2021 $ 15,809 $ 14,352 $ 427 $ 14,779 107 %
Core EPS. Core EPS is a measure of the Company's diluted net earnings per share from continuing operations adjusted as indicated. Management views this
non-GAAP measure as a useful supplemental measure of Company performance over time. Core EPS is also used in assessing the achievement of management
goals for at-risk compensation. The table below provides a reconciliation of diluted net earnings per share to Core EPS, including the following reconciling
items:
• Charges for early debt extinguishment: During fiscal year 2021 the Company recorded after tax charges of $427 million ($512 million before tax), due to
the early extinguishment of certain long-term debt. These charges represent the difference between the reacquisition price and the par value of the debt
extinguished.
We do not view the above items to be indicative of underlying business results and its exclusion from Core earnings measures provides a more comparable
measure of year-on-year results. This item is also excluded when evaluating senior management in determining their at-risk compensation.
THE PROCTER & GAMBLE COMPANY AND SUBSIDIARIES
(Amounts in Millions Except Per Share Amounts)
Reconciliation of Non-GAAP Measures
Twelve Months Ended June 30, 2022 Twelve Months Ended June 30, 2021
AS REPORTED (GAAP) AS REPORTED (GAAP) EARLY DEBT
EXTINGUISHMENT NON-GAAP (CORE)
NET EARNINGS ATTRIBUTABLE TO P&G $ 14,742 $ 14,306 $ 427 $ 14,733
Core EPS
DILUTED NET EARNINGS PER COMMON SHARE $ 5.81 $ 5.50 $ 0.16 $ 5.66
Diluted net earnings per share are calculated on Net earnings attributable to Procter & Gamble.
CHANGE IN CURRENT YEAR REPORTED (GAAP) VERSUS NON-GAAP (CORE)
CORE EPS 3 %
Change versus year ago is calculated based on As Reported (GAAP) values for the twelve months ended June 30, 2022, versus the Non-GAAP (Core) values for the twelve months ended June 30, 2021.
Item 7A. Quantitative and Qualitative Disclosures About Market Risk.
The information required by this item is incorporated by reference to the section entitled Other Information under Management's Disclosure and Analysis and
Note 9 to the Consolidated Financial Statements.
(1)
(1)
(1)
(1)
-- 34 of 137 --
The Procter & Gamble Company 33
Item 8. Financial Statements and Supplementary Data.
MANAGEMENT'S REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING
Management is responsible for establishing and maintaining adequate internal control over financial reporting of The Procter & Gamble Company (as defined
in Rule 13a-15(f) under the Securities Exchange Act of 1934, as amended). Our internal control over financial reporting is designed to provide reasonable
assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted
accounting principles in the United States of America.
Strong internal controls is an objective that is reinforced through our Worldwide Business Conduct Manual, which sets forth our commitment to conduct
business with integrity, and within both the letter and the spirit of the law. Our people are deeply committed to our Purpose, Values and Principles, which unite
us in doing what’s right. Our system of internal controls includes written policies and procedures, segregation of duties and the careful selection and
development of employees. Additional key elements of our internal control structure include our Global Leadership Council, which is actively involved in
oversight of the business strategies, initiatives, results and controls, our Disclosure Committee, which is responsible for evaluating disclosure implications of
significant business activities and events, our Board of Directors, which provides strong and effective corporate governance, and our Audit Committee, which
reviews significant accounting policies, financial reporting and internal control matters.
Global Internal Audit performs audits of internal controls over financial reporting as well as broader financial, operational and compliance audits around the
world, provides training and continually improves our internal control processes. The Company’s internal control over financial reporting also includes a robust
Control Self-Assessment Program that is conducted annually on critical financial reporting areas of the Company. Management takes the appropriate action to
correct any identified control deficiencies.
Because of its inherent limitations, any system of internal control over financial reporting, no matter how well designed, may not prevent or detect
misstatements due to the possibility that a control can be circumvented or overridden or that misstatements due to error or fraud may occur that are not
detected. Also, because of changes in conditions, internal control effectiveness may vary over time.
Management assessed the effectiveness of the Company's internal control over financial reporting as of June 30, 2022, using criteria established in Internal
Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) and concluded that the
Company maintained effective internal control over financial reporting as of June 30, 2022, based on these criteria.
Deloitte & Touche LLP, an independent registered public accounting firm, has audited the effectiveness of the Company's internal control over financial
reporting as of June 30, 2022, as stated in their report which is included herein.
/s/ Jon R. Moeller
(Jon R. Moeller)
Chairman of the Board, President and Chief Executive Officer
/s/ Andre Schulten
(Andre Schulten)
Chief Financial Officer
August 5, 2022
-- 35 of 137 --
34 The Procter & Gamble Company
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the shareholders and the Board of Directors of The Procter & Gamble Company
Opinion on the Financial Statements
We have audited the accompanying Consolidated Balance Sheets of The Procter & Gamble Company and subsidiaries (the "Company") as of June 30, 2022
and 2021, the related Consolidated Statements of Earnings, Comprehensive Income, Shareholders’ Equity and Cash Flows, for each of the three years in the
period ended June 30, 2022, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly,
in all material respects, the financial position of the Company as of June 30, 2022 and 2021, and the results of its operations and its cash flows for each of the
three years in the period ended June 30, 2022, in conformity with accounting principles generally accepted in the United States of America.
We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal
control over financial reporting as of June 30, 2022, based on criteria established in Internal Control — Integrated Framework (2013) issued by the Committee
of Sponsoring Organizations of the Treadway Commission and our report dated August 5, 2022, expressed an unqualified opinion on the Company's internal
control over financial reporting.
Basis for Opinion
These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial
statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in
accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable
assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to
assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such
procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating
the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We
believe that our audits provide a reasonable basis for our opinion.
Critical Audit Matter
The critical audit matter communicated below is a matter arising from the current-period audit of the financial statements that was communicated or required to
be communicated to the audit committee and that (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our
especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial
statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on
the accounts or disclosures to which it relates.
Intangible Assets — Gillette Indefinite Lived Intangible Asset — Refer to Notes 1 and 4 to the financial statements
Critical Audit Matter Description
The Company’s evaluation of indefinite lived intangible assets for impairment involves the comparison of the fair value of each indefinite lived intangible asset
to its carrying value. The Company estimates fair value using the income method, which is based on the present value of estimated future cash flows
attributable to the respective assets. This requires management to make significant estimates and assumptions related to forecasts of future net sales and
earnings, including growth rates beyond a 10-year time period, royalty rates, and discount rate. Changes in the assumptions could have a significant impact on
either the fair value, the amount of any impairment charge, or both. The Company performed their annual impairment assessment of the Gillette brand
indefinite lived intangible asset (the “Gillette brand”) as of December 31, 2021. Because the estimated fair value exceeds the carrying value, no impairment
was recorded. As of June 30, 2022, the carrying value of Gillette indefinite lived intangible asset was $14.1 billion.
We identified the Company’s impairment evaluation of the Gillette indefinite lived intangible asset as a critical audit matter because of the significant
judgments made by management to estimate the fair value of the indefinite lived intangible asset. A high degree of auditor judgment and an increased extent of
effort was required when performing audit procedures to evaluate the reasonableness of management’s estimates and assumptions related to the forecasts of
future net sales and earnings as well as the selection of royalty rates and discount rate, including the need to involve our fair value specialists.
How the Critical Audit Matter Was Addressed in the Audit
Our audit procedures related to forecasts of future net sales and earnings and the selection of the royalty rates and discount rate for the Gillette indefinite lived
intangible asset included the following, among others:
-- 36 of 137 --
The Procter & Gamble Company 35
• We tested the effectiveness of controls over indefinite lived intangible assets, including those over the determination of fair value, such as controls related to
management’s development of forecasts of future net sales and earnings, and the selection of royalty rates and discount rate.
• We evaluated management’s ability to accurately forecast net sales and earnings by comparing actual results to management’s historical forecasts.
• We evaluated the reasonableness of management’s forecast of net sales and earnings by comparing the forecasts to:
• Historical net sales and earnings.
• Underlying analysis detailing business strategies and growth plans including consideration of the effects related to the COVID-19 pandemic.
• Internal communications to management and the Board of Directors.
• Forecasted information included in Company press releases as well as in analyst and industry reports for the Company and certain of its peer
companies.
• With the assistance of our fair value specialists, we evaluated the net sales and earnings growth rates, royalty rates, and discount rate by:
• Testing the source information underlying the determination of net sales and earnings growth rates, royalty rates, and discount rate and the
mathematical accuracy of the calculations.
• Developing a range of independent estimates for the discount rate and comparing the discount rate selected by management to that range.
/s/ Deloitte & Touche LLP
Cincinnati, Ohio
August 5, 2022
We have served as the Company’s auditor since 1890.
-- 37 of 137 --
36 The Procter & Gamble Company
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the shareholders and the Board of Directors of The Procter & Gamble Company
Opinion on Internal Control over Financial Reporting
We have audited the internal control over financial reporting of The Procter & Gamble Company and subsidiaries (the "Company") as of June 30, 2022, based
on criteria established in Internal Control — Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission
(COSO). In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of June 30, 2022, based on
criteria established in Internal Control — Integrated Framework (2013) issued by COSO.
We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated
financial statements as of and for the year ended June 30, 2022, of the Company and our report dated August 5, 2022, expressed an unqualified opinion on
those financial statements.
Basis for Opinion
The Company's management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of
internal control over financial reporting, included in the accompanying Management’s Report on Internal Control over Financial Reporting. Our responsibility
is to express an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the
PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and
regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable
assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an
understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating
effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe
that our audit provides a reasonable basis for our opinion.
Definition and Limitations of Internal Control over Financial Reporting
A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and
the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over
financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect
the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit
preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being
made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or
timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of
effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance
with the policies or procedures may deteriorate.
/s/ Deloitte & Touche LLP
Cincinnati, Ohio
August 5, 2022
-- 38 of 137 --
The Procter & Gamble Company 37
Consolidated Statements of Earnings
Amounts in millions except per share amounts; Years ended June 30 2022 2021 2020
NET SALES $ 80,187 $ 76,118 $ 70,950
Cost of products sold 42,157 37,108 35,250
Selling, general and administrative expense 20,217 21,024 19,994
OPERATING INCOME 17,813 17,986 15,706
Interest expense (439) (502) (465)
Interest income 51 45 155
Other non-operating income, net 570 86 438
EARNINGS BEFORE INCOME TAXES 17,995 17,615 15,834
Income taxes 3,202 3,263 2,731
NET EARNINGS 14,793 14,352 13,103
Less: Net earnings attributable to noncontrolling interests 51 46 76
NET EARNINGS ATTRIBUTABLE TO PROCTER & GAMBLE $ 14,742 $ 14,306 $ 13,027
NET EARNINGS PER COMMON SHARE:
Basic $ 6.00 $ 5.69 $ 5.13
Diluted $ 5.81 $ 5.50 $ 4.96
Basic net earnings per common share and Diluted net earnings per common share are calculated on Net earnings attributable to Procter & Gamble.
(1)
(1)
See accompanying Notes to Consolidated Financial Statements.
-- 39 of 137 --
38 The Procter & Gamble Company
Consolidated Statements of Comprehensive Income
Amounts in millions; Years ended June 30 2022 2021 2020
NET EARNINGS $ 14,793 $ 14,352 $ 13,103
OTHER COMPREHENSIVE INCOME/(LOSS), NET OF TAX
Foreign currency translation (net of tax of $515, $(266) and $59, respectively) (1,450) 1,023 (1,083)
Unrealized gains/(losses) on investment securities (net of tax of $1, $5 and $(1), respectively) 5 16 (12)
Unrealized gains/(losses) on defined benefit postretirement plans (net of tax of $1,022, $445 and $(42),
respectively) 2,992 1,386 (150)
TOTAL OTHER COMPREHENSIVE INCOME/(LOSS), NET OF TAX 1,547 2,425 (1,245)
TOTAL COMPREHENSIVE INCOME 16,340 16,777 11,858
Less: Comprehensive income attributable to noncontrolling interests 43 50 60
TOTAL COMPREHENSIVE INCOME ATTRIBUTABLE TO PROCTER & GAMBLE $ 16,297 $ 16,727 $ 11,798
See accompanying Notes to Consolidated Financial Statements.
-- 40 of 137 --
The Procter & Gamble Company 39
Consolidated Balance Sheets
Amounts in millions except stated values; As of June 30 2022 2021
Assets
CURRENT ASSETS
Cash and cash equivalents $ 7,214 $ 10,288
Accounts receivable 5,143 4,725
INVENTORIES
Materials and supplies 2,168 1,645
Work in process 856 719
Finished goods 3,900 3,619
Total inventories 6,924 5,983
Prepaid expenses and other current assets 2,372 2,095
TOTAL CURRENT ASSETS 21,653 23,091
PROPERTY, PLANT AND EQUIPMENT, NET 21,195 21,686
GOODWILL 39,700 40,924
TRADEMARKS AND OTHER INTANGIBLE ASSETS, NET 23,679 23,642
OTHER NONCURRENT ASSETS 10,981 9,964
TOTAL ASSETS $ 117,208 $ 119,307
Liabilities and Shareholders' Equity
CURRENT LIABILITIES
Accounts payable $ 14,882 $ 13,720
Accrued and other liabilities 9,554 10,523
Debt due within one year 8,645 8,889
TOTAL CURRENT LIABILITIES 33,081 33,132
LONG-TERM DEBT 22,848 23,099
DEFERRED INCOME TAXES 6,809 6,153
OTHER NONCURRENT LIABILITIES 7,616 10,269
TOTAL LIABILITIES 70,354 72,653
SHAREHOLDERS' EQUITY
Convertible Class A preferred stock, stated value $1 per share (600 shares authorized) 843 870
Non-Voting Class B preferred stock, stated value $1 per share (200 shares authorized) — —
Common stock, stated value $1 per share (10,000 shares authorized; shares issued: 2022 - 4,009.2, 2021 - 4,009.2) 4,009 4,009
Additional paid-in capital 65,795 64,848
Reserve for ESOP debt retirement (916) (1,006)
Accumulated other comprehensive loss (12,189) (13,744)
Treasury stock, at cost (shares held: 2022 - 1,615.4, 2021 - 1,579.5) (123,382) (114,973)
Retained earnings 112,429 106,374
Noncontrolling interest 265 276
TOTAL SHAREHOLDERS' EQUITY 46,854 46,654
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY $ 117,208 $ 119,307
See accompanying Notes to Consolidated Financial Statements.
-- 41 of 137 --
40 The Procter & Gamble Company
Consolidated Statements of Shareholders' Equity
Dollars in millions except per share
amounts; shares in thousands
Common Stock Preferred
Stock
Additional
Paid-In
Capital
Reserve for
ESOP Debt
Retirement
Accumulated
Other
Comp-rehensive
Income/(Loss) Treasury Stock Retained
Earnings
Non-
controlling
Interest
Total Share-
holders'
Equity Shares Amount
BALANCE JUNE 30, 2019 2,504,751 $4,009 $928 $63,827 ($1,146) ($14,936) ($100,406) $94,918 $385 $47,579
Net earnings 13,027 76 13,103
Other comprehensive income/(loss) (1,229) (16) (1,245)
Dividends and dividend equivalents
($3.0284 per share):
Common (7,551) (7,551)
Preferred (263) (263)
Treasury stock purchases (61,346) (7,405) (7,405)
Employee stock plans 32,603 362 2,212 2,574
Preferred stock conversions 3,738 (31) 5 26 —
ESOP debt impacts 66 108 174
Noncontrolling interest, net (88) (88)
BALANCE JUNE 30, 2020 2,479,746 $4,009 $897 $64,194 ($1,080) ($16,165) ($105,573) $100,239 $357 $46,878
Net earnings 14,306 46 14,352
Other comprehensive income/(loss) 2,421 4 2,425
Dividends and dividend equivalents
($3.2419 per share):
Common (8,020) (8,020)
Preferred (271) (271)
Treasury stock purchases (81,343) (11,009) (11,009)
Employee stock plans 28,001 650 1,586 2,236
Preferred stock conversions 3,302 (27) 4 23 —
ESOP debt impacts 74 120 194
Noncontrolling interest, net (131) (131)
BALANCE JUNE 30, 2021 2,429,706 $4,009 $870 $64,848 ($1,006) ($13,744) ($114,973) $106,374 $276 $46,654
Net earnings 14,742 51 14,793
Other comprehensive income/(loss) 1,555 (8) 1,547
Dividends and dividend equivalents
($3.5227 per share):
Common (8,514) (8,514)
Preferred (281) (281)
Treasury stock purchases (67,088) (10,003) (10,003)
Employee stock plans 28,042 945 1,571 2,516
Preferred stock conversions 3,217 (27) 4 23 —
ESOP debt impacts 90 108 198
Noncontrolling interest, net (2) (54) (56)
BALANCE JUNE 30, 2022 2,393,877 $4,009 $843 $65,795 ($916) ($12,189) ($123,382) $112,429 $265 $46,854
See accompanying Notes to Consolidated Financial Statements.
-- 42 of 137 --
The Procter & Gamble Company 41
Consolidated Statements of Cash Flows
Amounts in millions; Years ended June 30 2022 2021 2020
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING OF YEAR $ 10,288 $ 16,181 $ 4,239
OPERATING ACTIVITIES
Net earnings 14,793 14,352 13,103
Depreciation and amortization 2,807 2,735 3,013
Loss on early extinguishment of debt — 512 —
Share-based compensation expense 528 540 558
Deferred income taxes (402) (258) (596)
Loss/(gain) on sale of assets (85) (16) 7
Change in accounts receivable (694) (342) 634
Change in inventories (1,247) (309) (637)
Change in accounts payable, accrued and other liabilities 1,429 1,391 1,923
Change in other operating assets and liabilities (635) (369) (710)
Other 229 135 108
TOTAL OPERATING ACTIVITIES 16,723 18,371 17,403
INVESTING ACTIVITIES
Capital expenditures (3,156) (2,787) (3,073)
Proceeds from asset sales 110 42 30
Acquisitions, net of cash acquired (1,381) (34) (58)
Purchases of investment securities — (55) —
Proceeds from sales and maturities of investment securities — — 6,151
Change in other investments 3 — (5)
TOTAL INVESTING ACTIVITIES (4,424) (2,834) 3,045
FINANCING ACTIVITIES
Dividends to shareholders (8,770) (8,263) (7,789)
Additions to short-term debt with original maturities of more than three months 10,411 7,675 14,371
Reductions in short-term debt with original maturities of more than three months (11,478) (7,577) (12,984)
Additions/(reductions) in other short-term debt 917 (3,431) 958
Additions to long-term debt 4,385 4,417 4,951
Reductions of long-term debt (2,343) (4,987) (2,447)
Treasury stock purchases (10,003) (11,009) (7,405)
Impact of stock options and other 2,005 1,644 1,978
TOTAL FINANCING ACTIVITIES (14,876) (21,531) (8,367)
EFFECT OF EXCHANGE RATE CHANGES ON CASH, CASH EQUIVALENTS AND RESTRICTED
CASH (497) 101 (139)
CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH (3,074) (5,893) 11,942
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, END OF YEAR $ 7,214 $ 10,288 $ 16,181
SUPPLEMENTAL DISCLOSURE
Cash payments for interest $ 451 $ 531 $ 434
Cash payments for income taxes 3,818 3,822 3,550
Includes early extinguishment of debt costs of $512 in 2021.
(1)
(1)
See accompanying Notes to Consolidated Financial Statements.
-- 43 of 137 --
42 The Procter & Gamble Company
Notes to Consolidated Financial Statements
NOTE 1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Nature of Operations
The Procter & Gamble Company's (the "Company," "Procter & Gamble,"
"we" or "us") business is focused on providing branded consumer packaged
goods of superior quality and value. Our products are sold in approximately
180 countries and territories primarily through mass merchandisers, e-
commerce (including social commerce) channels, grocery stores,
membership club stores, drug stores, department stores, distributors,
wholesalers, specialty beauty stores (including airport duty-free stores),
high-frequency stores, pharmacies, electronics stores and professional
channels. We also sell direct to consumers. We have on-the-ground
operations in approximately 70 countries.
Basis of Presentation
The Consolidated Financial Statements include the Company and its
controlled subsidiaries. Intercompany transactions are eliminated.
Because of a lack of control over Venezuelan subsidiaries caused by a
number of currency and other operating controls and restrictions, our
Venezuelan subsidiaries are not consolidated for any year presented. We
account for those subsidiaries at cost, less impairments, plus or minus
observable price changes.
Beginning in fiscal year 2022, the Company began to present increases and
reductions in short-term debt with maturities of more than three months
separately within the Consolidated Statements of Cash Flows. The
presentation for the twelve months ended June 30, 2021, and June 30, 2020,
have been revised to align with the current period presentation. This change
had no impact on total financing activities, and we have concluded the
change is not material.
Use of Estimates
Preparation of financial statements in conformity with accounting principles
generally accepted in the United States of America (U.S. GAAP) requires
management to make estimates and assumptions that affect the amounts
reported in the Consolidated Financial Statements and accompanying
disclosures. These estimates are based on management's best knowledge of
current events and actions the Company may undertake in the future.
Estimates are used in accounting for, among other items, consumer and
trade promotion accruals, restructuring reserves, pensions, postretirement
benefits, stock options, valuation of acquired intangible assets, useful lives
for depreciation and amortization of long-lived assets, future cash flows
associated with impairment testing for goodwill, indefinite-lived intangible
assets and other long-lived assets, deferred tax assets and liabilities,
uncertain income tax positions and contingencies. Actual results may
ultimately differ from estimates, although management does not generally
believe such differences would materially affect the financial statements in
any individual year. However, regarding
ongoing impairment testing of goodwill and indefinite-lived intangible
assets, significant deterioration in future cash flow projections or other
assumptions used in estimating fair values versus those anticipated at the
time of the initial valuations, could result in impairment charges that
materially affect the financial statements in a given year.
Revenue Recognition
Our revenue is primarily generated from the sale of finished product to
customers. Those sales predominantly contain a single performance
obligation and revenue is recognized at a single point in time when
ownership, risks and rewards transfer, which can be on the date of shipment
or the date of receipt by the customer. A provision for payment discounts
and product return allowances is recorded as a reduction of sales in the
same period the revenue is recognized. The revenue recorded is presented
net of sales and other taxes we collect on behalf of governmental
authorities. The revenue includes shipping and handling costs, which
generally are included in the list price to the customer.
Trade promotions, consisting primarily of customer pricing allowances,
merchandising funds and consumer coupons, are offered through various
programs to customers and consumers. Sales are recorded net of trade
promotion spending, which is recognized as incurred at the time of the sale.
Most of these arrangements have terms of approximately one year. Accruals
for expected payouts under these programs are included as accrued
marketing and promotion in the Accrued and other liabilities line item in the
Consolidated Balance Sheets.
Cost of Products Sold
Cost of products sold is primarily comprised of direct materials and supplies
consumed in the manufacturing of product, as well as manufacturing labor,
depreciation expense and direct overhead expenses necessary to acquire and
convert the purchased materials and supplies into finished products. Cost of
products sold also includes the cost to distribute products to customers,
inbound freight costs, internal transfer costs, warehousing costs and other
shipping and handling activity.
Selling, General and Administrative Expense
Selling, general and administrative expense (SG&A) is primarily comprised
of marketing expenses, selling expenses, research and development costs,
administrative and other indirect overhead costs, depreciation and
amortization expense on non-manufacturing assets and other miscellaneous
operating items. Research and development costs are charged to expense as
incurred and were $2.0 billion in 2022, $1.9 billion in 2021 and $1.8 billion
in 2020. Advertising costs, charged to expense as incurred, include
worldwide television, print, radio, internet and in-store advertising expenses
and were $7.9 billion in 2022, $8.2 billion in 2021 and $7.3 billion in 2020.
Non-advertising related components of the Company's total marketing
spending reported in SG&A include costs associated with consumer
promotions, product sampling and sales aids.
Amounts in millions of dollars except per share amounts or as otherwise specified.
-- 44 of 137 --
The Procter & Gamble Company 43
Other Non-Operating Income, Net
Other non-operating income, net primarily includes net acquisition and
divestiture gains, net non-service impacts related to postretirement benefit
plans, investment income and other non-operating items.
Currency Translation
Financial statements of operating subsidiaries outside the U.S. generally are
measured using the local currency as the functional currency. Adjustments
to translate those statements into U.S. dollars are recorded in Other
comprehensive income (OCI). For subsidiaries operating in highly
inflationary economies, the U.S. dollar is the functional currency. Re-
measurement adjustments for financial statements in highly inflationary
economies and other transactional exchange gains and losses are reflected
in earnings.
Cash Flow Presentation
The Consolidated Statements of Cash Flows are prepared using the indirect
method, which reconciles net earnings to cash flows from operating
activities. Cash flows from foreign currency transactions and operations are
translated at monthly exchange rates for each period. Cash flows from
hedging activities are included in the same category as the items being
hedged. Cash flows from derivative instruments designated as net
investment hedges are classified as financing activities. Realized gains and
losses from non-qualifying derivative instruments used to hedge currency
exposures resulting from intercompany financing transactions are also
classified as financing activities. Cash flows from other derivative
instruments used to manage interest rates, commodity or other currency
exposures are classified as operating activities. Cash payments related to
income taxes are classified as operating activities.
Investments
The Company holds minor equity investments in certain companies over
which we exert significant influence, but do not control the financial and
operating decisions. These are accounted for as equity method investments.
Other equity investments that are not controlled, and over which we do not
have the ability to exercise significant influence, and for which there is a
readily determinable market value, are recorded at fair value, with gains and
losses recorded through net earnings. Equity investments without readily
determinable fair values are measured at cost, less impairments, plus or
minus observable price changes. Equity investments are included as Other
noncurrent assets in the Consolidated Balance Sheets.
The Company also holds highly-liquid investments, primarily money
market funds and time deposits. Such investments are considered cash
equivalents and are included within Cash and cash equivalents in the
Consolidated Balance Sheets.
Inventory Valuation
Inventories are valued at the lower of cost or net realizable value. Product-
related inventories are maintained on the
first-in, first-out method. The cost of spare part inventories is maintained
using the average-cost method.
Property, Plant and Equipment
Property, plant and equipment is recorded at cost reduced by accumulated
depreciation. Depreciation expense is recognized over the assets' estimated
useful lives using the straight-line method. Machinery and equipment
includes office furniture and fixtures (15-year life), computer equipment
and capitalized software (3- to 5-year lives) and manufacturing equipment
(3- to 20-year lives). Buildings are depreciated over an estimated useful life
of 40 years. Estimated useful lives are periodically reviewed and, when
appropriate, changes are made prospectively. When certain events or
changes in operating conditions occur, asset lives may be adjusted and an
impairment assessment may be performed on the recoverability of the
carrying amounts.
Goodwill and Other Intangible Assets
Goodwill and indefinite-lived intangible assets are not amortized but are
evaluated for impairment annually or more often if indicators of a potential
impairment are present. Our annual impairment testing of goodwill is
performed separately from our impairment testing of indefinite-lived
intangible assets.
We have acquired brands that have been determined to have indefinite lives.
We evaluate several factors to determine whether an indefinite life is
appropriate, including the competitive environment, market share, brand
history, underlying product life cycles, operating plans and the
macroeconomic environment of the countries in which the brands are sold.
In addition, when certain events or changes in operating conditions occur,
an additional impairment assessment is performed and indefinite-lived
assets may be adjusted to a determinable life.
The cost of intangible assets with determinable useful lives is amortized to
reflect the pattern of economic benefits consumed, either on a straight-line
or accelerated basis over the estimated periods benefited. Patents,
technology and other intangible assets with contractual terms are generally
amortized over their respective legal or contractual lives. Customer
relationships, brands and other non-contractual intangible assets with
determinable lives are amortized over periods generally ranging from 5 to
30 years. When certain events or changes in operating conditions occur, an
impairment assessment is performed and remaining lives of intangible
assets with determinable lives may be adjusted.
For additional details on goodwill and intangible assets see Note 4.
Amounts in millions of dollars except per share amounts or as otherwise specified.
-- 45 of 137 --
44 The Procter & Gamble Company
Fair Values of Financial Instruments
Certain financial instruments are required to be recorded at fair value.
Changes in assumptions or estimation methods could affect the fair value
estimates; however, we do not believe any such changes would have a
material impact on our financial condition, results of operations or cash
flows. Other financial instruments, including cash equivalents, certain
investments and certain short-term debt, are recorded at cost, which
approximates fair value. The fair values of long-term debt and financial
instruments are disclosed in Note 9.
New Accounting Pronouncements and Policies
In March 2020, the Financial Accounting Standards Board (FASB) issued
Accounting Standards Update (ASU) 2020-04, "Reference Rate Reform
(Topic 848): Facilitation of the Effects of Reference Rate Reform on
Financial Reporting." In January 2021, the FASB issued ASU 2021-01,
"Reference Rate Reform (Topic 848): Scope." The amendments were
effective upon issuance and provide optional expedients and exceptions for
applying generally accepted accounting principles (GAAP) to contracts,
hedging relationships and other transactions affected by reference rate
reform if certain criteria are met. We have completed our evaluation of
significant contracts. Most contracts reviewed will mature prior to the
termination of LIBOR or will be modified to apply a new reference rate,
primarily the Secured Overnight Financing Rate (SOFR) where applicable.
As a result, the guidance has not had, and is not expected to have, a material
impact on the Company's Consolidated Financial Statements.
In November 2021, the FASB issued ASU 2021-10, "Government
Assistance (Topic 832): Disclosures by Business Entities about Government
Assistance". This guidance requires annual disclosures for transactions with
a government authority that are accounted for by applying a grant or
contribution model. These amendments are effective for annual periods
beginning after December 15, 2021, with early adoption permitted. We plan
to adopt the standard for the fiscal year ending June 30, 2023. We are
currently assessing the impact of this guidance and do not expect a material
impact at this time.
No other new accounting pronouncements issued or effective during the
fiscal year or in future years had, or are expected to have, a material impact
on our Consolidated Financial Statements.
NOTE 2
SEGMENT INFORMATION
Under U.S. GAAP, our operating segments are aggregated into five
reportable segments: 1) Beauty, 2) Grooming, 3) Health Care, 4) Fabric &
Home Care and 5) Baby, Feminine & Family Care. Our five reportable
segments are comprised of:
• Beauty: Hair Care (Conditioner, Shampoo, Styling Aids, Treatments);
Skin and Personal Care (Antiperspirant and Deodorant, Personal
Cleansing, Skin Care);
• Grooming: Shave Care (Female Blades & Razors, Male Blades &
Razors, Pre- and Post-Shave Products, Other Shave Care); Appliances
• Health Care: Oral Care (Toothbrushes, Toothpaste, Other Oral Care);
Personal Health Care (Gastrointestinal, Rapid Diagnostics, Respiratory,
Vitamins/Minerals/Supplements, Pain Relief, Other Personal Health
Care);
• Fabric & Home Care: Fabric Care (Fabric Enhancers, Laundry
Additives, Laundry Detergents); Home Care (Air Care, Dish Care,
P&G Professional, Surface Care); and
• Baby, Feminine & Family Care: Baby Care (Baby Wipes, Taped
Diapers and Pants); Feminine Care (Adult Incontinence, Feminine
Care); Family Care (Paper Towels, Tissues, Toilet Paper).
While none of our reportable segments are highly seasonal, components
within certain reportable segments, such as Appliances (Grooming) and
Personal Health Care (Health), are seasonal.
The accounting policies of the segments are generally the same as those
described in Note 1. Differences between these policies and U.S. GAAP
primarily reflect income taxes, which are reflected in the segments using
applicable blended statutory rates. Adjustments to arrive at our effective tax
rate are included in Corporate. In addition, capital expenditures in the
segments are on an accrual basis consistent with the balance sheet.
Adjustments to move from an accrual to cash basis, for purposes of the cash
flow statement, are reflected in Corporate.
Corporate includes certain operating and non-operating activities that are
not reflected in the operating results used internally to measure and evaluate
the businesses, as well as items to adjust management reporting principles
to U.S. GAAP. Operating activities in Corporate include the results of
incidental businesses managed at the corporate level. Operating elements
also include certain employee benefit costs, the costs of certain
restructuring-type activities to maintain a competitive cost structure,
including manufacturing and workforce optimization, asset impairment
charges and other general Corporate items. The non-operating elements in
Corporate primarily include interest expense, certain pension and other
postretirement benefit costs, certain acquisition and divestiture gains,
interest and investing income and other financing costs.
Total assets for the reportable segments include those assets managed by the
reportable segment, primarily inventory, fixed assets and intangible assets.
Other assets, primarily cash, accounts receivable, investment securities and
goodwill, are included in Corporate.
Amounts in millions of dollars except per share amounts or as otherwise specified.
-- 46 of 137 --
The Procter & Gamble Company 45
Our operating segments are comprised of similar product categories.
Operating segments that individually accounted for 5% or more of
consolidated net sales are as follows:
% of Net sales by operating segment
Years ended June 30 2022 2021 2020
Fabric Care 23% 22% 22%
Home Care 12% 12% 11%
Baby Care 10% 10% 11%
Skin and Personal Care 9% 10% 10%
Hair Care 9% 9% 9%
Family Care 9% 9% 9%
Oral Care 8% 8% 8%
Shave Care 6% 7% 7%
Feminine Care 6% 6% 6%
Personal Health Care 6% 5% 5%
All Other 2% 2% 2%
TOTAL 100% 100% 100%
% of Net sales by operating segment excludes sales recorded in Corporate.
Net sales and long-lived assets in the United States and internationally were
as follows (in billions):
Years ended June 30 2022 2021 2020
NET SALES
United States $ 36.5 $ 33.7 $ 31.3
International $ 43.7 $ 42.4 $ 39.7
LONG-LIVED ASSETS
United States $ 10.7 $ 10.1 $ 9.9
International $ 10.5 $ 11.6 $ 10.8
Long-lived assets consists of property, plant and equipment.
No country, other than the United States, exceeds 10% of the Company's
consolidated net sales or long-lived assets.
Our largest customer, Walmart Inc. and its affiliates, accounted for
consolidated net sales of approximately 15% in 2022, 2021 and 2020. No
other customer represents more than 10% of our consolidated net sales.
Global Segment Results Net Sales
Earnings/(Loss)
Before
Income Taxes Net Earnings/(Loss)
Depreciation
and
Amortization
Total
Assets
Capital
Expenditures
BEAUTY 2022 $ 14,740 $ 3,946 $ 3,160 $ 348 $ 6,055 $ 331
2021 14,417 4,018 3,210 333 5,587 386
2020 13,359 3,437 2,737 320 5,531 397
GROOMING 2022 6,587 1,835 1,490 361 20,482 260
2021 6,440 1,728 1,427 378 20,668 291
2020 6,069 1,613 1,329 406 20,589 305
HEALTH CARE 2022 10,824 2,618 2,006 376 7,888 410
2021 9,956 2,398 1,851 372 7,976 364
2020 9,028 2,156 1,652 350 7,726 338
FABRIC & HOME CARE 2022 27,556 5,729 4,386 672 8,567 988
2021 26,014 5,986 4,622 646 8,334 1,006
2020 23,735 5,426 4,154 605 7,745 887
BABY, FEMININE & FAMILY
CARE 2022 19,736 4,267 3,266 826 8,443 932
2021 18,850 4,723 3,629 846 8,666 814
2020 18,364 4,534 3,465 839 8,628 764
CORPORATE 2022 744 (400) 485 224 65,773 235
2021 441 (1,238) (387) 160 68,076 (74)
2020 395 (1,332) (234) 493 70,481 382
TOTAL COMPANY 2022 $ 80,187 $ 17,995 $ 14,793 $ 2,807 $ 117,208 $ 3,156
2021 76,118 17,615 14,352 2,735 119,307 2,787
2020 70,950 15,834 13,103 3,013 120,700 3,073
(1)
(1)
(1)
(1)
Amounts in millions of dollars except per share amounts or as otherwise specified.
-- 47 of 137 --
46 The Procter & Gamble Company
NOTE 3
SUPPLEMENTAL FINANCIAL INFORMATION
The components of property, plant and equipment were as follows:
As of June 30 2022 2021
PROPERTY, PLANT AND EQUIPMENT
Buildings $ 8,087 $ 8,165
Machinery and equipment 35,098 35,367
Land 756 808
Construction in progress 2,756 2,358
TOTAL PROPERTY, PLANT AND
EQUIPMENT 46,697 46,698
Accumulated depreciation (25,502) (25,012)
PROPERTY, PLANT AND
EQUIPMENT, NET $ 21,195 $ 21,686
Selected components of current and noncurrent liabilities were as follows:
As of June 30 2022 2021
ACCRUED AND OTHER LIABILITIES - CURRENT
Marketing and promotion $ 3,878 $ 4,140
Compensation expenses 1,797 2,145
Taxes payable 587 637
Restructuring reserves 147 278
Leases 205 219
Other 2,940 3,104
TOTAL $ 9,554 $ 10,523
OTHER NONCURRENT LIABILITIES
Pension benefits $ 3,139 $ 5,452
U.S. Tax Act transitional tax payable 1,661 1,891
Other retiree benefits 672 922
Uncertain tax positions 752 794
Long term operating leases 595 631
Other 797 579
TOTAL $ 7,616 $ 10,269
RESTRUCTURING PROGRAM
The Company has historically incurred an ongoing annual level of
restructuring-type activities to maintain a competitive cost structure,
including manufacturing and workforce optimization. Before tax costs
incurred under ongoing programs have generally ranged from $250 to $500
annually.
Restructuring costs incurred consist primarily of costs to separate
employees, asset-related costs to exit facilities and other costs. Employee
separation costs relate to severance packages that are primarily voluntary
and the amounts calculated are based on salary levels and past service
periods. Severance costs related to voluntary separations are generally
charged to earnings when the employee accepts the offer. Asset-related costs
consist of both asset write-downs and accelerated depreciation. Asset write-
downs relate to the establishment of a new fair value basis for assets held-
for-sale or for disposal. These assets are written down to the lower of their
current carrying basis or amounts expected to be realized upon disposal,
less minor disposal costs. Charges for accelerated depreciation relate to
long-lived assets that will be taken out of service prior to the end of their
normal service period. These assets relate primarily to manufacturing
consolidations and technology standardizations. The asset-related charges
will not have a significant impact on future depreciation charges. Other
restructuring-type charges primarily include asset removal and termination
of contracts related to supply chain and overhead optimization. The
Company incurred total restructuring charges of $253 and $330 for the
years ended June 30, 2022 and 2021. Of the charges incurred for fiscal year
2022, $67 were recorded in SG&A, $182 in Costs of products sold and $4
in Other non-operating income, net. Of the charges incurred in fiscal year
2021, $176 were recorded in SG&A, $134 in Costs of products sold and
$20 in Other non-operating income, net. The following table presents
restructuring activity for the years ended June 30, 2022 and 2021:
Separations
Asset-Related
Costs Other Total
RESERVE JUNE 30,
2020 $ 285 $ — $ 187 $ 472
Cost incurred and
charged to expense 127 24 179 330
Cost paid/settled (236) (24) (264) (524)
RESERVE JUNE 30,
2021 176 — 102 278
Cost incurred and
charged to expense 88 87 78 253
Cost paid/settled (143) (87) (154) (384)
RESERVE JUNE 30,
2022 $ 121 $ — $ 26 $ 147
Amounts in millions of dollars except per share amounts or as otherwise specified.
-- 48 of 137 --
The Procter & Gamble Company 47
Consistent with our historical policies for ongoing restructuring-type
activities, the restructuring charges are funded by and included within
Corporate for both management and segment reporting. Accordingly, all of
the charges are included within the Corporate reportable segment.
However, for information purposes, the following table summarizes the
total restructuring costs related to our reportable segments:
Years ended June 30 2022 2021 2020
Beauty $ 11 $ 13 $ 54
Grooming 14 25 102
Health Care 32 51 136
Fabric & Home Care 42 22 75
Baby, Feminine & Family Care 83 29 192
Corporate 71 190 223
Total Company $ 253 $ 330 $ 782
Corporate includes costs related to allocated overheads, including charges related to our
Enterprise Markets, Global Business Services and Corporate Functions activities.
Fiscal 2020 includes incremental restructuring charges above ongoing programs and tied to
a multi-year productivity and cost savings plan (announced in 2017) to further reduce
costs in the areas of supply chain, certain marketing activities and overhead expense.
NOTE 4
GOODWILL AND INTANGIBLE ASSETS
The change in the net carrying amount of goodwill by reportable segment was as follows:
Beauty Grooming Health Care
Fabric & Home
Care
Baby, Feminine
& Family Care Total Company
BALANCE AT JUNE 30, 2020 - NET $ 12,902 $ 12,815 $ 7,786 $ 1,841 $ 4,557 $ 39,901
Acquisitions and divestitures — — 16 — — 16
Translation and other 355 280 244 32 96 1,007
BALANCE AT JUNE 30, 2021 - NET 13,257 13,095 8,046 1,873 4,653 40,924
Acquisitions and divestitures 781 — 1 — — 782
Translation and other (742) (524) (458) (65) (217) (2,006)
BALANCE AT JUNE 30, 2022 - NET $ 13,296 $ 12,571 $ 7,589 $ 1,808 $ 4,436 $ 39,700
Grooming goodwill balance is net of $7.9 billion accumulated impairment losses.
Goodwill and indefinite-lived intangibles are tested for impairment at least annually by comparing the estimated fair values of our reporting units and
underlying indefinite-lived intangible assets to their respective carrying values. We typically use an income method to estimate the fair value of these assets,
which is based on forecasts of the expected future cash flows attributable to the respective assets. Significant estimates and assumptions inherent in the
valuations reflect a consideration of other marketplace participants and include the amount and timing of future cash flows (including expected growth rates
and profitability). Significant judgement by management is required to estimate the impact of macroeconomic and other factors on future cash flows, including
those related to the COVID-19 pandemic and the Russia-Ukraine War. Estimates utilized in the projected cash flows include consideration of macroeconomic
conditions, overall category growth rates, competitive activities, cost containment and margin expansion, Company business plans, the underlying product or
technology life cycles, economic barriers to entry, a brand's relative market position and the discount rate applied to the cash flows. Unanticipated market or
macroeconomic events and circumstances may occur, which could affect the accuracy or validity of the estimates and assumptions.
We believe the estimates and assumptions utilized in our impairment testing are reasonable and are comparable to those that would be used by other
marketplace participants. However, actual events and results could differ substantially from those used in our valuations. To the extent such factors result in a
failure to achieve the level of projected cash flows initially used to estimate fair value for purposes of establishing or subsequently impairing the carrying
amount of goodwill and related intangible assets, we may need to record additional non-cash impairment charges in the future.
Goodwill decreased during fiscal 2022 due to currency translation across all reportable segments, partially offset by three acquisitions (Farmacy Beauty, Ouai
and TULA) in the Beauty reportable segment.
(2)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
Amounts in millions of dollars except per share amounts or as otherwise specified.
-- 49 of 137 --
48 The Procter & Gamble Company
Goodwill increased during fiscal 2021 driven by a minor brand acquisition
in the Health Care reportable segment and currency translation across all
reportable segments. Identifiable intangible assets were comprised of:
2022 2021
As of June 30
Gross
Carrying
Amount
Accumulated
Amortization
Gross
Carrying
Amount
Accumulated
Amortization
INTANGIBLE ASSETS WITH DETERMINABLE LIVES
Brands $ 4,299 $ (2,628) $ 3,908 $ (2,546)
Patents and
technology 2,769 (2,609) 2,781 (2,575)
Customer
relationships 1,797 (939) 1,789 (882)
Other 147 (97) 150 (97)
TOTAL $ 9,012 $ (6,273) $ 8,628 $ (6,100)
INTANGIBLE ASSETS WITH INDEFINITE LIVES
Brands 20,940 — 21,114 —
TOTAL $ 29,952 $ (6,273) $ 29,742 $ (6,100)
Amortization expense of intangible assets was as follows:
Years ended June 30 2022 2021 2020
Intangible asset amortization $ 312 $ 318 $ 360
Estimated amortization expense over the next five fiscal years is as follows:
Years ending June 30 2023 2024 2025 2026 2027
Estimated amortization
expense $ 316 $ 305 $ 288 $ 268 $ 258
NOTE 5
INCOME TAXES
Income taxes are recognized for the amount of taxes payable for the current
year and for the impact of deferred tax assets and liabilities, which represent
future tax consequences of events that have been recognized differently in
the financial statements than for tax purposes. Deferred tax assets and
liabilities are established using the enacted statutory tax rates and are
adjusted for any changes in such rates in the period of change.
We have elected to account for the tax effects of Global Intangible Low-
Taxed Income (GILTI) as a current period expense when incurred.
Earnings before income taxes consisted of the following:
Years ended June 30 2022 2021 2020
United States $ 11,698 $ 10,858 $ 10,338
International 6,297 6,757 5,496
TOTAL $ 17,995 $ 17,615 $ 15,834
Income taxes consisted of the following:
Years ended June 30 2022 2021 2020
CURRENT TAX EXPENSE
U.S. federal $ 1,916 $ 1,663 $ 1,266
International 1,333 1,534 1,769
U.S. state and local 355 324 292
TOTAL 3,604 3,521 3,327
DEFERRED TAX EXPENSE/(BENEFIT)
U.S. federal (320) (65) 39
International and other (82) (193) (635)
TOTAL (402) (258) (596)
TOTAL TAX EXPENSE $ 3,202 $ 3,263 $ 2,731
A reconciliation of the U.S. federal statutory income tax rate to our actual
effective income tax rate is provided below:
Years ended June 30 2022 2021 2020
U.S. federal statutory income
tax rate 21.0 % 21.0 % 21.0 %
Country mix impacts of foreign
operations (0.3)% (0.5)% (0.1)%
State income taxes, net of
federal benefit 1.5 % 1.3 % 1.4 %
Excess tax benefits from the
exercise of stock options (2.0)% (1.6)% (1.6)%
Tax benefit from simplification
of legal entity structure — % — % (1.4)%
Foreign derived intangible
income deduction (FDII) (1.1)% (1.0)% (1.0)%
Changes in uncertain tax
positions (0.4)% (0.1)% 0.1 %
Other (0.9)% (0.6)% (1.2)%
EFFECTIVE INCOME TAX
RATE 17.8 % 18.5 % 17.2 %
Country mix impacts of foreign operations includes the effects of foreign
subsidiaries' earnings taxed at rates other than the U.S. statutory rate, the
U.S. tax impacts of non-U.S. earnings repatriation and any net impacts of
intercompany transactions. Changes in uncertain tax positions represent
changes in our net liability related to prior year tax positions. Excess tax
benefits from the exercise of stock options reflect the excess of actual tax
benefits received on employee exercises of stock options and other share-
based payments (which generally equals the income taxable to the
employee) over the amount of tax benefits that were calculated and
recognized based on the grant date fair values of such instruments.
Tax costs charged to shareholders' equity totaled $1,538 for the year ended
June 30, 2022. This primarily relates to the tax effects of certain
adjustments to pension obligations recorded in shareholders' equity and the
tax effects of net investment hedges. Tax costs charged to shareholders'
equity totaled $215 for the year ended June 30, 2021. This primarily relates
to the tax effects of certain adjustments to
Amounts in millions of dollars except per share amounts or as otherwise specified.
-- 50 of 137 --
The Procter & Gamble Company 49
pension obligations recorded in shareholders' equity, partially offset by the
tax effects of net investment hedges.
Prior to the passage of the U.S. Tax Act, the Company asserted that
substantially all of the undistributed earnings of its foreign subsidiaries
were considered indefinitely invested and, accordingly, no deferred taxes
were provided. Pursuant to the provisions of the U.S. Tax Act, these
earnings were subjected to a one-time transition tax. This charge included
taxes for all U.S. income taxes and for the related foreign withholding taxes
for the portion of those earnings which are no longer considered indefinitely
invested. We have not provided deferred taxes on approximately $22 billion
of earnings that are considered indefinitely invested.
A reconciliation of the beginning and ending liability for uncertain tax
positions is as follows:
Years ended June 30 2022 2021 2020
BEGINNING OF YEAR $ 627 $ 485 $ 466
Increases in tax positions for
prior years 102 157 60
Decreases in tax positions for
prior years (118) (34) (21)
Increases in tax positions for
current year 53 60 82
Settlements with taxing
authorities (42) (26) (83)
Lapse in statute of limitations (17) (24) (12)
Currency translation (22) 9 (7)
END OF YEAR $ 583 $ 627 $ 485
Included in the total liability for uncertain tax positions at June 30, 2022, is
$363 that, depending on the ultimate resolution, could impact the effective
tax rate in future periods.
The Company is present in approximately 70 countries and over 150 taxable
jurisdictions and, at any point in time, has 40-50 jurisdictional audits
underway at various stages of completion. We evaluate our tax positions
and establish liabilities for uncertain tax positions that may be challenged
by local authorities and may not be fully sustained, despite our belief that
the underlying tax positions are fully supportable. Uncertain tax positions
are reviewed on an ongoing basis and are adjusted in light of changing facts
and circumstances, including progress of tax audits, developments in case
law and the closing of statutes of limitation. Such adjustments are reflected
in the tax provision as appropriate. We have tax years open ranging from
2010 and forward. We are generally not able to reliably estimate the
ultimate settlement amounts until the close of the audit. Based on
information currently available, we anticipate that over the next 12-month
period, audit activity could be completed related to uncertain tax positions
in multiple jurisdictions for which we have accrued existing
liabilities of approximately $12, including interest and penalties.
We recognize the additional accrual of any possible related interest and
penalties relating to the underlying uncertain tax position in income tax
expense. As of June 30, 2022, 2021 and 2020, we had accrued interest of
$179, $166 and $141 and accrued penalties of $12, $10 and $17,
respectively, which are not included in the above table. During the fiscal
years ended June 30, 2022, 2021 and 2020, we recognized $21, $38 and $39
in interest expense and $2, $6 and $1 in penalties expense, respectively.
Deferred income tax assets and liabilities were comprised of the following:
As of June 30 2022 2021
DEFERRED TAX ASSETS
Loss and other carryforwards 914 1,030
Pension and other retiree benefits $ 740 $ 1,476
Capitalized research & development 646 358
Accrued marketing and promotion 420 424
Stock-based compensation 386 386
Fixed assets 209 223
Lease liabilities 185 196
Unrealized loss on financial and foreign
exchange transactions 138 109
Advance payments 82 —
Inventory 41 31
Accrued interest and taxes 22 22
Other 717 878
Valuation allowances (409) (569)
TOTAL $ 4,091 $ 4,564
DEFERRED TAX LIABILITIES
Goodwill and intangible assets $ 5,783 $ 5,761
Fixed assets 1,542 1,512
Other retiree benefits 1,031 645
Unrealized gain on financial and foreign
exchange transactions 439 111
Lease right-of-use assets 179 191
Foreign withholding tax on earnings to be
repatriated 70 108
Other 244 175
TOTAL $ 9,288 $ 8,503
Net operating loss carryforwards were $2.5 billion at June 30, 2022, and
$3.0 billion at June 30, 2021. If unused, approximately $300 will expire
between 2022 and 2041. The remainder, totaling $2.2 billion at June 30,
2022, may be carried forward indefinitely.
Amounts in millions of dollars except per share amounts or as otherwise specified.
-- 51 of 137 --
50 The Procter & Gamble Company
NOTE 6
EARNINGS PER SHARE
Basic net earnings per common share are calculated by dividing Net earnings attributable to Procter & Gamble less preferred dividends by the weighted
average number of common shares outstanding during the year. Diluted net earnings per common share are calculated by dividing Net earnings attributable to
Procter & Gamble by the diluted weighted average number of common shares outstanding during the year. The diluted shares include the dilutive effect of
stock options and other stock-based awards based on the treasury stock method (see Note 7) and the assumed conversion of preferred stock (see Note 8).
Net earnings per share were calculated as follows:
Years ended June 30 2022 2021 2020
CONSOLIDATED AMOUNTS
Net earnings $ 14,793 $ 14,352 $ 13,103
Less: Net earnings attributable to noncontrolling interests 51 46 76
Net earnings attributable to P&G 14,742 14,306 13,027
Less: Preferred dividends 281 271 263
Net earnings attributable to P&G available to common shareholders (Basic) $ 14,461 $ 14,035 $ 12,764
Net earnings attributable to P&G available to common shareholders (Diluted) $ 14,742 $ 14,306 $ 13,027
SHARES IN MILLIONS
Basic weighted average common shares outstanding 2,410.3 2,465.8 2,487.1
Add effect of dilutive securities:
Stock options and other unvested equity awards 49.5 52.5 52.7
Convertible preferred shares 79.3 82.7 86.0
Diluted weighted average common shares outstanding 2,539.1 2,601.0 2,625.8
NET EARNINGS PER SHARE
Basic $ 6.00 $ 5.69 $ 5.13
Diluted $ 5.81 $ 5.50 $ 4.96
Excludes 11 million, 9 million and 6 million in 2022, 2021 and 2020, respectively, of weighted average stock options outstanding because the exercise price of these options
was greater than the average market value of the Company's stock or their effect was antidilutive.
An overview of preferred shares can be found in Note 8.
Net earnings per share are calculated on Net earnings attributable to Procter & Gamble.
NOTE 7
STOCK-BASED COMPENSATION
The Company has two primary stock-based compensation programs under
which we annually grant stock option, restricted stock unit (RSU) and
performance stock unit (PSU) awards to key managers and directors.
In our main long-term incentive program, key managers can elect to receive
options or RSUs. All options vest after three years and have a 10-year life.
Exercise prices on options are set equal to the market price of the
underlying shares on the date of the grant. RSUs vest and settle in shares of
common stock three years from the grant date.
Senior-level executives participate in an additional long-term incentive
program that awards PSUs, which are paid in shares after the end of a three-
year performance period subject to pre-established performance goals. The
program includes a Relative Total Shareholder Return (R-TSR) modifier
under which the number of shares ultimately granted is also impacted by the
Company's actual
shareholder return relative to our consumer products competitive peer set.
In addition to these long-term incentive programs, we award RSUs to the
Company's non-employee directors and make other minor stock option and
RSU grants to employees for which the terms are not substantially different
from our long-term incentive awards.
A total of 150 million shares of common stock were newly authorized for
issuance under the stock-based compensation plan approved by
shareholders in 2019. A total of 119 million shares remain available for
grant under the 2019 plan.
The Company recognizes stock-based compensation expense based on the
fair value of the awards at the date of grant. The fair value is amortized on a
straight-line basis over the requisite service period. Awards to employees
eligible for retirement prior to the award becoming fully vested are
recognized as compensation expense from the grant date through the date
the employee first becomes eligible to retire
(1)
(2)
(3)
(1)
(2)
(3)
Amounts in millions of dollars except per share amounts or as otherwise specified.
-- 52 of 137 --
The Procter & Gamble Company 51
and/or is no longer required to provide services to earn the award. Stock-
based compensation expense is included as part of Cost of products sold
and SG&A in the Consolidated Statement of Earnings and includes an
estimate of forfeitures, which is based on historical data. Total expense and
related tax benefit were as follows:
Years ended June 30 2022 2021 2020
Stock options $ 271 $ 279 $ 249
RSUs and PSUs 257 261 309
Total stock-based expense $ 528 $ 540 $ 558
Income tax benefit $ 88 $ 102 $ 97
We utilize an industry standard lattice-based valuation model to calculate
the fair value for stock options granted. Assumptions utilized in the model,
which are evaluated and revised to reflect market conditions and
experience, were as follows:
Years ended June 30 2022 2021 2020
Interest rate 0.1 - 1.6 % 0.1 - 0.7 % 1.1 - 1.4 %
Weighted average
interest rate 1.5 % 0.6 % 1.3 %
Dividend yield 2.4 % 2.4 % 2.4 %
Expected volatility 19 % 20 % 17 %
Expected life in
years 9.1 9.2 9.2
Lattice-based option valuation models incorporate ranges of assumptions
for inputs and those ranges are disclosed in the preceding table. Expected
volatilities are based on a combination of historical volatility of our stock
and implied volatilities of call options on our stock. We use historical data
to estimate option exercise and employee termination patterns within the
valuation model. The expected life of options granted is derived from the
output of the option valuation model and represents the average period of
time that options granted are expected to be outstanding. The interest rate
for periods within the contractual life of the options is based on the U.S.
Treasury yield curve in effect at the time of grant.
A summary of options outstanding under the plans as of June 30, 2022, and
activity during the year then ended is presented below:
Options
Options (in
thousands)
Weighted
Average
Exercise Price
Weighted
Average
Contract-ual
Life in Years
Aggregate
Intrinsic Value
Outstanding at July 1,
2021 138,272 $ 91.24
Granted 14,369 141.67
Exercised (25,040) 77.07
Forfeited/expired (886) 116.38
Outstanding at June
30, 2022 126,715 $ 99.59 5.4 $ 5,618
Exercisable 86,992 $ 84.89 4.0 $ 5,124
The following table provides additional information on stock options:
Years ended June 30 2022 2021 2020
Weighted average grant-date fair
value of options granted $ 21.55 $ 20.94 $ 15.60
Intrinsic value of options exercised 1,886 1,401 1,455
Grant-date fair value of options that
vested 177 236 217
Cash received from options exercised 1,930 1,705 2,019
Actual tax benefit from options
exercised 399 292 298
At June 30, 2022, $166 of compensation cost had not yet been recognized
related to stock option grants. That cost is expected to be recognized over a
remaining weighted average period of 1.5 years.
A summary of non-vested RSUs and PSUs outstanding under the plans as of
June 30, 2022, and activity during the year then ended is presented below:
RSUs PSUs
RSU and PSU
awards
Units (in
thousands)
Weighted
Average Grant
Date Fair Value
Units (in
thousands)
Weighted
Average Grant
Date Fair Value
Non-vested at July
1, 2021 3,237 $ 114.68 971 $ 135.24
Granted 1,365 141.13 539 152.69
Vested (1,656) 109.08 (550) 121.62
Forfeited (114) 123.06 (32) 152.89
Non-vested at
June 30, 2022 2,832 $ 130.37 928 $ 152.94
At June 30, 2022, $216 of compensation cost had not yet been recognized
related to RSUs and PSUs. That cost is expected to be recognized over a
remaining weighted average period of 1.6 years. The total grant date fair
value of shares vested was $248, $266 and $264 in 2022, 2021 and 2020,
respectively.
The Company settles equity issuances with treasury shares. We have no
specific policy to repurchase common shares to mitigate the dilutive impact
of options, RSUs and PSUs. However, we have historically made adequate
discretionary purchases, based on cash availability, market trends and other
factors, to offset the impacts of such activity.
NOTE 8
POSTRETIREMENT BENEFITS AND EMPLOYEE STOCK
OWNERSHIP PLAN
We offer various postretirement benefits to our employees.
Defined Contribution Retirement Plans
We have defined contribution plans, which cover the majority of our U.S.
employees, as well as employees in certain other countries. These plans are
fully funded. We generally make contributions to participants' accounts
based on individual base salaries and years of service. Total global defined
contribution expense was $366, $340 and $317 in 2022, 2021 and 2020,
respectively.
Amounts in millions of dollars except per share amounts or as otherwise specified.
-- 53 of 137 --
52 The Procter & Gamble Company
The primary U.S. defined contribution plan (the U.S. DC plan) comprises
the majority of the expense for the Company's defined contribution plans.
For the U.S. DC plan, the contribution rate is set annually. Total
contributions for this plan approximated 14% of total participants' annual
wages and salaries in 2022, 2021 and 2020.
We maintain The Procter & Gamble Profit Sharing Trust (Trust) and
Employee Stock Ownership Plan (ESOP) to provide a portion of the
funding for the U.S. DC plan and other retiree benefits (described below).
Operating details of the ESOP are provided at the end of this Note. The fair
value of the ESOP Series A shares allocated to participants reduces our cash
contribution required to fund the U.S. DC plan.
Defined Benefit Retirement Plans and Other Retiree Benefits
We offer defined benefit retirement pension plans to certain employees.
These benefits relate primarily to plans outside the U.S. and, to a lesser
extent, plans assumed in previous acquisitions covering U.S. employees.
We also provide certain other retiree benefits, primarily health care benefits
for the majority of our U.S. employees who become eligible for these
benefits when they meet minimum age and service requirements. The plans
require cost sharing with retirees and pay a stated percentage of expenses,
reduced by deductibles and other coverages. These benefits are funded by
ESOP Series B shares and certain other assets contributed by the Company.
Obligation and Funded Status. The following provides a reconciliation of benefit obligations, plan assets and funded status of these defined benefit plans:
Pension Benefits Other Retiree Benefits
Years ended June 30 2022 2021 2022 2021
CHANGE IN BENEFIT OBLIGATION
Benefit obligation at beginning of year $ 18,469 $ 17,761 $ 4,206 $ 4,770
Service cost 253 275 86 94
Interest cost 253 240 99 114
Participants' contributions 14 13 67 76
Amendments 5 34 (586) —
Net actuarial loss/(gain) (4,067) (466) (586) (678)
Special termination benefits 4 17 1 2
Currency translation and other (1,720) 1,220 51 64
Benefit payments (603) (625) (268) (236)
BENEFIT OBLIGATION AT END OF YEAR $ 12,608 $ 18,469 $ 3,070 $ 4,206
CHANGE IN PLAN ASSETS
Fair value of plan assets at beginning of year $ 13,041 $ 11,484 $ 6,444 $ 5,618
Actual return on plan assets (1,233) 1,058 526 879
Employer contributions 222 202 37 34
Participants' contributions 14 13 67 76
Currency translation and other (1,268) 909 1 2
ESOP debt impacts — — 82 71
Benefit payments (603) (625) (268) (236)
FAIR VALUE OF PLAN ASSETS AT END OF YEAR $ 10,173 $ 13,041 $ 6,889 $ 6,444
FUNDED STATUS $ (2,435) $ (5,428) $ 3,819 $ 2,238
Primarily non-U.S.-based defined benefit retirement plans.
Primarily U.S.-based other postretirement benefit plans.
For the pension benefit plans, the benefit obligation is the projected benefit obligation. For other retiree benefit plans, the benefit obligation is the accumulated
postretirement benefit obligation.
Represents the net impact of ESOP debt service requirements, which is netted against plan assets for other retiree benefits.
Primarily relates to adjustments in the self-insured U.S. retiree health care program to utilize fully-insured Medicare Advantage Programs beginning in January 2022.
The actuarial gain for pension plans in 2022 was primarily related to increases in discount rates. The actuarial gain for other retiree benefits in 2022 was
primarily related to increases in discount rates, partially offset by unfavorable medical claim experience. The actuarial gain for pension plans in 2021 was
primarily related to increases in discount rates, partially offset by unfavorable actuarial assumptions, including inflation assumptions. The actuarial gain for
other retiree benefits in 2021 was primarily related to favorable medical cost trends.
(1) (2)
(3)
(5)
(3)
(4)
(1)
(2)
(3)
(4)
(5)
Amounts in millions of dollars except per share amounts or as otherwise specified.
-- 54 of 137 --
The Procter & Gamble Company 53
The underfunding of pension benefits is primarily a function of the different funding incentives that exist outside of the U.S. In certain countries, there are no
legal requirements or financial incentives provided to companies to pre-fund pension obligations prior to their due date. In these instances, benefit payments are
typically paid directly from the Company's cash as they become due.
Pension Benefits Other Retiree Benefits
As of June 30 2022 2021 2022 2021
CLASSIFICATION OF NET AMOUNT RECOGNIZED
Noncurrent assets $ 765 $ 88 $ 4,525 $ 3,193
Current liabilities (61) (64) (34) (33)
Noncurrent liabilities (3,139) (5,452) (672) (922)
NET AMOUNT RECOGNIZED $ (2,435) $ (5,428) $ 3,819 $ 2,238
AMOUNTS RECOGNIZED IN ACCUMULATED OTHER COMPREHENSIVE (INCOME)/LOSS (AOCI)
Net actuarial loss/(gain) $ 1,906 $ 4,869 $ (1,093) $ (504)
Prior service cost/(credit) 170 198 (907) (471)
NET AMOUNTS RECOGNIZED IN AOCI $ 2,076 $ 5,067 $ (2,000) $ (975)
The accumulated benefit obligation for all defined benefit pension plans, which differs from the projected obligation in that it excludes the assumption of future
salary increases, was $11.9 billion and $17.3 billion as of June 30, 2022 and 2021, respectively. Information related to the funded status of selected pension and
other retiree benefits at June 30 is as follows:
As of June 30 2022 2021
PENSION PLANS WITH A PROJECTED BENEFIT OBLIGATION IN EXCESS OF PLAN ASSETS
Projected benefit obligation $ 7,989 $ 11,747
Fair value of plan assets 4,789 6,231
PENSION PLANS WITH AN ACCUMULATED BENEFIT OBLIGATION IN EXCESS OF PLAN ASSETS
Accumulated benefit obligation $ 7,191 $ 11,005
Fair value of plan assets 4,433 6,226
OTHER RETIREE BENEFIT PLANS WITH AN ACCUMULATED BENEFIT OBLIGATION IN EXCESS OF PLAN ASSETS
Accumulated benefit obligation $ 808 $ 1,082
Fair value of plan assets 102 127
Amounts in millions of dollars except per share amounts or as otherwise specified.
-- 55 of 137 --
54 The Procter & Gamble Company
Net Periodic Benefit Cost. Components of the net periodic benefit cost were as follows:
Pension Benefits Other Retiree Benefits
Years ended June 30 2022 2021 2020 2022 2021 2020
AMOUNTS RECOGNIZED IN NET PERIODIC BENEFIT COST/(CREDIT)
Service cost $ 253 $ 275 $ 247 $ 86 $ 94 $ 100
Interest cost 253 240 276 99 114 160
Expected return on plan assets (684) (783) (740) (564) (508) (473)
Amortization of net actuarial loss 337 423 340 11 47 68
Amortization of prior service cost/(credit) 28 25 25 (107) (60) (48)
Amortization of net actuarial (gain)/loss due to settlements (5) 5 7 — — —
Special termination benefits 4 17 11 1 2 2
GROSS BENEFIT COST/(CREDIT) 186 202 166 (474) (311) (191)
Dividends on ESOP preferred stock — — — — (8) (19)
NET PERIODIC BENEFIT COST/(CREDIT) $ 186 $ 202 $ 166 $ (474) $ (319) $ (210)
CHANGE IN PLAN ASSETS AND BENEFIT OBLIGATIONS RECOGNIZED IN AOCI
Net actuarial loss/(gain) - current year $ (2,150) $ (741) $ (548) $ (1,049)
Prior service cost/(credit) - current year 5 34 (586) —
Amortization of net actuarial loss (337) (423) (11) (47)
Amortization of prior service (cost)/credit (28) (25) 107 60
Amortization of net actuarial loss/(gain) due to settlements 5 (5) — —
Currency translation and other (486) 367 13 —
TOTAL CHANGE IN AOCI (2,991) (793) (1,025) (1,036)
NET AMOUNTS RECOGNIZED IN PERIODIC BENEFIT
COST/(CREDIT) AND AOCI $ (2,805) $ (591) $ (1,499) $ (1,355)
The service cost component of the net periodic benefit cost is included in the Consolidated Statements of Earnings in Cost of products sold and SG&A. All
other components are included in the Consolidated Statements of Earnings in Other non-operating income/(expense), net, unless otherwise noted.
Assumptions. We determine our actuarial assumptions on an annual basis. These assumptions are weighted to reflect each country that may have an impact on
the cost of providing retirement benefits. The weighted average assumptions used to determine benefit obligations recorded on the Consolidated Balance Sheets
as of June 30, 2022 and 2021, were as follows:
Pension Benefits Other Retiree Benefits
As of June 30 2022 2021 2022 2021
Discount rate 3.7 % 1.7 % 5.0 % 3.2 %
Rate of compensation increase 2.8 % 2.7 % N/A N/A
Interest crediting rate for cash balance plans 4.3 % 4.4 % N/A N/A
Health care cost trend rates assumed for next year N/A N/A 6.4 % 6.4 %
Rate to which the health care cost trend rate is assumed to decline (ultimate trend rate) N/A N/A 4.5 % 4.5 %
Year that the rate reaches the ultimate trend rate N/A N/A 2028 2028
Determined as of end of fiscal year.
(1)
(1)
Amounts in millions of dollars except per share amounts or as otherwise specified.
-- 56 of 137 --
The Procter & Gamble Company 55
The weighted average assumptions used to determine net benefit cost recorded on the Consolidated Statement of Earnings for the years ended June 30 were as
follows:
Pension Benefits Other Retiree Benefits
Years ended June 30 2022 2021 2020 2022 2021 2020
Discount rate 1.7 % 1.5 % 1.9 % 3.2 % 3.1 % 3.7 %
Expected return on plan assets 5.5 % 6.5 % 6.6 % 8.4 % 8.4 % 8.4 %
Rate of compensation increase 2.7 % 2.5 % 2.6 % N/A N/A N/A
Interest crediting rate for cash balance plans 4.4 % 4.4 % 4.4 % N/A N/A N/A
Determined as of beginning of fiscal year.
For plans that make up the majority of our obligation, the Company calculates the benefit obligation and the related impacts on service and interest costs using
specific spot rates along the corporate bond yield curve. For the remaining plans, the Company determines these amounts utilizing a single weighted average
discount rate derived from the corporate bond yield curve used to measure the plan obligations.
Several factors are considered in developing the estimate for the long-term expected rate of return on plan assets. For the defined benefit retirement plans, these
factors include historical rates of return of broad equity and bond indices and projected long-term rates of return obtained from pension investment consultants.
The expected long-term rates of return for plan assets are 8 - 9% for equities and 3 - 5% for bonds. For other retiree benefit plans, the expected long-term rate
of return reflects that the assets are comprised primarily of Company stock. The expected rate of return on Company stock is based on the long-term projected
return of 8.5% and reflects the historical pattern of returns.
Plan Assets. Our investment objective for defined benefit retirement plan assets is to meet the plans' benefit obligations and to improve plan self-sufficiency for
future benefit obligations. The investment strategies focus on asset class diversification, liquidity to meet benefit payments and an appropriate balance of long-
term investment return and risk. Target ranges for asset allocations are determined by assessing different investment risks and matching the actuarial
projections of the plans' future liabilities and benefit payments with current as well as expected long-term rates of return on the assets, taking into account
investment return volatility and correlations across asset classes. Plan assets are diversified across several investment managers and are generally invested in
liquid funds that are selected to track broad market equity and bond indices. Investment risk is carefully controlled with plan assets rebalanced to target
allocations on a periodic basis and with continual monitoring of investment managers' performance relative to the investment guidelines established with each
investment manager.
Our target asset allocation for the year ended June 30, 2022, and actual asset allocation by asset category as of June 30, 2022 and 2021, were as follows:
Target Asset Allocation Actual Asset Allocation at June 30
Pension Benefits Other Retiree
Benefits
Pension Benefits Other Retiree Benefits
Asset Category 2022 2021 2022 2021
Cash — % 2 % 1 % 1 % 2 % 2 %
Debt securities 61 % 2 % 58 % 59 % 1 % 2 %
Equity securities 39 % 96 % 41 % 40 % 97 % 96 %
TOTAL 100 % 100 % 100 % 100 % 100 % 100 %
(1)
(1)
Amounts in millions of dollars except per share amounts or as otherwise specified.
-- 57 of 137 --
56 The Procter & Gamble Company
The following table sets forth the fair value of the Company's plan assets as of June 30, 2022 and 2021, segregated by level within the fair value hierarchy
(refer to Note 9 for further discussion on the fair value hierarchy and fair value principles). Investments valued using net asset value as a practical expedient are
not valued using the fair value hierarchy, but rather valued using the net asset value reported by the managers of the funds and as supported by the unit prices of
actual purchase and sale transactions.
Pension Benefits Other Retiree Benefits
As of June 30
Fair Value Hierarchy
Level 2022 2021 Fair Value Hierarchy
Level 2022 2021
ASSETS AT FAIR VALUE
Cash and cash equivalents 1 $ 78 $ 82 1 $ 130 $ 131
Company common stock — — 1 319 275
Company preferred stock — — 2 6,340 5,911
Fixed income securities 2 1,545 1,931 2 — 3
Insurance contracts 3 94 111 — —
TOTAL ASSETS IN THE FAIR VALUE
HIERARCHY 1,717 2,124 6,789 6,320
Investments valued at net asset value 8,456 10,917 100 124
TOTAL ASSETS AT FAIR VALUE $ 10,173 13,041 $ 6,889 6,444
Company preferred stock is valued based on the value of Company common stock and is presented net of ESOP debt discussed below.
Fixed income securities, classified as Level 2, are estimated by using pricing models or quoted prices of securities with similar characteristics.
Fair values of insurance contracts are valued based on either their cash equivalent value or models that project future cash flows and discount the future amounts to a
present value using market-based observable inputs, including credit risk and interest rate curves. The activity for Level 3 assets is not significant for all years presented.
Investments valued using net asset value as a practical expedient are primarily equity and fixed income collective funds.
Cash Flows. Management's best estimate of cash requirements and
discretionary contributions for the defined benefit retirement plans and
other retiree benefit plans for the year ending June 30, 2023, is $244 and
$47, respectively. Expected contributions are dependent on many variables,
including the variability of the market value of the plan assets as compared
to the benefit obligation and other market or regulatory conditions. In
addition, we take into consideration our business investment opportunities
and resulting cash requirements. Accordingly, actual funding may differ
significantly from current estimates.
Total benefit payments expected to be paid to participants, which include
payments funded from the Company's assets and payments from the plans
are as follows:
Years ending June 30
Pension
Benefits Other Retiree
Benefits
EXPECTED BENEFIT PAYMENTS
2023 $ 571 $ 177
2024 564 186
2025 590 190
2026 585 193
2027 601 198
2028 - 2032 3,459 1,076
Employee Stock Ownership Plan
We maintain the ESOP to provide funding for certain employee benefits
discussed in the preceding paragraphs.
The ESOP borrowed $1.0 billion in 1989 and the proceeds were used to
purchase Series A ESOP Convertible Class A Preferred Stock to fund a
portion of the U.S. DC plan. Principal and interest requirements of the
borrowing were paid by the Trust from dividends on the preferred shares
and from advances provided by the Company. The original borrowing of
$1.0 billion has been repaid in full, and advances from the Company of $15
remain outstanding at June 30, 2022. Each share is convertible at the option
of the holder into one share of the Company's common stock. The dividend
for the current year was equal to the common stock dividend of $3.52 per
share. The liquidation value is $6.82 per share.
(1)
(2)
(3)
(4)
(1)
(2)
(3)
(4)
Amounts in millions of dollars except per share amounts or as otherwise specified.
-- 58 of 137 --
The Procter & Gamble Company 57
In 1991, the ESOP borrowed an additional $1.0 billion. The proceeds were
used to purchase Series B ESOP Convertible Class A Preferred Stock to
fund a portion of retiree health care benefits. These shares, net of the
ESOP's debt, are considered plan assets of the other retiree benefits plan
discussed above. The original borrowings of $1.0 billion were repaid in
2021. Debt service requirements were funded by preferred stock dividends,
cash contributions and advances provided by the Company, of which $901
are outstanding at June 30, 2022. Each share is convertible at the option of
the holder into one share of the Company's common stock. The dividend for
the current year was equal to the common stock dividend of $3.52 per share.
The liquidation value is $12.96 per share.
Our ESOP accounting practices are consistent with current ESOP
accounting guidance, including the permissible continuation of certain
provisions from prior accounting guidance. ESOP debt, which was
guaranteed by the Company, was recorded as debt with an offset to the
Reserve for ESOP debt retirement, which is presented within Shareholders'
equity. Advances to the ESOP by the Company are recorded as an increase
in the Reserve for ESOP debt retirement. Interest incurred on the ESOP debt
was recorded as Interest expense. Dividends on all preferred shares are
charged to Retained earnings.
The series A and B preferred shares of the ESOP are allocated to employees
based on debt service requirements. The number of preferred shares
outstanding at June 30 was as follows:
Shares in thousands 2022 2021 2020
Allocated 25,901 27,759 29,591
Unallocated 1,123 1,769 2,479
TOTAL SERIES A 27,024 29,528 32,070
Allocated 30,719 29,203 27,894
Unallocated 20,120 22,349 24,418
TOTAL SERIES B 50,839 51,552 52,312
For purposes of calculating diluted net earnings per common share, the
preferred shares held by the ESOP are considered converted from inception.
NOTE 9
RISK MANAGEMENT ACTIVITIES AND FAIR VALUE
MEASUREMENTS
As a multinational company with diverse product offerings, we are exposed
to market risks, such as changes in interest rates, currency exchange rates
and commodity prices. We evaluate exposures on a centralized basis to take
advantage of natural exposure correlation and netting. To the extent we
choose to manage volatility associated with the net exposures, we enter into
various financial transactions that we account for using the applicable
accounting guidance for derivative instruments and hedging activities.
These financial transactions are governed by our policies covering
acceptable counterparty exposure, instrument types and other hedging
practices.
If the Company elects to do so and if the instrument meets certain specified
accounting criteria, management designates derivative instruments as cash
flow hedges, fair value hedges or net investment hedges. We record
derivative instruments at fair value and the accounting for changes in the
fair value depends on the intended use of the derivative, the resulting
designation and the effectiveness of the instrument in offsetting the risk
exposure it is designed to hedge. We generally have a high degree of
effectiveness between the exposure being hedged and the hedging
instrument.
Credit Risk Management
We have counterparty credit guidelines and normally enter into transactions
with investment grade financial institutions, to the extent commercially
viable. Counterparty exposures are monitored daily and downgrades in
counterparty credit ratings are reviewed on a timely basis. We have not
incurred, and do not expect to incur, material credit losses on our risk
management or other financial instruments.
Substantially all of the Company's financial instruments used in hedging
transactions are governed by industry standard netting and collateral
agreements with counterparties. If the Company's credit rating were to fall
below the levels stipulated in the agreements, the counterparties could
demand either collateralization or termination of the arrangements. The
aggregate fair value of the instruments covered by these contractual features
that are in a net liability position as of June 30, 2022, was not material. The
Company has not been required to post collateral as a result of these
contractual features.
Interest Rate Risk Management
Our policy is to manage interest cost using a mixture of fixed-rate and
variable-rate debt. To manage this risk in a cost-efficient manner, we enter
into interest rate swaps whereby we agree to exchange with the
counterparty, at specified intervals, the difference between fixed and
variable interest amounts calculated by reference to a notional amount.
We designate certain interest rate swaps on fixed rate debt that meet specific
accounting criteria as fair value hedges. For fair value hedges, the changes
in the fair value of both the hedging instruments and the underlying debt
obligations are immediately recognized in earnings.
Foreign Currency Risk Management
We manufacture and sell our products and finance our operations in a
number of countries throughout the world. As a result, we are exposed to
movements in foreign currency exchange rates. We leverage the Company’s
diversified portfolio of exposures as a natural hedge. In certain cases, we
enter into non-qualifying foreign currency contracts to hedge certain
balance sheet items subject to revaluation. The change in fair value of these
instruments and the underlying exposure are both immediately recognized
in earnings.
Amounts in millions of dollars except per share amounts or as otherwise specified.
-- 59 of 137 --
58 The Procter & Gamble Company
To manage exchange rate risk related to our intercompany financing, we
primarily use forward contracts and currency swaps. The change in fair
value of these non-qualifying instruments is immediately recognized in
earnings, substantially offsetting the foreign currency mark-to-market
impact of the related exposure.
Net Investment Hedging
We hedge certain net investment positions in foreign subsidiaries. To
accomplish this, we either borrow directly in foreign currencies and
designate all or a portion of the foreign currency debt as a hedge of the
applicable net investment position or we enter into foreign currency swaps
that are designated as hedges of net investments. Changes in the fair value
of these instruments are recognized in the Foreign Currency Translation
component of OCI and offset the change in the value of the net investment
being hedged. The time value component of the net investment hedge
currency swaps is excluded from the assessment of hedge effectiveness.
Changes in the fair value of the swap, including changes in the fair value of
the excluded time value component, are recognized in OCI and offset the
value of the underlying net assets. The time value component is
subsequently reported in income on a systematic basis.
Commodity Risk Management
Certain raw materials used in our products or production processes are
subject to price volatility caused by weather, supply conditions, political
and economic variables and other unpredictable factors. As of and during
the years ended June 30, 2022 and 2021, we did not have any material
financial commodity hedging activity.
Insurance
We self-insure for most insurable risks. However, we purchase insurance for
Directors and Officers Liability and
certain other coverage where it is required by law or by contract.
Fair Value Hierarchy
Accounting guidance on fair value measurements for certain financial assets
and liabilities requires that financial assets and liabilities carried at fair
value be classified and disclosed in one of the following categories:
• Level 1: Quoted market prices in active markets for identical assets or
liabilities.
• Level 2: Observable market-based inputs or unobservable inputs that
are corroborated by market data.
• Level 3: Unobservable inputs reflecting the reporting entity's own
assumptions or external inputs from inactive markets.
When applying fair value principles in the valuation of assets and liabilities,
we are required to maximize the use of quoted market prices and minimize
the use of unobservable inputs. The Company has not changed its valuation
techniques used in measuring the fair value of any financial assets or
liabilities during the year.
When active market quotes are not available for financial assets and
liabilities, we use industry standard valuation models. Where applicable,
these models project future cash flows and discount the future amounts to a
present value using market-based observable inputs including credit risk,
interest rate curves and forward and spot prices for currencies. In
circumstances where market-based observable inputs are not available,
management judgment is used to develop assumptions to estimate fair
value.
Assets and Liabilities Measured at Fair Value
Cash equivalents were $6.0 billion and $9.1 billion as of June 30, 2022 and 2021, respectively, and are classified as Level 1 within the fair value hierarchy.
Other investments had a fair value of $140 and $192 as of June 30, 2022 and 2021, respectively, including equity securities of $113 and $163 as of June 30,
2022 and 2021, respectively, and are presented in Other noncurrent assets. Investments are measured at fair value and primarily classified as Level 1 and Level
2 within the fair value hierarchy. Level 1 are based on quoted market prices in active markets for identical assets, and Level 2 are based on quoted market
prices for similar investments. There are no material investment balances classified as Level 3 within the fair value hierarchy or using net asset value as a
practical expedient. Unrealized gains/(losses) on equity securities were $(45) and $69 for the fiscal years ended June 30, 2022 and 2021, respectively, and are
recognized in the Consolidated Statements of Earnings in Other non-operating income, net.
The fair value of long-term debt was $25.7 billion and $28.8 billion as of June 30, 2022 and 2021, respectively. This includes the current portion of long-term
debt instruments ($3.6 billion as of June 30, 2022 and 2021). Certain long-term debt (debt designated as a fair value hedge) is recorded at fair value. All other
long-term debt is recorded at amortized cost, but is measured at fair value for disclosure purposes. We consider our debt to be Level 2 in the fair value
hierarchy. Fair values are generally estimated based on quoted market prices for identical or similar instruments.
Amounts in millions of dollars except per share amounts or as otherwise specified.
-- 60 of 137 --
The Procter & Gamble Company 59
Disclosures about Financial Instruments
The notional amounts and fair values of financial instruments used in hedging transactions as of June 30, 2022 and 2021, are as follows:
Notional Amount Fair Value Asset Fair Value (Liability)
As of June 30 2022 2021 2022 2021 2022 2021
DERIVATIVES IN FAIR VALUE HEDGING RELATIONSHIPS
Interest rate contracts $ 4,972 $ 7,415 $ 3 $ 146 $ (307) $ —
DERIVATIVES IN NET INVESTMENT HEDGING RELATIONSHIPS
Foreign currency interest rate contracts $ 7,943 $ 8,484 $ 561 $ 89 $ (1) $ (94)
TOTAL DERIVATIVES DESIGNATED AS HEDGING
INSTRUMENTS $ 12,915 $ 15,899 $ 564 $ 235 $ (308) $ (94)
DERIVATIVES NOT DESIGNATED AS HEDGING INSTRUMENTS
Foreign currency contracts $ 5,625 $ 5,060 $ 6 $ 20 $ (61) $ (22)
TOTAL DERIVATIVES AT FAIR VALUE $ 18,540 $ 20,959 $ 570 $ 255 $ (369) $ (116)
All derivative assets are presented in Prepaid expenses and other current assets or Other noncurrent assets. All derivative liabilities are presented in Accrued
and other liabilities or Other noncurrent liabilities.
The fair value of the interest rate derivative asset/liability directly offsets the cumulative amount of the fair value hedging adjustment included in the carrying
amount of the underlying debt obligation. The carrying amount of the underlying debt obligation, which includes the unamortized discount or premium and the
fair value adjustment, was $4.7 billion and $7.5 billion as of June 30, 2022 and 2021, respectively. In addition to the foreign currency derivative contracts
designated as net investment hedges, certain of our foreign currency denominated debt instruments are designated as net investment hedges. The carrying value
of those debt instruments designated as net investment hedges, which includes the adjustment for the foreign currency transaction gain or loss on those
instruments, was $11.2 billion and $12.0 billion as of June 30, 2022 and 2021, respectively. The decrease in the notional balance of interest rate contracts was
primarily due to the maturity of interest rate swaps that were associated with multiple bonds maturing in the period.
All of the Company's derivative assets and liabilities are measured at fair value that is derived from observable market data, including interest rate yield curves
and foreign exchange rates, and are classified as Level 2 within the fair value hierarchy. There was no significant activity within the Level 3 assets and
liabilities during the periods presented. There were no significant assets or liabilities that were re-measured at fair value on a non-recurring basis during the
years ended June 30, 2022 and 2021.
Amounts in millions of dollars except per share amounts or as otherwise specified.
-- 61 of 137 --
60 The Procter & Gamble Company
Before tax gains/(losses) on our financial instruments in hedging
relationships are categorized as follows:
Amount of Gain/(Loss) Recognized in OCI on
Derivatives
Years ended June 30 2022 2021
DERIVATIVES IN NET INVESTMENT HEDGING
RELATIONSHIPS
Foreign currency interest rate
contracts $ 1,033 $ (232)
For the derivatives in net investment hedging relationships, the amount of gain
excluded from effectiveness testing, which was recognized in earnings, was
$73 and $60 for the fiscal years ended June 30, 2022 and 2021, respectively.
In addition to the foreign currency derivative contracts designated as net
investment hedges, certain of our foreign currency denominated debt
instruments are designated as net investment hedges. The amount of gain/(loss)
recognized in AOCI for such instruments was $1,639 and $(918), for the fiscal
years ended June 30, 2022 and 2021, respectively.
Amount of Gain/(Loss) Recognized in
Earnings
Years ended June 30 2022 2021
DERIVATIVES IN FAIR VALUE HEDGING RELATIONSHIPS
Interest rate contracts $ (450) $ (123)
DERIVATIVES NOT DESIGNATED AS HEDGING
INSTRUMENTS
Foreign currency contracts $ (149) $ 296
The gain/(loss) on the derivatives in fair value hedging relationships is fully
offset by the mark-to-market impact of the related exposure. These are both
recognized in the Consolidated Statement of Earnings in Interest Expense.
The gain/(loss) on derivatives not designated as hedging instruments is
substantially offset by the currency mark-to-market of the related exposure.
These are both recognized in the Consolidated Statements of Earnings in
SG&A.
NOTE 10
SHORT-TERM AND LONG-TERM DEBT
As of June 30 2022 2021
DEBT DUE WITHIN ONE YEAR
Current portion of long-term debt $ 3,647 $ 3,620
Commercial paper 4,805 5,171
Other 193 98
TOTAL $ 8,645 $ 8,889
Short-term weighted average interest
rates 0.8 % 0.2 %
Short-term weighted average interest rates include the effects of interest rate
swaps discussed in Note 9.
As of June 30 2022 2021
LONG-TERM DEBT
2.15% USD note due August 2022 $ 1,250 $ 1,250
2.00% EUR note due August 2022 1,045 1,190
3.10% USD note due August 2023 1,000 1,000
1.13% EUR note due November 2023 1,306 1,488
0.50% EUR note due October 2024 523 595
0.63% EUR note due October 2024 836 952
0.55% USD note due October 2025 1,000 1,000
2.70% USD note due February 2026 600 600
1.00% USD note due April 2026 1,000 1,000
2.45% USD note due November 2026 875 875
1.90% USD note due February 2027 1,000 —
2.80% USD note due March 2027 500 500
4.88% EUR note due May 2027 1,045 1,190
2.85% USD note due August 2027 750 750
1.20% EUR note due October 2028 836 952
1.25% EUR note due October 2029 523 595
3.00% USD note due March 2030 1,500 1,500
0.35% EUR note due May 2030 523 —
1.20% USD note due October 2030 1,250 1,250
1.95% USD note due April 2031 1,000 1,000
2.30% USD note due February 2032 850 —
5.55% USD note due March 2037 716 716
1.88% EUR note due October 2038 523 595
3.55% USD note due March 2040 516 516
0.90% EUR note due November 2041 627 —
All other long-term debt 4,901 7,205
Current portion of long-term debt (3,647) (3,620)
TOTAL $ 22,848 $ 23,099
Long-term weighted average interest rates 2.2% 2.0%
Long-term weighted average interest rates include the effects of interest rate
swaps discussed in Note 9.
Long-term debt maturities during the next five fiscal years are as follows:
Years ending June 30 2023 2024 2025 2026 2027
Debt maturities $3,647 $2,298 $1,879 $2,713 $3,686
(1) (2)
(1)
(2)
(1)
(1)
(1)
(1)
Amounts in millions of dollars except per share amounts or as otherwise specified.
-- 62 of 137 --
The Procter & Gamble Company 61
NOTE 11
ACCUMULATED OTHER COMPREHENSIVE INCOME/(LOSS)
The table below presents the changes in Accumulated other comprehensive income/(loss) attributable to Procter & Gamble (AOCI), including the
reclassifications out of AOCI by component:
Changes in Accumulated Other Comprehensive Income/(Loss) by Component
Investment
Securities
Post-retirement
Benefit Plans
Foreign
Currency
Translation Total AOCI
BALANCE at JUNE 30, 2020 $ (1) $ (4,350) $ (11,814) $ (16,165)
OCI before reclassifications 20 1,046 1,023 2,089
Amounts reclassified to the Consolidated Statement of Earnings (4) 340 — 336
Net current period OCI 16 1,386 1,023 2,425
Less: OCI attributable to non-controlling interests — (1) 5 4
BALANCE at JUNE 30, 2021 15 (2,963) (10,796) (13,744)
OCI before reclassifications 4 2,797 (1,451) 1,350
Amounts reclassified to the Consolidated Statement of Earnings 1 195 1 197
Net current period OCI 5 2,992 (1,450) 1,547
Less: OCI attributable to non-controlling interests — 2 (10) (8)
BALANCE at JUNE 30, 2022 $ 20 $ 27 $ (12,236) $ (12,189)
Net of tax (benefit)/expense of $5, $345 and $(266) for gains/losses on investment securities, postretirement benefit plans and foreign currency translation, respectively, for
the period ended June 30, 2021. Income tax effects within foreign currency translation include impacts from items such as net investment hedge transactions. Foreign
cumulative translation is not adjusted for income taxes related to permanent investments in international subsidiaries.
Net of tax (benefit)/expense of $0, $100 and $0 for gains/losses on investment securities, postretirement benefit plans and foreign currency translation, respectively, for the
period ended June 30, 2021.
Net of tax (benefit)/expense of $1, $953 and $515 for gains/losses on investment securities, postretirement benefit plans and foreign currency translation, respectively, for
the period ended June 30, 2022. Income tax effects within foreign currency translation include impacts from items such as net investment hedge transactions. Foreign
cumulative translation is not adjusted for income taxes related to permanent investments in international subsidiaries.
Net of tax (benefit)/expense of $0, $69 and $0 for gains/losses on investment securities, postretirement benefit plans and foreign currency translation, respectively, for the
period ended June 30, 2022.
The below provides additional details on amounts reclassified from AOCI into the Consolidated Statement of Earnings:
• Investment securities: amounts reclassified from AOCI into Other non-operating income, net.
• Postretirement benefit plans: amounts reclassified from AOCI into Other non-operating income, net and included in the computation of net periodic
postretirement costs (see Note 8).
(1)
(2)
(3)
(4)
(1)
(2)
(3)
(4)
Amounts in millions of dollars except per share amounts or as otherwise specified.
-- 63 of 137 --
62 The Procter & Gamble Company
NOTE 12
LEASES
The Company determines whether a contract contains a lease at the
inception of a contract by determining if the contract conveys the right to
control the use of identified property, plant or equipment for a period of
time in exchange for consideration. We lease certain real estate, machinery,
equipment, vehicles and office equipment for varying periods. Many of
these leases include an option to either renew or terminate the lease. For
purposes of calculating lease liabilities, these options are included within
the lease term when it has become reasonably certain that the Company will
exercise such options. The incremental borrowing rate utilized to calculate
our lease liabilities is based on the information available at commencement
date, as most of the leases do not provide an implicit borrowing rate. Our
operating lease agreements do not contain any material guarantees or
restrictive covenants. The Company does not have any material finance
leases or sublease activities. Short-term leases, defined as leases with initial
terms of 12 months or less, are not reflected on the Consolidated Balance
Sheets. Lease expense for such short-term leases is not material. The most
significant assets in our leasing portfolio relate to real estate and vehicles.
For purposes of calculating lease liabilities for such leases, we have
combined lease and non-lease components.
The components of the Company’s total operating lease cost for the years
ended June 30, 2022, 2021 and 2020, were as follows:
Years ended June 30 2022 2021 2020
Operating lease cost 220 245 271
Variable lease cost 89 75 76
Total lease cost $ 309 $ 320 $ 347
Includes primarily costs for utilities, common area maintenance, property taxes
and other operating costs associated with operating leases that are not included
in the lease liability and are recognized in the period in which they are incurred.
Supplemental balance sheet and other information related to leases is as
follows:
As of June 30 2022 2021
Operating leases:
Right-of-use assets (Other
noncurrent assets) $ 760 $ 808
Current lease liabilities (Accrued and
other liabilities) 205 219
Noncurrent lease liabilities (Other
noncurrent liabilities) 595 631
Total operating lease liabilities $ 800 $ 850
Weighted average remaining lease term:
Operating leases 6.4 years 6.4 years
Weighted average discount rate:
Operating leases 3.2 % 3.8 %
At June 30, 2022, future payments of operating lease liabilities were as
follows:
Operating Leases
June 30, 2022
1 year $ 206
2 years 179
3 years 135
4 years 92
5 years 64
Over 5 years 209
Total lease payments 885
Less: Interest (85)
Present value of lease liabilities $ 800
Total cash paid for amounts included in the measurement of lease liabilities
was $228 and $253 for the years ended June 30, 2022, and June 30, 2021,
respectively.
The right-of-use assets obtained in exchange for lease liabilities were $217
and $163 for the years ended June 30, 2022, and June 30, 2021,
respectively.
(1)
(1)
Amounts in millions of dollars except per share amounts or as otherwise specified.
-- 64 of 137 --
The Procter & Gamble Company 63
NOTE 13
COMMITMENTS AND CONTINGENCIES
Guarantees
In conjunction with certain transactions, primarily divestitures, we may
provide routine indemnifications (e.g., indemnification for representations
and warranties and retention of previously existing environmental, tax and
employee liabilities) for which terms range in duration and, in some
circumstances, are not explicitly defined. The maximum obligation under
some indemnifications is also not explicitly stated and, as a result, the
overall amount of these obligations cannot be reasonably estimated. Other
than obligations recorded as liabilities at the time of divestiture, we have not
made significant payments for these indemnifications. We believe that if we
were to incur a loss on any of these matters, the loss would not have a
material effect on our financial position, results of operations or cash flows.
In certain situations, we guarantee loans for suppliers and customers. The
total amount of guarantees issued under such arrangements is not material.
Off-Balance Sheet Arrangements
We do not have off-balance sheet financing arrangements, including
variable interest entities, that have a material impact on our financial
statements.
Purchase Commitments
We have purchase commitments for materials, supplies, services and
property, plant and equipment as part of the normal course of business.
Commitments made under take-or-pay obligations are as follows:
Years ending June
30 2023 2024 2025 2026 2027
There-
after
Purchase
obligations $ 1,082 $ 494 $ 332 $ 259 $ 193 $ 425
Such amounts represent minimum commitments under take-or-pay
agreements with suppliers and are in line with expected usage. These
amounts include purchase commitments related to service contracts for
information technology, human resources management and facilities
management activities that have been outsourced to third-party suppliers.
Due to the proprietary nature of many of our materials and processes,
certain supply contracts contain penalty provisions for early termination.
We do not expect to incur penalty payments under these provisions that
would materially affect our financial position, results of operations or cash
flows.
Litigation
We are subject, from time to time, to certain legal proceedings and claims
arising out of our business, which cover a wide range of matters, including
antitrust and trade regulation, product liability, advertising, contracts,
environmental, patent and trademark matters, labor and employment
matters and tax.
While considerable uncertainty exists, in the opinion of management and
our counsel, the ultimate resolution of the various lawsuits and claims will
not materially affect our financial position, results of operations or cash
flows.
We are also subject to contingencies pursuant to environmental laws and
regulations that in the future may require us to take action to correct the
effects on the environment of prior manufacturing and waste disposal
practices. Based on currently available information, we do not believe the
ultimate resolution of environmental remediation will materially affect our
financial position, results of operations or cash flows.
Item 9. Changes in and Disagreements with Accountants on Accounting and
Financial Disclosure.
Not applicable.
Item 9A. Controls and Procedures.
Evaluation of Disclosure Controls and Procedures.
The Company's Chairman of the Board, President and Chief Executive
Officer, Jon R. Moeller, and the Company's Chief Financial Officer, Andre
Schulten, performed an evaluation of the Company's disclosure controls and
procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities
Exchange Act of 1934 (Exchange Act)) as of the end of the period covered
by this Annual Report on Form 10-K.
Messrs. Moeller and Schulten have concluded that the Company's
disclosure controls and procedures were effective to ensure that information
required to be disclosed in reports we file or submit under the Exchange Act
is (1) recorded, processed, summarized and reported within the time periods
specified in Securities and Exchange Commission rules and forms, and
(2) accumulated and communicated to our management, including Messrs.
Moeller and Schulten, to allow their timely decisions regarding required
disclosure.
Changes in Internal Control over Financial Reporting.
There were no changes in our internal control over financial reporting that
occurred during the Company's fourth fiscal quarter that have materially
affected, or are reasonably likely to materially affect, the Company's
internal control over financial reporting.
Item 9B. Other Information.
Not applicable.
Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent
Inspections.
Not applicable.
Amounts in millions of dollars except per share amounts or as otherwise specified.
-- 65 of 137 --
64 The Procter & Gamble Company
PART III
Item 10. Directors, Executive Officers and Corporate Governance.
The Board of Directors has determined that the following members of the
Audit Committee are independent and are Audit Committee financial
experts as defined by SEC rules: Ms. Patricia A. Woertz (Chair) and Ms.
Christine M. McCarthy.
The information required by this item is incorporated by reference to the
following sections of the 2022 Proxy Statement filed pursuant to Regulation
14A, which will be filed no later than 120 days after June 30, 2022: the
section entitled Election of Directors; the subsection of the Corporate
Governance section entitled Board Meetings and Committees of the Board;
the subsection of the Corporate Governance section entitled Code of Ethics;
and the subsection of the Other Matters section entitled Shareholder
Recommendations or Nominations of Director Candidates.
Pursuant to the Instruction to Item 401 of Regulation S-K, Executive
Officers of the Registrant are reported in Part I of this report.
Item 11. Executive Compensation.
The information required by this item is incorporated by reference to the
following sections of the 2022 Proxy Statement filed pursuant to Regulation
14A, which will be filed no later than 120 days after June 30, 2022: the
subsections of the Corporate Governance section entitled Board Meetings
and Committees of the Board, Compensation Committee Interlocks and
Insider Participation, and The Board's Oversight of Risk - Compensation-
Related Risk; and the portion beginning with the section entitled Director
Compensation up to but not including the section entitled Security
Ownership of Management and Certain Beneficial Owners.
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.
The following table gives information about the Company's common stock that may be issued upon the exercise of options, warrants and rights under all of the
Company's equity compensation plans as of June 30, 2022. The table includes the following plans: The Procter & Gamble 1992 Stock Plan; The Procter &
Gamble 2001 Stock and Incentive Compensation Plan; The Procter & Gamble 2003 Non-Employee Directors' Stock Plan; The Procter & Gamble 2009 Stock
and Incentive Compensation Plan; The Procter & Gamble 2014 Stock and Incentive Compensation Plan; and The Procter & Gamble 2019 Stock and Incentive
Compensation Plan.
Plan Category
(a)
Number of securities to be
issued upon exercise of
outstanding options,
warrants and rights
(b)
Weighted average exercise
price of outstanding
options, warrants and
rights
(c)
Number of securities
remaining available for
future issuance under
equity compensation plans
(excluding securities
reflected in column (a))
Equity compensation plans approved by security
holders
Stock Options/Stock Appreciation Rights 126,737,581 $99.5228
Restricted Stock Units (RSUs)/Performance Stock Units
(PSUs) 6,448,414 N/A
TOTAL 133,185,995 $99.5228
Of the plans listed above, only The Procter & Gamble 2019 Stock and Incentive Compensation Plan (the “2019 Plan”) allows for future grants of securities. The maximum
number of shares that may be granted under this plan is 187 million shares. Stock options and stock appreciation rights are counted on a one-for-one basis while full value
awards (such as RSUs and PSUs) are counted as five shares for each share awarded. Total shares available for future issuance under this plan is 119 million.
Weighted average exercise price of outstanding options only.
Additional information required by this item is incorporated by reference to
the following section of the 2022 Proxy Statement filed pursuant to
Regulation 14A, which will be filed no later than 120 days after June 30,
2022: the subsection of the Beneficial Ownership section entitled Security
Ownership of Management and Certain Beneficial Owners.
Item 13. Certain Relationships and Related Transactions and Director
Independence.
The information required by this item is incorporated by reference to the
following sections of the 2022 Proxy Statement filed pursuant to Regulation
14A, which will be
filed no later than 120 days after June 30, 2022: the subsections of the
Corporate Governance section entitled Director Independence and Review
and Approval of Transactions with Related Persons.
Item 14. Principal Accountant Fees and Services.
The information required by this item is incorporated by reference to the
following section of the 2022 Proxy Statement filed pursuant to Regulation
14A, which will be filed no later than 120 days after June 30, 2022: Report
of the Audit Committee, which ends with the subsection entitled Services
Provided by Deloitte.
(1)
(1)
(2)
(1)
(2)
-- 66 of 137 --
The Procter & Gamble Company 65
PART IV
Item 15. Exhibits and Financial Statement Schedules.
1. Financial Statements:
The following Consolidated Financial Statements of The Procter & Gamble Company and subsidiaries, management's report and the reports of the independent
registered public accounting firm are incorporated by reference in Part II, Item 8 of this Form 10-K.
• Management's Report on Internal Control over Financial Reporting
• Report of Independent Registered Public Accounting Firm on Internal Control over Financial Reporting (PCAOB Firm ID is 34)
• Report of Independent Registered Public Accounting Firm on Consolidated Financial Statements
• Consolidated Statements of Earnings - for years ended June 30, 2022, 2021 and 2020
• Consolidated Statements of Comprehensive Income - for years ended June 30, 2022, 2021 and 2020
• Consolidated Balance Sheets - as of June 30, 2022 and 2021
• Consolidated Statements of Shareholders' Equity - for years ended June 30, 2022, 2021 and 2020
• Consolidated Statements of Cash Flows - for years ended June 30, 2022, 2021 and 2020
• Notes to Consolidated Financial Statements
2. Financial Statement Schedules:
These schedules are omitted because of the absence of the conditions under which they are required or because the information is set forth in the Consolidated
Financial Statements or Notes thereto.
EXHIBITS
Exhibit (3-1) - Amended Articles of Incorporation (as amended by shareholders at the annual meeting on October 11, 2011 and consolidated by the Board of
Directors on April 8, 2016) (Incorporated by reference to Exhibit (3-1) of the Company's Annual Report on Form 10-K for the year ended June 30,
2016).
(3-2) - Regulations (as approved by the Board of Directors on April 8, 2016, pursuant to authority granted by shareholders at the annual meeting on October
13, 2009) (Incorporated by reference to Exhibit (3-2) of the Company's Annual Report on Form 10-K for the year ended June 30, 2016).
Exhibit (4-1) - Indenture, dated as of September 3, 2009, between the Company and Deutsche Bank Trust Company Americas, as Trustee (Incorporated by reference
to Exhibit (4-1) of the Company's Annual Report on Form 10-K for the year ended June 30, 2015).
(4-2) - The Company agrees to furnish to the Securities and Exchange Commission, upon request, a copy of any other instrument defining the rights of
holders of the Company’s long-term debt.
(4-3) - Description of the Company’s Common Stock (Incorporated by reference to Exhibit (4-3) of the Company’s Annual report on Form 10-K for the year
ended June 30, 2019).
(4-4) - Description of the Company’s 0.625% Notes due 2024, 1.200% Notes due 2028, and 1.875% Notes due 2038 (Incorporated by reference to Exhibit
(4-4) of the Company’s Annual report on Form 10-K for the year ended June 30, 2019).
(4-5) - Description of the Company’s 4.875% EUR notes due May 2027, 6.250% GBP notes due January 2030, and 5.250% GBP notes due January 2033
(Incorporated by reference to Exhibit (4-5) of the Company’s Annual report on Form 10-K for the year ended June 30, 2021).
(4-6) - Description of the Company’s 0.500% Notes due 2024 and 1.250% Notes due 2029 (Incorporated by reference to Exhibit (4-6) of the Company’s
Annual report on Form 10-K for the year ended June 30, 2019).
(4-7) - Description of the Company’s 1.375% Notes due 2025 and 1.800% Notes due 2029 (Incorporated by reference to Exhibit (4-7) of the Company’s
Annual report on Form 10-K for the year ended June 30, 2019).
(4-8) - Description of the Company’s 1.125% Notes due 2023 (Incorporated by reference to Exhibit (4-8) of the Company’s Annual report on Form 10-K for
the year ended June 30, 2019).
(4-9) - Description of the Company’s 2.000% Notes due 2022 (Incorporated by reference to Exhibit (4-11) of the Company’s Annual report on Form 10-K
for the year ended June 30, 2019).
(4-10) - Description of the Company's 0.350% EUR Notes due 2030 and 0.900% EUR Notes due 2041. +
(4-11) - Description of the Company's 0.110% Yen Notes due 2026 and 0.230% Yen Notes due 2031. +
Exhibit (10-1) - The Procter & Gamble 2001 Stock and Incentive Compensation Plan (as amended), which was originally adopted by shareholders at the annual
meeting on October 9, 2001 (Incorporated by reference to Exhibit (10-1) of the Company’s Annual Report on Form 10-K for the year ended June 30,
2018).*
-- 67 of 137 --
66 The Procter & Gamble Company
(10-2) - The Procter & Gamble 2001 Stock and Incentive Compensation Plan related correspondence and terms and conditions (Incorporated by reference to
Exhibit (10-1) of the Company's Form 10-Q for the quarter ended December 31, 2013).*
(10-3) - The Procter & Gamble 1992 Stock Plan (as amended December 11, 2001), which was originally adopted by the shareholders at the annual meeting on
October 12, 1992 (Incorporated by reference to Exhibit (10-2) of the Company’s Annual Report on Form 10-K for the year ended June 30, 2018).*
(10-4) - The Procter & Gamble Executive Group Life Insurance Policy (Incorporated by reference to Exhibit (10-3) of the Company’s Annual Report on Form
10-K for the year ended June 30, 2018).*
(10-5) - Summary of the Company’s Retirement Plan Restoration Program (Incorporated by reference to Exhibit (10-5) of the Company's Form 10-Q for the
quarter ended December 31, 2019).*
(10-6) - Retirement Plan Restoration Program related correspondence and terms and conditions (Incorporated by reference to Exhibit (10-8) of the Company's
Form 10-Q for the quarter ended September 30, 2015).*
(10-7) - Summary of the Company’s Long-Term Incentive Program (Incorporated by reference to Exhibit (10-3) of the Company's Form 10-Q for the quarter
ended September 30, 2020).*
(10-8) - Long-Term Incentive Program related correspondence and terms and conditions (Incorporated by reference to Exhibit (10-3) of the Company's Form
10-Q for the quarter ended September 30, 2021).*
(10-9) - The Procter & Gamble Company Executive Deferred Compensation Plan (Incorporated by reference to Exhibit (10-2) of the Company's Form 10-Q
for the quarter ended March 31, 2020).*
(10-10) - Summary of the Company's Short Term Achievement Reward Program.* +
(10-11) - Short Term Achievement Reward Program – related correspondence and terms and conditions (Incorporated by reference to Exhibit (10-2) of the
Company's Form 10-Q for the quarter ended September 30, 2021).*
(10-12) - Company's Form of Separation Agreement & Release.* +
(10-13) - Company's Form of Separation Letter and Release.* +
(10-14) - Summary of personal benefits available to certain officers and non-employee directors (Incorporated by reference to Exhibit (10-5) of the Company's
Form 10-Q for the quarter ended September 30, 2021).*
(10-15) - The Gillette Company Deferred Compensation Plan (Incorporated by reference to Exhibit (10-18) of the Company’s Annual Report on Form 10-K for
the year ended June 30, 2017).*
(10-16) - Senior Executive Recoupment Policy (Incorporated by reference to Exhibit (10-19) of the Company’s Annual Report on Form 10-K for the year
ended June 30, 2018).*
(10-17) - The Gillette Company Deferred Compensation Plan (for salary deferrals prior to January 1, 2005) as amended through August 21, 2006 (Incorporated
by reference to Exhibit (10-20) of the Company's Annual Report on Form 10-K for the year ended June 30, 2017).*
(10-18) - The Procter & Gamble 2009 Stock and Incentive Compensation Plan, which was originally adopted by shareholders at the annual meeting on October
13, 2009 (Incorporated by reference to Exhibit (10-21) of the Company's Annual Report on Form 10-K for the year ended June 30, 2017).*
(10-19) - Regulations of the Compensation and Leadership Development Committee for The Procter & Gamble 2009 Stock and Incentive Compensation Plan,
The Procter & Gamble 2001 Stock and Incentive Compensation Plan, The Procter & Gamble 1992 Stock Plan, The Procter & Gamble 1992 Stock
Plan (Belgium Version), The Gillette Company 2004 Long-Term Incentive Plan and the Gillette Company 1971 Stock Option Plan (Incorporated by
reference to Exhibit (10-21) of the Company’s Annual Report on Form 10-K for the year ended June 30, 2018).*
(10-20) - The Procter & Gamble 2009 Stock and Incentive Compensation Plan - Additional terms and conditions and related correspondence (Incorporated by
reference to Exhibit (10-2) of the Company Form 10-Q for the quarter ended December 31, 2013).*
(10-21) - The Procter & Gamble Performance Stock Program Summary (Incorporated by reference to Exhibit (10-5) of the Company's Form 10-Q for the
quarter ended September 30, 2020).*
(10-22) - Performance Stock Program related correspondence and terms and conditions (Incorporated by reference to Exhibit (10-4) of the Company’s Form
10-Q for the quarter ended September 30, 2021).*
(10-23) - The Procter & Gamble 2013 Non-Employee Directors' Stock Plan (Incorporated by reference to Exhibit (10-3) of the Company's Form 10-Q for the
quarter ended December 31, 2013). *
(10-24) - The Procter & Gamble 2014 Stock and Incentive Compensation Plan, which was originally adopted by shareholders at the annual meeting on October
14, 2014 (Incorporated by reference to Exhibit (10-25) of the Company's Annual Report on Form 10-K for the year ended June 30, 2016).*
(10-25) - Regulations of the Compensation and Leadership Development Committee for The Procter & Gamble 2019 Stock and Incentive Compensation Plan
and The Procter & Gamble 2014 Stock and Incentive Compensation Plan (Incorporated by reference to Exhibit (10-1) of the Company's Form 10-Q
for the quarter ended December 31, 2019).*
-- 68 of 137 --
The Procter & Gamble Company 67
(10-26) - The Procter & Gamble 2014 Stock and Incentive Compensation Plan - Additional terms and conditions (Incorporated by reference to Exhibit (10-26)
of the Company's Annual Report on Form 10-K for the year ended June 30, 2017).*
(10-27) - The Procter & Gamble 2019 Stock and Incentive Compensation Plan, which was originally adopted by shareholders at the annual meeting on October
8, 2019 (Incorporated by reference to Exhibit (10-1) of the Company’s Current Report on Form 8-K filed October 11, 2019).*
(10-28) - The Procter & Gamble 2019 Stock and Incentive Compensation Plan - Additional terms and conditions (Incorporated by reference to Exhibit (10-28)
of the Company's Annual Report on Form 10-K for the year ended June 30, 2021).*
Exhibit (21) - Subsidiaries of the Registrant. +
Exhibit (23) - Consent of Independent Registered Public Accounting Firm. +
Exhibit (31) - Rule 13a-14(a)/15d-14(a) Certifications. +
Exhibit (32) - Section 1350 Certifications. +
Exhibit (99-1) - Summary of Directors and Officers Insurance Program. +
101.INS (1) Inline XBRL Instance Document
101.SCH (1) Inline XBRL Taxonomy Extension Schema Document
101.CAL (1) Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF (1) Inline XBRL Taxonomy Definition Linkbase Document
101.LAB (1) Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE (1) Inline XBRL Taxonomy Extension Presentation Linkbase Document
104 Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)
(1) Pursuant to Rule 406T of Regulation S-T, these interactive data files are deemed not filed or part of a registration statement or prospectus for
purposes of Sections 11 or 12 of the Securities Act of 1933 or Section 18 of the Securities Exchange Act of 1934 and otherwise are not subject to
liability.
* Compensatory plan or arrangement.
+ Filed herewith.
Item 16. Form 10-K Summary.
Not applicable.
-- 69 of 137 --
68 The Procter & Gamble Company
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized in the city of Cincinnati, State of Ohio.
THE PROCTER & GAMBLE COMPANY
By /s/ JON R. MOELLER
(Jon R. Moeller)
Chairman of the Board, President and Chief Executive Officer
August 05, 2022
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons in the capacities and on the
dates indicated.
Signature Title Date
/s/ JON R. MOELLER
(Jon R. Moeller)
Chairman of the Board, President and Chief Executive Officer
(Principal Executive Officer) August 05, 2022
/s/ ANDRE SCHULTEN
(Andre Schulten) Chief Financial Officer
(Principal Financial Officer) August 05, 2022
/s/ MATTHEW W. JANZARUK
(Matthew W. Janzaruk) Senior Vice President - Chief Accounting Officer
(Principal Accounting Officer) August 05, 2022
/s/ B. MARC ALLEN
(B. Marc Allen) Director August 05, 2022
/s/ ANGELA F. BRALY
(Angela F. Braly) Director August 05, 2022
/s/ AMY L. CHANG
(Amy L. Chang) Director August 05, 2022
/s/ JOSEPH JIMENEZ
(Joseph Jimenez) Director August 05, 2022
/s/ CHRISTOPHER J. KEMPCZINSKI
(Christopher J. Kempczinski) Director August 05, 2022
/s/ DEBRA L. LEE
(Debra L. Lee) Director August 05, 2022
/s/ TERRY J. LUNDGREN
(Terry J. Lundgren) Director August 05, 2022
/s/ CHRISTINE M. MCCARTHY
(Christine M. McCarthy) Director August 05, 2022
/s/ PATRICIA A. WOERTZ
(Patricia A. Woertz) Director August 05, 2022
-- 70 of 137 --
The Procter & Gamble Company 69
EXHIBIT INDEX
Exhibit (3-1) - Amended Articles of Incorporation (as amended by shareholders at the annual meeting on October 11, 2011 and consolidated by the Board of
Directors on April 8, 2016) (Incorporated by reference to Exhibit (3-1) of the Company's Annual Report on Form 10-K for the year ended June 30,
2016).
(3-2) - Regulations (as approved by the Board of Directors on April 8, 2016, pursuant to authority granted by shareholders at the annual meeting on October
13, 2009) (Incorporated by reference to Exhibit (3-2) of the Company's Annual Report on Form 10-K for the year ended June 30, 2016).
Exhibit (4-1) - Indenture, dated as of September 3, 2009, between the Company and Deutsche Bank Trust Company Americas, as Trustee (Incorporated by reference
to Exhibit (4-1) of the Company's Annual Report on Form 10-K for the year ended June 30, 2015).
(4-2) - The Company agrees to furnish to the Securities and Exchange Commission, upon request, a copy of any other instrument defining the rights of
holders of the Company’s long-term debt.
(4-3) - Description of the Company’s Common Stock (Incorporated by reference to Exhibit (4-3) of the Company’s Annual report on Form 10-K for the year
ended June 30, 2019).
(4-4) - Description of the Company’s 0.625% Notes due 2024, 1.200% Notes due 2028, and 1.875% Notes due 2038 (Incorporated by reference to Exhibit
(4-4) of the Company’s Annual report on Form 10-K for the year ended June 30, 2019).
(4-5) - Description of the Company’s 4.875% EUR notes due May 2027, 6.250% GBP notes due January 2030, and 5.250% GBP notes due January 2033
(Incorporated by reference to Exhibit (4-5) of the Company’s Annual report on Form 10-K for the year ended June 30, 2021).
(4-6) - Description of the Company’s 0.500% Notes due 2024 and 1.250% Notes due 2029 (Incorporated by reference to Exhibit (4-6) of the Company’s
Annual report on Form 10-K for the year ended June 30, 2019).
(4-7) - Description of the Company’s 1.375% Notes due 2025 and 1.800% Notes due 2029 (Incorporated by reference to Exhibit (4-7) of the Company’s
Annual report on Form 10-K for the year ended June 30, 2019).
(4-8) - Description of the Company’s 1.125% Notes due 2023 (Incorporated by reference to Exhibit (4-8) of the Company’s Annual report on Form 10-K for
the year ended June 30, 2019).
(4-9) - Description of the Company’s 2.000% Notes due 2022 (Incorporated by reference to Exhibit (4-11) of the Company’s Annual report on Form 10-K
for the year ended June 30, 2019).
(4-10) - Description of the Company's 0.350% EUR Notes due 2030 and 0.900% EUR Notes due 2041. +
(4-11) - Description of the Company's 0.110% Yen Notes due 2026 and .230% Yen Notes due 2031. +
Exhibit (10-1) - The Procter & Gamble 2001 Stock and Incentive Compensation Plan (as amended), which was originally adopted by shareholders at the annual
meeting on October 9, 2001 (Incorporated by reference to Exhibit (10-1) of the Company’s Annual Report on Form 10-K for the year ended June 30,
2018).
(10-2) - The Procter & Gamble 2001 Stock and Incentive Compensation Plan related correspondence and terms and conditions (Incorporated by reference to
Exhibit (10-1) of the Company's Form 10-Q for the quarter ended December 31, 2013).
(10-3) - The Procter & Gamble 1992 Stock Plan (as amended December 11, 2001), which was originally adopted by the shareholders at the annual meeting on
October 12, 1992 (Incorporated by reference to Exhibit (10-2) of the Company’s Annual Report on Form 10-K for the year ended June 30, 2018).
(10-4) - The Procter & Gamble Executive Group Life Insurance Policy (Incorporated by reference to Exhibit (10-3) of the Company’s Annual Report on Form
10-K for the year ended June 30, 2018).
(10-5) - Summary of the Company’s Retirement Plan Restoration Program (Incorporated by reference to Exhibit (10-5) of the Company's Form 10-Q for the
quarter ended December 31, 2019).
(10-6) - Retirement Plan Restoration Program related correspondence and terms and conditions (Incorporated by reference to Exhibit (10-8) of the Company's
Form 10-Q for the quarter ended September 30, 2015).
(10-7) - Summary of the Company’s Long-Term Incentive Program (Incorporated by reference to Exhibit (10-3) of the Company's Form 10-Q for the quarter
ended September 30, 2020).
(10-8) - Long-Term Incentive Program related correspondence and terms and conditions (Incorporated by reference to Exhibit (10-3) of the Company's Form
10-Q for the quarter ended September 30, 2021).
(10-9) - The Procter & Gamble Company Executive Deferred Compensation Plan (Incorporated by reference to Exhibit (10-2) of the Company's Form 10-Q
for the quarter ended March 31, 2020).
(10-10) - Summary of the Company's Short Term Achievement Reward Program. +
(10-11) - Short Term Achievement Reward Program – related correspondence and terms and conditions (Incorporated by reference to Exhibit (10-2) of the
Company's Form 10-Q for the quarter ended September 30, 2021).
(10-12) - Company's Form of Separation Agreement & Release. +
-- 71 of 137 --
70 The Procter & Gamble Company
(10-13) - Company's Form of Separation Letter and Release. +
(10-14) - Summary of personal benefits available to certain officers and non-employee directors (Incorporated by reference to Exhibit (10-5) of the Company's
Form 10-Q for the quarter ended September 30, 2021).
(10-15) - The Gillette Company Deferred Compensation Plan (Incorporated by reference to Exhibit (10-18) of the Company’s Annual Report on Form 10-K for
the year ended June 30, 2017).
(10-16) - Senior Executive Recoupment Policy (Incorporated by reference to Exhibit (10-19) of the Company’s Annual Report on Form 10-K for the year
ended June 30, 2018).
(10-17) - The Gillette Company Deferred Compensation Plan (for salary deferrals prior to January 1, 2005) as amended through August 21, 2006 (Incorporated
by reference to Exhibit (10-20) of the Company's Annual Report on Form 10-K for the year ended June 30, 2017).
(10-18) - The Procter & Gamble 2009 Stock and Incentive Compensation Plan, which was originally adopted by shareholders at the annual meeting on October
13, 2009 (Incorporated by reference to Exhibit (10-21) of the Company's Annual Report on Form 10-K for the year ended June 30, 2017).
(10-19) - Regulations of the Compensation and Leadership Development Committee for The Procter & Gamble 2009 Stock and Incentive Compensation Plan,
The Procter & Gamble 2001 Stock and Incentive Compensation Plan, The Procter & Gamble 1992 Stock Plan, The Procter & Gamble 1992 Stock
Plan (Belgium Version), The Gillette Company 2004 Long-Term Incentive Plan and the Gillette Company 1971 Stock Option Plan (Incorporated by
reference to Exhibit (10-21) of the Company’s Annual Report on Form 10-K for the year ended June 30, 2018).
(10-20) - The Procter & Gamble 2009 Stock and Incentive Compensation Plan - Additional terms and conditions and related correspondence (Incorporated by
reference to Exhibit (10-2) of the Company Form 10-Q for the quarter ended December 31, 2013).
(10-21) - The Procter & Gamble Performance Stock Program Summary (Incorporated by reference to Exhibit (10-5) of the Company's Form 10-Q for the
quarter ended September 30, 2020).
(10-22) - Performance Stock Program related correspondence and terms and conditions (Incorporated by reference to Exhibit (10-4) of the Company’s Form
10-Q for the quarter ended September 30, 2021).
(10-23) - The Procter & Gamble 2013 Non-Employee Directors' Stock Plan (Incorporated by reference to Exhibit (10-3) of the Company's Form 10-Q for the
quarter ended December 31, 2013).
(10-24) - The Procter & Gamble 2014 Stock and Incentive Compensation Plan, which was originally adopted by shareholders at the annual meeting on October
14, 2014 (Incorporated by reference to Exhibit (10-25) of the Company's Annual Report on Form 10-K for the year ended June 30, 2016).
(10-25) - Regulations of the Compensation and Leadership Development Committee for The Procter & Gamble 2019 Stock and Incentive Compensation Plan
and The Procter & Gamble 2014 Stock and Incentive Compensation Plan (Incorporated by reference to Exhibit (10-1) of the Company's Form 10-Q
for the quarter ended December 31, 2019).
(10-26) - The Procter & Gamble 2014 Stock and Incentive Compensation Plan - Additional terms and conditions (Incorporated by reference to Exhibit (10-26)
of the Company's Annual Report on Form 10-K for the year ended June 30, 2017).
(10-27) - The Procter & Gamble 2019 Stock and Incentive Compensation Plan, which was originally adopted by shareholders at the annual meeting on October
8, 2019 (Incorporated by reference to Exhibit (10-1) of the Company’s Current Report on Form 8-K filed October 11, 2019).
(10-28) - The Procter & Gamble 2019 Stock and Incentive Compensation Plan - Additional terms and conditions (Incorporated by reference to Exhibit (10-28)
of the Company's Annual Report on Form 10-K for the year ended June 30, 2021).
Exhibit (21) - Subsidiaries of the Registrant. +
Exhibit (23) - Consent of Independent Registered Public Accounting Firm. +
Exhibit (31) - Rule 13a-14(a)/15d-14(a) Certifications. +
Exhibit (32) - Section 1350 Certifications. +
Exhibit (99-1) - Summary of Directors and Officers Insurance Program. +
101.INS (1) Inline XBRL Instance Document
101.SCH (1) Inline XBRL Taxonomy Extension Schema Document
101.CAL (1) Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF (1) Inline XBRL Taxonomy Definition Linkbase Document
101.LAB (1) Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE (1) Inline XBRL Taxonomy Extension Presentation Linkbase Document
104 Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)
-- 72 of 137 --
The Procter & Gamble Company 71
(1) Pursuant to Rule 406T of Regulation S-T, these interactive data files are deemed not filed or part of a registration statement or prospectus for purposes
of Sections 11 or 12 of the Securities Act of 1933 or Section 18 of the Securities Exchange Act of 1934 and otherwise are not subject to liability.
+ Filed herewith.
-- 73 of 137 --
Exhibit (4-10)
Description of the Company’s 0.350% EUR Notes due 2030 and 0.900% EUR Notes
due 2041
-- 74 of 137 --
Description of the Company’s 0.350% EUR Notes due 2030 and 0.900% EUR Notes due 2041, Registered Under Section 12
of the Securities Exchange Act of 1934
The following summary of The Procter & Gamble Company’s above referenced debt securities is based on and qualified by the
Indenture, dated as of September 3, 2009, between the Company and Deutsche Bank Trust Company Americas, as Trustee (the
“Indenture”) and the 0.350% EUR notes due 2030 and 0.900% EUR notes due 2041 (collectively, the “Notes”). For a complete
description of the terms and provisions of the Company’s Notes, refer to the Indenture and to the forms of Notes, all of which are
filed as exhibits to the Form 8-A filed with the Securities and Exchange Commission on November 5, 2021.
General
The 0.350% notes:
• were issued in an aggregate initial principal amount of €500,000,000, subject to our ability to issue additional 0.350% notes
which may be of the same series as the 0.350% notes as described below under “Further Issues,”
• will mature on May 5, 2030,
• bear interest at a rate of 0.350% per annum, payable annually in arrear,
• are unsecured,
• are senior debt, ranking equally with all of our other present and future unsecured and unsubordinated indebtedness,
• were issued as a separate series under the Indenture, in registered, book-entry form only,
• were issued in euros in denominations of €100,000 and integral multiples of €1,000 in excess thereof,
• will be repaid at par at maturity,
• are redeemable by us at any time prior to maturity as described below under “Optional Redemption” and in connection with
certain events involving United States taxation,
• are subject to defeasance and covenant defeasance, and
• are not subject to any sinking fund.
The 0.900% notes:
• were issued in an aggregate initial principal amount of €600,000,000 subject to our ability to issue additional 0.900% notes
which may be of the same series as the 0.900% notes as described below under “Further Issues,”
• will mature on November 4, 2041,
• bear interest at a rate of 0.900% per annum, payable annually in arrear,
• are unsecured,
• are senior debt, ranking equally with all of our other present and future unsecured and unsubordinated indebtedness,
• were issued as a separate series under the Indenture, in registered, book-entry form only,
• were issued in euros in denominations of €100,000 and integral multiples of €1,000 in excess thereof,
• will be repaid at par at maturity,
• are redeemable by us at any time prior to maturity as described below under “Optional Redemption” and in connection with
certain events involving United States taxation,
• are subject to defeasance and covenant defeasance, and
• are not subject to any sinking fund.
-- 75 of 137 --
The indenture and the Notes do not limit the amount of indebtedness which may be incurred or the amount of securities which may
be issued by us or our subsidiaries, and contain no financial or similar restrictions on us or our subsidiaries, except as described in
the accompanying prospectus under the captions “Restrictions on Secured Debt” and “Restrictions on Sales and Leasebacks.”
The Notes are listed on the New York Stock Exchange.
Interest
We pay interest on the 0.350% notes and the 0.900% notes annually on May 5 and November 4 of each year, respectively, and on
any maturity date (each, an “interest payment date”), commencing May 5, 2022 (with respect to the 0.350% notes) and November 4,
2022 (with respect to the 0.900% notes) and ending on any maturity date, to the persons in whose names the 0.350% notes and the
0.900% notes are registered at the close of business on the Business Day immediately before the next interest payment date;
provided, however, that interest payable on any maturity date shall be payable to the person to whom the principal of such notes
shall be payable.
Interest payable on any interest payment date or maturity date shall be the amount of interest accrued from, and including, the
immediately preceding interest payment date in respect of which interest has been paid or duly provided for (or from and including
the original issue date, if no interest has been paid or duly provided for with respect to the notes) to, but excluding, such interest
payment date or maturity date, as the case may be. If any interest payment date is not a Business Day at the relevant place of
payment, we will pay interest on the next day that is a Business Day at such place of payment as if payment were made on the date
such payment was due, and no interest will accrue on the amounts so payable for the period from and after such date to the
immediately succeeding Business Day. If the maturity date or redemption date of the notes is not a Business Day at the relevant
place of payment, we will pay interest, if any, and principal and premium, if any, on the next day that is a Business Day at such place
of payment as if payment were made on the date such payment was due, and no interest will accrue on the amounts so payable for
the period from and after such date to the immediately succeeding Business Day.
Where interest is to be calculated in respect of a period which is equal to or shorter than the relevant period for which interest is to
be calculated (an “Interest Period”), it will be calculated on the basis of the actual number of days in the relevant period, from and
including the date from which interest begins to accrue, to, but excluding, the date on which it falls due, divided by the number of
days in the Interest Period in which the relevant period falls (including the first such day but excluding the last).
“Business Day” means any day that is not a Saturday or Sunday and that is not a day on which banking institutions are authorized or
obligated by law or executive order to close in the City of New York or London and, for any place of payment outside of the City of
New York or London, in such place of payment, and on which the Trans-European Automated Real-time Gross Settlement Express
Transfer system (the TARGET2 system), or any successor thereto, operates.
-- 76 of 137 --
The term “maturity,” when used with respect to a note, means the date on which the principal of such note or an installment of
principal becomes due and payable as therein provided or as provided in the Indenture, whether at the stated maturity or by
declaration of acceleration, call for redemption, repayment or otherwise.
Optional Redemption
We have the option to redeem the notes of either series, in whole or in part, at our option at any time, at a redemption price equal to
the greater of (1) 100% of the principal amount of the notes to be redeemed, plus accrued interest on the notes to be redeemed to, but
excluding, the date on which the notes are to be redeemed, or (2) the sum of the present values of the remaining scheduled payments
of principal and interest on the notes to be redeemed, not including any portion of these payments of interest accrued as of the date
of which the notes are to be redeemed, discounted to the date on which the notes are to be redeemed on an annual basis
(ACTUAL/ACTUAL (ICMA)) at the applicable Comparable Government Bond Rate (as defined below), plus 10 basis points with
respect to the 0.350% notes and at the applicable Comparable Government Bond Rate, plus 10 basis points with respect to the
0.900% notes, plus accrued interest on the notes to be redeemed to, but excluding, the date on which the notes are to be redeemed.
“Comparable Government Bond Rate” means the price, expressed as a percentage (rounded to three decimal places, with 0.0005
being rounded upwards), at which the gross redemption yield on the notes to be redeemed, if they were to be purchased at such price
on the third Business Day prior to the date fixed for redemption, would be equal to the gross redemption yield on such Business Day
of the Comparable Government Bond (as defined below) on the basis of the middle market price of the Comparable Government
Bond prevailing at 11:00 a.m. (London time) on such Business Day as determined by an independent investment bank selected by
us.
“Comparable Government Bond” means, in relation to any Comparable Government Bond Rate calculation, at the discretion of an
independent investment bank selected by us, a German government bond whose maturity is closest to the maturity of the notes to be
redeemed, or if such independent investment bank in its discretion determines that such similar bond is not in issue, such other
German government bond as such independent investment bank may, with the advice of three brokers of, and/or market makers in,
German government bonds selected by us, determine to be appropriate for determining the Comparable Government Bond Rate.
In the case of a partial redemption of any series of notes, the notes to be redeemed will be selected on a pro rata basis or by the
trustee by a method the trustee deems to be fair and appropriate or, in case the notes are represented by one or more global notes,
beneficial interests therein will be selected for redemption by Clearstream, Luxembourg and Euroclear in accordance with their
respective applicable procedures therefor; provided that the unredeemed portion of the note shall be €100,000 in principal amount
and €1,000 multiples above that amount. A new note in a principal amount equal to the unredeemed portion of the note will be issued
in the name of the holder of the note upon surrender of the original note.
Notice of any redemption will be sent at least 15 days but not more than 45 days before the redemption date to each holder of notes
of the applicable series to be redeemed.
-- 77 of 137 --
The notes of each series are also subject to redemption if certain events occur involving United States taxation. See “Tax
Redemption” below.
Additional Amounts
All payments of principal and interest in respect of the notes will be made free and clear of, and without deduction or withholding
for or on account of any present or future taxes, duties, assessments or other governmental charges of whatsoever nature imposed,
levied, collected, withheld or assessed by the United States or any political subdivision or taxing authority of or in the United States
(collectively, “Taxes”), unless such withholding or deduction is required by law.
In the event such withholding or deduction of Taxes is required by law, subject to the limitations described below, we will pay to the
holder or beneficial owner of any note that is not a United States holder such additional amounts (“Additional Amounts”) as may be
necessary in order that every net payment by us or any paying agent of principal of or interest on the notes (including upon
redemption), after deduction or withholding for or on account of such Taxes, will not be less than the amount provided for in such
note to be then due and payable before deduction or withholding for or on account of such Taxes.
However, our obligation to pay Additional Amounts shall not apply to:
(a) any Taxes which would not have been so imposed but for:
(1) the existence of any present or former connection between such holder or beneficial owner (or between a fiduciary, settlor,
beneficiary, member or shareholder or other equity owner of, or a person having a power over, such holder or beneficial owner, if
such holder or beneficial owner is an estate, a trust, a limited liability company, a partnership, a corporation or other entity) and the
United States, including, without limitation, such holder or beneficial owner (or such fiduciary, settlor, beneficiary, member,
shareholder or other equity owner or person having such a power) being or having been a citizen or resident or treated as a resident
of the United States or being or having been engaged in a trade or business in the United States or being or having been present in
the United States or having had a permanent establishment in the United States;
(2) the failure of such holder or beneficial owner to comply with any requirement under United States tax laws and regulations to
establish entitlement to a partial or complete exemption from such Taxes (including, but not limited to, the requirement to provide
Internal Revenue Service Form W-8BEN, Form W-8BEN-E, Form W-8ECI, or any subsequent versions thereof or successor
thereto); or
(3) such holder’s or beneficial owner’s present or former status as a personal holding company or a foreign personal holding
company with respect to the United States, as a controlled foreign corporation with respect to the United States, as a passive foreign
investment company with respect to the United States, as a foreign tax exempt organization with respect to the United States or as a
corporation which accumulates earnings to avoid U.S. federal income tax;
(b) any Taxes imposed by reason of the holder or beneficial owner:
-- 78 of 137 --
(1) owning or having owned, directly or indirectly, actually or constructively, 10% or more of the total combined voting
power of all classes of our stock,
(2) being a bank receiving interest described in section 881(c)(3)(A) of the Internal Revenue Code of 1986, as amended (the
“Code”), or
(3) being a controlled foreign corporation with respect to the United States that is related to us by stock ownership;
(c) any Taxes which would not have been so imposed but for the presentation by the holder or beneficial owner of such note for
payment on a date more than 10 days after the date on which such payment became due and payable or the date on which payment
of the note is duly provided for and notice is given to holders, whichever occurs later, except to the extent that the holder or
beneficial owner would have been entitled to such additional amounts on presenting such note on any date during such 10-day
period;
(d) any estate, inheritance, gift, sales, transfer, personal property, wealth, interest equalization or similar Taxes;
(e) any Taxes which are payable otherwise than by withholding from payment of principal of or interest on such note;
(f) any Taxes which are payable by a holder that is not the beneficial owner of the note, or a portion of the note, or that is a fiduciary,
partnership, limited liability company or other similar entity, but only to the extent that a beneficial owner, a beneficiary or settlor
with respect to such fiduciary or member of such partnership, limited liability company or similar entity would not have been
entitled to the payment of an additional amount had such beneficial owner, settlor, beneficiary or member received directly its
beneficial or distributive share of the payment;
(g) any Taxes required to be withheld by any paying agent from any payment of principal of or interest on any note, if such payment
can be made without such withholding by any other paying agent;
(h) any Taxes imposed under Sections 1471 through 1474 of the Code (or any amended or successor provisions that are substantively
comparable) and any current or future regulations or official interpretations thereof; or
(i) any combination of items (a), (b), (c), (d), (e), (f), (g) and (h).
For purposes of this section, the acquisition, ownership, enforcement or holding of or the receipt of any payment with respect to a
note will not constitute a connection (1) between the holder or beneficial owner and the United States or (2) between a fiduciary,
settlor, beneficiary, member or shareholder or other equity owner of, or a person having a power over, such holder or beneficial
owner if such holder or beneficial owner is an estate, a trust, a limited liability company, a partnership, a corporation or other entity
and the United States.
-- 79 of 137 --
Any reference in this exhibit, in the indenture or in the notes to principal or interest shall be deemed to refer also to Additional
Amounts which may be payable under the provisions of this section.
We will pay all stamp and other duties, if any, which may be imposed by the United States or any political subdivision thereof or
taxing authority therein with respect to the issuance of the notes.
Except as specifically provided in the notes, we will not be required to make any payment with respect to any tax, duty, assessment
or other governmental charge imposed by any government or any political subdivision or taxing authority of or in the United States.
Tax Redemption
The notes of either series may be redeemed at our option, in whole but not in part, at a redemption price equal to 100% of the
principal amount of the notes to be redeemed, together with interest accrued and unpaid to the date fixed for redemption, at any time,
on giving not less than 15 nor more than 45 days’ notice in accordance with “Notices” below if:
(a) we have or will become obligated to pay Additional Amounts as a result of any change in or amendment to the laws, regulations
or rulings of the United States or any political subdivision or any taxing authority of or in the United States affecting taxation, or any
change in or amendment to an official application, interpretation, administration or enforcement of such laws, regulations or rulings,
which change or amendment is announced or becomes effective on or after October 26, 2021, or
(b) any action shall have been taken by a taxing authority, or any action has been brought in a court of competent jurisdiction, in the
United States or any political subdivision or taxing authority of or in the United States, including any of those actions specified in (a)
above, whether or not such action was taken or brought with respect to us, or any change, clarification, amendment, application or
interpretation of such laws, regulations or rulings shall be officially proposed, in any such case on or after October 26, 2021, which
results in a substantial likelihood that we will be required to pay Additional Amounts on the next interest payment date.
However, no such notice of redemption shall be given earlier than 90 days prior to the earliest date on which we would be, in the
case of a redemption for the reasons specified in (a) above, or there would be a substantial likelihood that we would be, in the case of
a redemption for the reasons specified in (b) above, obligated to pay such Additional Amounts if a payment in respect of the notes
were then due and at the time such notification of redemption is given such circumstances remain in effect.
Such notice, once delivered by us to the trustee, will be irrevocable.
Prescription
Under New York’s statute of limitations, any legal action to enforce our payment obligations evidenced by the notes or the coupons
must be commenced within six years after the payment thereof is due; thereafter our payment obligations will generally become
unenforceable.
-- 80 of 137 --
Further Issues
We may from time to time, without notice to or the consent of the registered holders of notes of any series, create and issue further
notes ranking equally with the notes of any series in all respects. Such further notes may be consolidated and form a single series
with the notes of any such series and have the same terms as to status, redemption or otherwise as the other notes of such series
(other than the issue date of such further notes and first payment of interest following the issue date of such further notes).
Restricted Covenants
Restrictions on Secured Debt
If we or any Domestic Subsidiary shall incur, issue, assume or guarantee any Debt secured by a Mortgage on any Principal Domestic
Manufacturing Property of ours or any Domestic Subsidiary’s or on any shares of stock of any Domestic Subsidiary that owns a
Principal Domestic Manufacturing Property, we will secure, or cause such Domestic Subsidiary to secure, the debt securities then
outstanding equally and ratably with (or prior to) such Debt. However, we will not be restricted by this covenant if, after giving
effect to the particular Debt so secured the total amount of all Debt so secured, together with all Attributable Debt in respect of sale
and leaseback transactions involving Principal Domestic Manufacturing Properties, would not exceed 15% of our and our
consolidated subsidiaries’ Consolidated Net Tangible Assets.
In addition, the restriction will not apply to, and there shall be excluded in computing secured Debt for the purpose of the restriction,
Debt secured by
1. with respect to any series of debt securities, Mortgages existing on the date of the original issuance of the debt securities of
such series;
2. Mortgages on property of, or on any shares of stock of, any corporation existing at the time the corporation becomes a
Domestic Subsidiary or at the time it is merged into or consolidated with us or a Domestic Subsidiary;
3. Mortgages in favor of us or a Domestic Subsidiary;
4. Mortgages in favor of U.S., State or foreign governmental bodies to secure progress or advance payments;
5. Mortgages on property or shares of stock existing at the time of their acquisition, including acquisition through merger or
consolidation, purchase money Mortgages and construction or improvement cost Mortgages; and
6. any extension, renewal or refunding of any Mortgage referred to in the immediately preceding clauses (1) through (5),
inclusive.
The indenture does not restrict the incurrence of unsecured debt by us or our subsidiaries
Restrictions on Sales and Leasebacks
Neither we nor any Domestic Subsidiary may enter into any sale and leaseback transaction involving any Principal Domestic
Manufacturing Property, the completion of construction and commencement of full operation of which has occurred more than 180
days prior to the transaction, unless
• we or the Domestic Subsidiary could incur a lien on the property under the restrictions described above under “Restrictions
on Secured Debt” in an amount equal to the
-- 81 of 137 --
Attributable Debt with respect to the sale and leaseback transaction without equally and ratably securing the debt securities
then outstanding, or
• we, within 180 days, apply to either (or a combination of) the investment in one or more other Principal Domestic
Manufacturing Properties or the retirement of our Funded Debt an amount not less than the greater of (1) the net proceeds of
the sale of the Principal Domestic Manufacturing Property leased pursuant to such arrangement or (2) the fair market value
of the Principal Domestic Manufacturing Property so leased, subject to credits for various voluntary retirements of Funded
Debt.
a. subject to credits for various voluntary retirements of Funded Debt.
This restriction will not apply to any sale and leaseback transaction
• between us and a Domestic Subsidiary,
• between Domestic Subsidiaries, or
• involving the taking back of a lease for a period of less than three years.
Definitions Applicable to Covenants
The term “Attributable Debt” means the lesser of (1) the fair market value of the Principal Domestic Manufacturing Property sold
and leased back at the time of entering into a sale and leaseback transaction and (2) the total net amount of rent, discounted at 10%
per annum compounded annually, required to be paid during the remaining term of any lease.
The term “Consolidated Net Tangible Assets” means our total assets, less net goodwill and other intangible assets, less total current
liabilities, all as described on our and our consolidated subsidiaries’ most recent balance sheet and calculated based on positions as
reported in our consolidated financial statements in accordance with generally accepted accounting principles.
The term “Debt” means notes, bonds, debentures or other similar evidences of indebtedness for money borrowed.
The term “Domestic Subsidiary” means any of our subsidiaries except a subsidiary which neither transacts any substantial portion of
its business nor regularly maintains any substantial portion of its fixed assets within the United States or which is engaged primarily
in financing our and our subsidiaries’ operations outside the United States.
The term “Funded Debt” means Debt having a maturity of more than 12 months from its date of creation.
The term “Mortgage” means pledges, mortgages and other liens.
The term “Principal Domestic Manufacturing Property” means any facility (together with the land on which it is erected and fixtures
comprising a part of the land) used primarily for manufacturing or processing, located in the United States, owned or leased by us or
one of our subsidiaries and having a gross book value in excess of 1.0% of Consolidated Net Tangible Assets. However, the term
“Principal Domestic Manufacturing Property” does not include any facility or portion of a facility (1) which is financed by
obligations the interest on which is exempt from U.S. federal income tax pursuant to Section 103 of the Code (or any predecessor or
-- 82 of 137 --
successor provision thereof), or (2) which, in the opinion of our board of directors, is not of material importance to the total business
conducted by us and our subsidiaries as an entirety.
Events of Default
Any one of the following are events of default under the Indenture with respect to debt securities of either series:
1. our failure to pay principal of or premium, if any, on any debt security of that series when due;
2. our failure to pay any interest on any debt security of that series when due, continued for 30 days;
3. our failure to deposit any sinking fund payment, when due, in respect of any debt security of that series;
4. our failure to perform any other of our covenants in the Indenture which affects or is applicable to the debt securities of that
series, other than a covenant included in the Indenture solely for the benefit of other series of debt securities, continued for 90
days after written notice as provided in the indenture;
5. certain events involving bankruptcy, insolvency or reorganization; and
6. any other event of default provided with respect to debt securities of that series.
If an event of default with respect to outstanding debt securities of any series shall occur and be continuing, either the trustee or the
holders of at least 25% in principal amount of the outstanding debt securities of that series may declare the principal amount (or, if
the debt securities of that series are original issue discount securities, the portion of the principal amount as may be specified in the
terms of that series) of all the debt securities of that series to be due and payable immediately. At any time after a declaration of
acceleration with respect to debt securities of any series has been made, but before a judgment or decree based on acceleration has
been obtained, the holders of a majority in principal amount of the outstanding debt securities of that series may, under some
circumstances, rescind and annul the acceleration. For information as to waiver of defaults, see the section below entitled
“Modification and Waiver.”
During default, the trustee has a duty to act with the required standard of care. Otherwise, the Indenture provides that the trustee will
be under no obligation to exercise any of its rights or powers under the Indenture at the request or direction of any of the holders,
unless the holders shall have offered to the trustee reasonable indemnity. If the provisions for indemnification of the trustee have
been satisfied, the holders of a majority in principal amount of the outstanding debt securities of any series will have the right to
direct the time, method and place of conducting any proceeding for any remedy available to the trustee, or exercising any trust or
power conferred on the trustee, with respect to the debt securities of that series.
We will furnish to the trustee annually a certificate as to our compliance with all conditions and covenants under the Indenture.
Defeasance and Discharge
We will be discharged from any and all obligations in respect of the debt securities of any series if we deposit with the trustee, in
trust, money and/or U.S. government securities which through
-- 83 of 137 --
the payment of interest and principal will provide money in an amount sufficient to pay the principal of and premium, if any, and
each installment of interest on the debt securities of the series on the dates those payments are due and payable.
If we defease a series of debt securities, the holders of the debt securities of the series will not be entitled to the benefits of the
Indenture, except for
• the rights of holders to receive from the trust funds payment of principal, premium and interest on the debt securities,
• our obligation to register the transfer or exchange of debt securities of the series,
• our obligation to replace stolen, lost or mutilated debt securities of the series,
• our obligation to maintain paying agencies,
• our obligation to hold monies for payment in trust, and
• the rights of holders to benefit, as applicable, from the rights, powers, trusts, duties and immunities of the trustee.
We may defease a series of debt securities only if, among other things, we have delivered to the Trustee an opinion of counsel to the
effect that we have received from, or there has been published by, the U.S. Internal Revenue Service a ruling to the effect that
holders and beneficial owners of the debt securities of the series will not recognize income, gain or loss for U.S. federal income tax
purposes as a result of the deposit, defeasance and discharge and will be subject to U.S. federal income tax on the same amount and
in the same manner and at the same times as would have been the case if the deposit, defeasance and discharge had not occurred.
Defeasance of Covenants and Events of Default
We may omit to comply with the covenants described above under “Restrictions on Secured Debt” and “Restrictions on Sales and
Leasebacks”, and the failure to comply with these covenants will not be deemed an event of default, if we deposit with the trustee, in
trust, money and/or U.S. government securities which through the payment of interest and principal will provide money in an
amount sufficient to pay the principal of and premium, if any, and each installment of interest on the debt securities of the series on
the dates those payments are due and payable. Our obligations under the Indenture and the debt securities of the series will remain in
full force and effect, other than with respect to the defeased covenants and related events of default.
We may defease the covenants and the related events of default described above only if, among other things, we have delivered to
the trustee an opinion of counsel, who may be our employee or counsel, to the effect that the holders and beneficial owners of the
debt securities of the series will not recognize income, gain or loss for U.S. federal income tax purposes as a result of the deposit and
defeasance of the covenants and events of default, and the holders and beneficial owners of the debt securities of the series will be
subject to U.S. federal income tax on the same amount and in the same manner and at the same times as would have been the case if
the deposit and defeasance had not occurred.
If we choose covenant defeasance with respect to the debt securities of any series as described above and the debt securities of the
series are declared due and payable because of the occurrence of any event of default other than the event of default described in
clause (4) under
-- 84 of 137 --
“Events of Default,” the amount of money and U.S. government securities on deposit with the trustee will be sufficient to pay
amounts due on the debt securities of the series at the time of their stated maturity. The amount on deposit with the trustee may not
be sufficient to pay amounts due on the debt securities of the series at the time of the acceleration resulting from the event of default.
However, we will remain liable for these payments.
Modification and Waiver
Procter & Gamble and the trustee may make modifications of and amendments to the indenture if the holders of at least a majority in
principal amount of the outstanding debt securities of each series affected by the modification or amendment consent to the
modification or amendment.
However, the consent of the holder of each debt security affected will be required for any modification or amendment that
• changes the stated maturity of the principal of, or any installment of principal of or interest on, any debt security,
• reduces the principal amount of, or the premium, if any, or interest, if any, on, any debt security,
• reduces the amount of principal of an original issue discount security payable upon acceleration of the maturity of the
security,
• changes the place or currency of payment of principal of, or premium, if any, or interest, if any, on, any debt security,
• impairs the right to institute suit for the enforcement of any payment on any debt security, or
• reduces the percentage in principal amount of debt securities of any series necessary to modify or amend the Indenture or to
waive compliance with various provisions of the Indenture or to waive various defaults.
Without the consent of any holder of debt securities, we and the trustee may make modifications or amendments to the Indenture in
order to
• evidence the succession of another person to us and the assumption by that person of the covenants in the Indenture,
• add to the covenants for the benefit of the holders,
• add additional events of default,
• permit or facilitate the issuance of securities in bearer form or uncertificated form,
• add to, change, or eliminate any provision of the Indenture in respect of a series of debt securities to be created in the future,
• secure the securities as required by “—Restrictive Covenants-Restrictions on Secured Debt,”
• establish the form or terms of securities of any series,
• evidence the appointment of a successor trustee, or
• cure any ambiguity, correct or supplement any provision which may be inconsistent with another provision, or make any
other provision, provided that any action may not adversely affect the interests of holders of debt securities in any material
respect.
The holders of at least a majority in principal amount of the outstanding debt securities of any series may on behalf of the holders of
all debt securities of that series waive compliance by us with various restrictive provisions of the Indenture.
-- 85 of 137 --
The holders of a majority in principal amount of the outstanding debt securities of any series may on behalf of the holders of all debt
securities of that series waive any past default with respect to that series, except
• a default in the payment of the principal of or premium, if any, or interest on any debt security of that series, or
• a default in respect of a provision which under the Indenture cannot be modified or amended without the consent of the
holder of each outstanding debt security of that series that would be affected.
Consolidation, Merger and Sale of Assets
If the conditions below are met, we may, without the consent of any holders of outstanding debt securities:
• consolidate or merge with or into another entity, or
• transfer or lease our assets as an entirety to another entity.
We have agreed that we will engage in a consolidation, merger or transfer or lease of assets as an entirety only if
• either we are the surviving entity or the entity formed by the consolidation or into which we are merged or which acquires or
leases our assets is a corporation, partnership, limited liability company or trust organized and existing under the laws of any
United States jurisdiction and assumes our obligations on the debt securities and under the indenture,
• after giving effect to the transaction no event of default would have happened and be continuing, and
• various other conditions are met.
Regarding the Trustee
Deutsche Bank Trust Company Americas is the trustee under the indenture. In addition, affiliates of Deutsche Bank Trust Company
Americas may perform various commercial banking and investment banking services for Procter & Gamble and its subsidiaries from
time to time in the ordinary course of business.
-- 86 of 137 --
Exhibit (4-11)
Description of the Company’s 0.110% Yen Notes due 2026 and 0.230% Yen Notes due
2031
-- 87 of 137 --
Description of the Company’s 0.275% Notes due 2020, Registered Under Section 12 of the Securities Exchange Act of 1934
The following summary of The Procter & Gamble Company’s above referenced debt securities is based on and qualified by the
Indenture, dated as of September 3, 2009, between the Company and Deutsche Bank Trust Company Americas, as Trustee (the
“Indenture”) and the 0.110% Yen notes due 2026 and 0.230% Yen notes due 2031 (collectively, the “Notes”). For a complete
description of the terms and provisions of the Company’s Notes, refer to the Indenture and to the forms of Notes, all of which are
filed as exhibits to the Form 8-A filed with the Securities and Exchange Commission on November 8, 2021.
General
The 0.110% notes:
• were issued in an aggregate initial principal amount of ¥50,000,000,000, subject to our ability to issue additional 0.110%
notes which may be of the same series as the 0.110% notes as described under “Further Issues,”
• mature on November 6, 2026,
• bear interest at a rate of 0.110% per annum,
• are unsecured,
• are senior debt, ranking equally with all of our other present and future unsecured and unsubordinated indebtedness,
• were issued as a separate series under the Indenture, in registered, book-entry form only,
• were issued in Japanese Yen in denominations of ¥100,000,000 and integral multiples of ¥10,000,000 in excess thereof,
• will be repaid at par at maturity,
• are not redeemable prior to maturity, other than as described below in connection with certain events involving United States
taxation,
• are subject to defeasance and covenant defeasance, and
• are not subject to any sinking fund.
The 0.230% notes:
• were issued in an aggregate initial principal amount of ¥50,000,000,000, subject to our ability to issue additional 0.230%
notes which may be of the same series as the 0.230% notes as described under “—Further Issues,”
• mature on November 6, 2031,
• bear interest at a rate of 0.230% per annum,
• are unsecured,
• are senior debt, ranking equally with all of our other present and future unsecured and unsubordinated indebtedness,
• were issued as a separate series under the Indenture, in registered, book-entry form only,
• were issued in Japanese Yen in denominations of ¥100,000,000 and integral multiples of ¥10,000,000 in excess thereof,
• will be repaid at par at maturity,
• are not redeemable prior to maturity, other than as described below in connection with certain events involving United States
taxation,
• are subject to defeasance and covenant defeasance, and
• are not subject to any sinking fund.
-- 88 of 137 --
The Indenture and the notes do not limit the amount of indebtedness which may be incurred or the amount of securities which may
be issued by us or our subsidiaries, and contain no financial or similar restrictions on us or our subsidiaries, except as described in
the accompanying prospectus under the captions “Restrictions on Secured Debt” and “Restrictions on Sales and Leasebacks.”
The Notes are listed on the New York Stock Exchange.
Interest
We pay interest on the 0.110% notes and the 0.230% notes semi-annually on May 6 and November 6 of each year, as applicable, and
on any maturity date (each, an “interest payment date”), commencing May 6, 2022 and ending on any maturity date, to the persons
in whose names the 0.110% notes and the 0.230% notes are registered at the close of business on May 1 or November 1 , as
applicable (in each case, whether or not a Business Day), immediately preceding the related interest payment date; provided,
however, that interest payable on any maturity date shall be payable to the person to whom the principal of such notes shall be
payable. Interest on the notes will be computed on the basis of a 360-day year of twelve 30-day months.
Interest payable on any interest payment date or maturity date shall be the amount of interest accrued from, and including, the
immediately preceding interest payment date in respect of which interest has been paid or duly provided for (or from and including
the original issue date, if no interest has been paid or duly provided for with respect to the notes) to, but excluding, such interest
payment date or maturity date, as the case may be. If any interest payment date is not a Business Day at the relevant place of
payment, we will pay interest on the next day that is a Business Day at such place of payment as if payment were made on the date
such payment was due, and no interest will accrue on the amounts so payable for the period from and after such date to the
immediately succeeding Business Day. If the maturity date or redemption date of the notes is not a Business Day at the relevant
place of payment, we will pay interest, if any, and principal and premium, if any, on the next day that is a Business Day at such place
of payment as if payment were made on the date such payment was due, and no interest will accrue on the amounts so payable for
the period from and after such date to the immediately succeeding Business Day.
“Business Day” means any day which is a day on which commercial banks settle payments and are open for general business in: (a)
the relevant place of payment, and (b) The City of New York, Tokyo and London.
The term “maturity,” when used with respect to a note, means the date on which the principal of such note or an installment of
principal becomes due and payable as therein provided or as provided in the Indenture, whether at the stated maturity or by
declaration of acceleration, call for redemption, repayment or otherwise.
Additional Amounts
All payments of principal and interest in respect of the notes will be made free and clear of, and without deduction or withholding
for or on account of any present or future taxes, duties,
-- 89 of 137 --
assessments or other governmental charges of whatsoever nature imposed, levied, collected, withheld or assessed by the United
States or any political subdivision or taxing authority of or in the United States (collectively, “Taxes”), unless such withholding or
deduction is required by law.
In the event such withholding or deduction of Taxes is required by law, subject to the limitations described below, we will pay to the
holder or beneficial owner of any note that is not a United States holder such additional amounts (“Additional Amounts”) as may be
necessary in order that every net payment by us or any paying agent of principal of or interest on the notes (including upon
redemption), after deduction or withholding for or on account of such Taxes, will not be less than the amount provided for in such
note to be then due and payable before deduction or withholding for or on account of such Taxes.
However, our obligation to pay Additional Amounts shall not apply to:
(a) any Taxes which would not have been so imposed but for:
(1) the existence of any present or former connection between such holder or beneficial owner (or between a fiduciary,
settlor, beneficiary, member or shareholder or other equity owner of, or a person having a power over, such holder or beneficial
owner, if such holder or beneficial owner is an estate, a trust, a limited liability company, a partnership, a corporation or other entity)
and the United States, including, without limitation, such holder or beneficial owner (or such fiduciary, settlor, beneficiary, member,
shareholder or other equity owner or person having such a power) being or having been a citizen or resident or treated as a resident
of the United States or being or having been engaged in a trade or business in the United States or being or having been present in
the United States or having had a permanent establishment in the United States;
(2) the failure of such holder or beneficial owner to comply with any requirement under United States tax laws and
regulations to establish entitlement to a partial or complete exemption from such Taxes (including, but not limited to, the
requirement to provide Internal Revenue Service Form W-8BEN, Form W-8BEN-E, Form W-8ECI, or any subsequent versions
thereof or successor thereto); or
(3) such holder’s or beneficial owner’s present or former status as a personal holding company or a foreign personal holding
company with respect to the United States, as a controlled foreign corporation with respect to the United States, as a passive foreign
investment company with respect to the United States, as a foreign tax exempt organization with respect to the United States or as a
corporation which accumulates earnings to avoid U.S. federal income tax;
(b) any Taxes imposed by reason of the holder or beneficial owner:
(1) owning or having owned, directly or indirectly, actually or constructively, 10% or more of the total combined voting
power of all classes of our stock,
(2) being a bank receiving interest described in section 881(c)(3)(A) of the Internal Revenue Code of 1986, as amended (the
“Code”), or
-- 90 of 137 --
(3) being a controlled foreign corporation with respect to the United States that is related to us by stock ownership;
(c) any Taxes which would not have been so imposed but for the presentation by the holder or beneficial owner of such note for
payment on a date more than 10 days after the date on which such payment became due and payable or the date on which payment
of the note is duly provided for and notice is given to holders, whichever occurs later, except to the extent that the holder or
beneficial owner would have been entitled to such additional amounts on presenting such note on any date during such 10-day
period;
(d) any estate, inheritance, gift, sales, transfer, personal property, wealth, interest equalization or similar Taxes;
(e) any Taxes which are payable otherwise than by withholding from payment of principal of or interest on such note;
(f) any Taxes which are payable by a holder that is not the beneficial owner of the note, or a portion of the note, or that is a fiduciary,
partnership, limited liability company or other similar entity, but only to the extent that a beneficial owner, a beneficiary or settlor
with respect to such fiduciary or member of such partnership, limited liability company or similar entity would not have been
entitled to the payment of an additional amount had such beneficial owner, settlor, beneficiary or member received directly its
beneficial or distributive share of the payment;
(g) any Taxes required to be withheld by any paying agent from any payment of principal of or interest on any note, if such payment
can be made without such withholding by any other paying agent;
(h) any Taxes imposed under Sections 1471 through 1474 of the Code (or any amended or successor provisions that are substantively
comparable) and any current or future regulations or official interpretations thereof; or
(i) any combination of items (a), (b), (c), (d), (e), (f), (g) and (h).
For purposes of this section, the acquisition, ownership, enforcement or holding of or the receipt of any payment with respect to a
note will not constitute a connection (1) between the holder or beneficial owner and the United States or (2) between a fiduciary,
settlor, beneficiary, member or shareholder or other equity owner of, or a person having a power over, such holder or beneficial
owner if such holder or beneficial owner is an estate, a trust, a limited liability company, a partnership, a corporation or other entity
and the United States.
Any reference in this exhibit, in the Indenture or in the notes to principal or interest shall be deemed to refer also to Additional
Amounts which may be payable under the provisions of this section.
We will pay all stamp and other duties, if any, which may be imposed by the United States or any political subdivision thereof or
taxing authority therein with respect to the issuance of the notes.
-- 91 of 137 --
Except as specifically provided in the notes, we will not be required to make any payment with respect to any tax, duty, assessment
or other governmental charge imposed by any government or any political subdivision or taxing authority of or in the United States.
Tax Redemption
Except as provided below, the notes may not be redeemed prior to maturity. Unless previously redeemed or repurchased and
canceled, the notes will be repayable at par, including Additional Amounts, if any, on November 6, 2026 in the case of the 0.110%
notes and on November 6, 2031 in the case of the 0.230% notes, or such earlier date on which the same shall be due and payable in
accordance with the terms and conditions of the notes. However, if the maturity date of the notes is not a Business Day, the notes
will be payable on the next succeeding Business Day and no interest shall accrue for the period from November 6, 2026 in case of
the 0.110% notes and from November 6, 2031 in case of the 0.230% notes to such payment date.
The notes of either series may be redeemed at our option, in whole but not in part, at a redemption price equal to 100% of the
principal amount of the notes to be redeemed, together with interest accrued and unpaid to the date fixed for redemption, at any time,
on giving not less than 15 nor more than 45 days’ notice if:
(a) we have or will become obligated to pay Additional Amounts as a result of any change in or amendment to the laws, regulations
or rulings of the United States or any political subdivision or any taxing authority of or in the United States affecting taxation, or any
change in or amendment to an official application, interpretation, administration or enforcement of such laws, regulations or rulings,
which change or amendment is announced or becomes effective on or after October 29, 2021, or
(b) any action shall have been taken by a taxing authority, or any action has been brought in a court of competent jurisdiction, in the
United States or any political subdivision or taxing authority of or in the United States, including any of those actions specified in (a)
above, whether or not such action was taken or brought with respect to us, or any change, clarification, amendment, application or
interpretation of such laws, regulations or rulings shall be officially proposed, in any such case on or after October 29, 2021, which
results in a substantial likelihood that we will be required to pay Additional Amounts on the next interest payment date.
However, no such notice of redemption shall be given earlier than 90 days prior to the earliest date on which we would be, in the
case of a redemption for the reasons specified in (a) above, or there would be a substantial likelihood that we would be, in the case of
a redemption for the reasons specified in (b) above, obligated to pay such Additional Amounts if a payment in respect of the notes
were then due and at the time such notification of redemption is given such circumstances remain in effect.
Such notice, once delivered by us to the trustee, will be irrevocable.
Prescription
Under New York’s statute of limitations, any legal action to enforce our payment obligations evidenced by the notes or the coupons
must be commenced within six years after the payment thereof is due; thereafter our payment obligations will generally become
unenforceable.
-- 92 of 137 --
Further Issues
We may from time to time, without notice to or the consent of the registered holders of notes, create and issue further notes ranking
equally with the notes in all respects. Such further notes may be consolidated and form a single series with the notes and have the
same terms as to status, redemption or otherwise as the other notes (other than the issue date of such further notes and first payment
of interest following the issue date of such further notes).
Restricted Covenants
Restrictions on Secured Debt
If we or any Domestic Subsidiary shall incur, issue, assume or guarantee any Debt secured by a Mortgage on any Principal Domestic
Manufacturing Property of ours or any Domestic Subsidiary’s or on any shares of stock of any Domestic Subsidiary that owns a
Principal Domestic Manufacturing Property, we will secure, or cause such Domestic Subsidiary to secure, the debt securities then
outstanding equally and ratably with (or prior to) such Debt. However, we will not be restricted by this covenant if, after giving
effect to the particular Debt so secured the total amount of all Debt so secured, together with all Attributable Debt in respect of sale
and leaseback transactions involving Principal Domestic Manufacturing Properties, would not exceed 15% of our and our
consolidated subsidiaries’ Consolidated Net Tangible Assets.
In addition, the restriction will not apply to, and there shall be excluded in computing secured Debt for the purpose of the restriction,
Debt secured by
1. with respect to any series of debt securities, Mortgages existing on the date of the original issuance of the debt securities of
such series;
2. Mortgages on property of, or on any shares of stock of, any corporation existing at the time the corporation becomes a
Domestic Subsidiary or at the time it is merged into or consolidated with us or a Domestic Subsidiary;
3. Mortgages in favor of us or a Domestic Subsidiary;
4. Mortgages in favor of U.S., State or foreign governmental bodies to secure progress or advance payments;
5. Mortgages on property or shares of stock existing at the time of their acquisition, including acquisition through merger or
consolidation, purchase money Mortgages and construction or improvement cost Mortgages; and
6. any extension, renewal or refunding of any Mortgage referred to in the immediately preceding clauses (1) through (5),
inclusive.
The indenture does not restrict the incurrence of unsecured debt by us or our subsidiaries
Restrictions on Sales and Leasebacks
Neither we nor any Domestic Subsidiary may enter into any sale and leaseback transaction involving any Principal Domestic
Manufacturing Property, the completion of construction and commencement of full operation of which has occurred more than 180
days prior to the transaction, unless
• we or the Domestic Subsidiary could incur a lien on the property under the restrictions described above under “Restrictions
on Secured Debt” in an amount equal to the
-- 93 of 137 --
Attributable Debt with respect to the sale and leaseback transaction without equally and ratably securing the debt securities
then outstanding, or
• we, within 180 days, apply to either (or a combination of) the investment in one or more other Principal Domestic
Manufacturing Properties or the retirement of our Funded Debt an amount not less than the greater of (1) the net proceeds of
the sale of the Principal Domestic Manufacturing Property leased pursuant to such arrangement or (2) the fair market value
of the Principal Domestic Manufacturing Property so leased, subject to credits for various voluntary retirements of Funded
Debt.
This restriction will not apply to any sale and leaseback transaction
• between us and a Domestic Subsidiary,
• between Domestic Subsidiaries, or
• involving the taking back of a lease for a period of less than three years.
Definitions Applicable to Covenants
The term “Attributable Debt” means the lesser of (1) the fair market value of the Principal Domestic Manufacturing Property sold
and leased back at the time of entering into a sale and leaseback transaction and (2) the total net amount of rent, discounted at 10%
per annum compounded annually, required to be paid during the remaining term of any lease.
The term “Consolidated Net Tangible Assets” means our total assets, less net goodwill and other intangible assets, less total current
liabilities, all as described on our and our consolidated subsidiaries’ most recent balance sheet and calculated based on positions as
reported in our consolidated financial statements in accordance with generally accepted accounting principles.
The term “Debt” means notes, bonds, debentures or other similar evidences of indebtedness for money borrowed.
The term “Domestic Subsidiary” means any of our subsidiaries except a subsidiary which neither transacts any substantial portion of
its business nor regularly maintains any substantial portion of its fixed assets within the United States or which is engaged primarily
in financing our and our subsidiaries’ operations outside the United States.
The term “Funded Debt” means Debt having a maturity of more than 12 months from its date of creation.
The term “Mortgage” means pledges, mortgages and other liens.
The term “Principal Domestic Manufacturing Property” means any facility (together with the land on which it is erected and fixtures
comprising a part of the land) used primarily for manufacturing or processing, located in the United States, owned or leased by us or
one of our subsidiaries and having a gross book value in excess of 1.0% of Consolidated Net Tangible Assets. However, the term
“Principal Domestic Manufacturing Property” does not include any facility or portion of a facility (1) which is financed by
obligations the interest on which is exempt from U.S. federal income tax pursuant to Section 103 of the Code (or any predecessor or
-- 94 of 137 --
successor provision thereof), or (2) which, in the opinion of our board of directors, is not of material importance to the total business
conducted by us and our subsidiaries as an entirety.
Events of Default
Any one of the following are events of default under the Indenture with respect to debt securities of either series:
1. our failure to pay principal of or premium, if any, on any debt security of that series when due;
2. our failure to pay any interest on any debt security of that series when due, continued for 30 days;
3. our failure to deposit any sinking fund payment, when due, in respect of any debt security of that series;
4. our failure to perform any other of our covenants in the Indenture which affects or is applicable to the debt securities of that
series, other than a covenant included in the Indenture solely for the benefit of other series of debt securities, continued for 90
days after written notice as provided in the indenture;
5. certain events involving bankruptcy, insolvency or reorganization; and
6. any other event of default provided with respect to debt securities of that series.
If an event of default with respect to outstanding debt securities of any series shall occur and be continuing, either the trustee or the
holders of at least 25% in principal amount of the outstanding debt securities of that series may declare the principal amount (or, if
the debt securities of that series are original issue discount securities, the portion of the principal amount as may be specified in the
terms of that series) of all the debt securities of that series to be due and payable immediately. At any time after a declaration of
acceleration with respect to debt securities of any series has been made, but before a judgment or decree based on acceleration has
been obtained, the holders of a majority in principal amount of the outstanding debt securities of that series may, under some
circumstances, rescind and annul the acceleration. For information as to waiver of defaults, see the section below entitled
“Modification and Waiver.”
During default, the trustee has a duty to act with the required standard of care. Otherwise, the Indenture provides that the trustee will
be under no obligation to exercise any of its rights or powers under the Indenture at the request or direction of any of the holders,
unless the holders shall have offered to the trustee reasonable indemnity. If the provisions for indemnification of the trustee have
been satisfied, the holders of a majority in principal amount of the outstanding debt securities of any series will have the right to
direct the time, method and place of conducting any proceeding for any remedy available to the trustee, or exercising any trust or
power conferred on the trustee, with respect to the debt securities of that series.
We will furnish to the trustee annually a certificate as to our compliance with all conditions and covenants under the Indenture.
Defeasance and Discharge
We will be discharged from any and all obligations in respect of the debt securities of any series if we deposit with the trustee, in
trust, money and/or U.S. government securities which through
-- 95 of 137 --
the payment of interest and principal will provide money in an amount sufficient to pay the principal of and premium, if any, and
each installment of interest on the debt securities of the series on the dates those payments are due and payable.
If we defease a series of debt securities, the holders of the debt securities of the series will not be entitled to the benefits of the
Indenture, except for
• the rights of holders to receive from the trust funds payment of principal, premium and interest on the debt securities,
• our obligation to register the transfer or exchange of debt securities of the series,
• our obligation to replace stolen, lost or mutilated debt securities of the series,
• our obligation to maintain paying agencies,
• our obligation to hold monies for payment in trust, and
• the rights of holders to benefit, as applicable, from the rights, powers, trusts, duties and immunities of the trustee.
We may defease a series of debt securities only if, among other things, we have delivered to the Trustee an opinion of counsel to the
effect that we have received from, or there has been published by, the U.S. Internal Revenue Service a ruling to the effect that
holders and beneficial owners of the debt securities of the series will not recognize income, gain or loss for U.S. federal income tax
purposes as a result of the deposit, defeasance and discharge and will be subject to U.S. federal income tax on the same amount and
in the same manner and at the same times as would have been the case if the deposit, defeasance and discharge had not occurred.
Defeasance of Covenants and Events of Default
We may omit to comply with the covenants described above under “Restrictions on Secured Debt” and “Restrictions on Sales and
Leasebacks”, and the failure to comply with these covenants will not be deemed an event of default, if we deposit with the trustee, in
trust, money and/or U.S. government securities which through the payment of interest and principal will provide money in an
amount sufficient to pay the principal of and premium, if any, and each installment of interest on the debt securities of the series on
the dates those payments are due and payable. Our obligations under the Indenture and the debt securities of the series will remain in
full force and effect, other than with respect to the defeased covenants and related events of default.
We may defease the covenants and the related events of default described above only if, among other things, we have delivered to
the trustee an opinion of counsel, who may be our employee or counsel, to the effect that the holders and beneficial owners of the
debt securities of the series will not recognize income, gain or loss for U.S. federal income tax purposes as a result of the deposit and
defeasance of the covenants and events of default, and the holders and beneficial owners of the debt securities of the series will be
subject to U.S. federal income tax on the same amount and in the same manner and at the same times as would have been the case if
the deposit and defeasance had not occurred.
If we choose covenant defeasance with respect to the debt securities of any series as described above and the debt securities of the
series are declared due and payable because of the occurrence of any event of default other than the event of default described in
clause (4) under
-- 96 of 137 --
“Events of Default,” the amount of money and U.S. government securities on deposit with the trustee will be sufficient to pay
amounts due on the debt securities of the series at the time of their stated maturity. The amount on deposit with the trustee may not
be sufficient to pay amounts due on the debt securities of the series at the time of the acceleration resulting from the event of default.
However, we will remain liable for these payments.
Modification and Waiver
Procter & Gamble and the trustee may make modifications of and amendments to the indenture if the holders of at least a majority in
principal amount of the outstanding debt securities of each series affected by the modification or amendment consent to the
modification or amendment.
However, the consent of the holder of each debt security affected will be required for any modification or amendment that
• changes the stated maturity of the principal of, or any installment of principal of or interest on, any debt security,
• reduces the principal amount of, or the premium, if any, or interest, if any, on, any debt security,
• reduces the amount of principal of an original issue discount security payable upon acceleration of the maturity of the
security,
• changes the place or currency of payment of principal of, or premium, if any, or interest, if any, on, any debt security,
• impairs the right to institute suit for the enforcement of any payment on any debt security, or
• reduces the percentage in principal amount of debt securities of any series necessary to modify or amend the Indenture or to
waive compliance with various provisions of the Indenture or to waive various defaults.
Without the consent of any holder of debt securities, we and the trustee may make modifications or amendments to the Indenture in
order to
• evidence the succession of another person to us and the assumption by that person of the covenants in the Indenture,
• add to the covenants for the benefit of the holders,
• add additional events of default,
• permit or facilitate the issuance of securities in bearer form or uncertificated form,
• add to, change, or eliminate any provision of the Indenture in respect of a series of debt securities to be created in the future,
• secure the securities as required by “—Restrictive Covenants-Restrictions on Secured Debt,”
• establish the form or terms of securities of any series,
• evidence the appointment of a successor trustee, or
• cure any ambiguity, correct or supplement any provision which may be inconsistent with another provision, or make any
other provision, provided that any action may not adversely affect the interests of holders of debt securities in any material
respect.
The holders of at least a majority in principal amount of the outstanding debt securities of any series may on behalf of the holders of
all debt securities of that series waive compliance by us with various restrictive provisions of the Indenture.
-- 97 of 137 --
The holders of a majority in principal amount of the outstanding debt securities of any series may on behalf of the holders of all debt
securities of that series waive any past default with respect to that series, except
• a default in the payment of the principal of or premium, if any, or interest on any debt security of that series, or
• a default in respect of a provision which under the Indenture cannot be modified or amended without the consent of the
holder of each outstanding debt security of that series that would be affected.
Consolidation, Merger and Sale of Assets
If the conditions below are met, we may, without the consent of any holders of outstanding debt securities:
• consolidate or merge with or into another entity, or
• transfer or lease our assets as an entirety to another entity.
We have agreed that we will engage in a consolidation, merger or transfer or lease of assets as an entirety only if
• either we are the surviving entity or the entity formed by the consolidation or into which we are merged or which acquires or
leases our assets is a corporation, partnership, limited liability company or trust organized and existing under the laws of any
United States jurisdiction and assumes our obligations on the debt securities and under the indenture,
• after giving effect to the transaction no event of default would have happened and be continuing, and
• various other conditions are met.
Regarding the Trustee
Deutsche Bank Trust Company Americas is the trustee under the indenture. In addition, affiliates of Deutsche Bank Trust Company
Americas may perform various commercial banking and investment banking services for Procter & Gamble and its subsidiaries from
time to time in the ordinary course of business.
-- 98 of 137 --
Exhibit (10-10)
STAR Program Summary
-- 99 of 137 --
SHORT TERM ACHIEVEMENT REWARD PROGRAM
(Effective July 1, 2022)
The Short-Term Achievement Reward (“STAR”) Program is The Procter & Gamble Company’s (the “Company”) annual
bonus program designed to motivate and reward employees for achieving outstanding short-term business results for
the Company and its subsidiaries. STAR awards are made pursuant to authority delegated to the Compensation &
Leadership Development Committee (the “C&LD Committee”) by the Board of Directors for awarding compensation to
the Company’s principal officers and for making awards under the Procter & Gamble 2019 Stock and Incentive
Compensation Plan (the “2019 Plan”) or any successor stock plan approved in accordance with applicable listing
standards.
I. ELIGIBILITY
Employees at Band 1 or above and who worked at least 28 days (four calendar weeks) during the applicable fiscal year
are eligible to participate. Eligible employees who do not work a full schedule (e.g., leaves of absence, disability, and
less-than-full time schedules) in the fiscal year in which the award is payable may have awards pro-rated.
II. CALCULATION
The individual STAR Award is calculated as follows:
(STAR Target) x [ (Business Unit Performance Factor x 70% weighting) + (Total Company Performance Factor X
30% weighting) ]
• The STAR Target for each participant is calculated as:
(Base Salary) x (STAR Target percent) where Base Salary at the end of the applicable fiscal year is used to
calculate the STAR award; except in cases where an employee has a reduction in salary during the fiscal year, in
which case the salary would be prorated, or in cases where an employee becomes ineligible for the program during
the fiscal year, in which case base salary as of the end of the STAR eligible level will be used. Generally, the STAR
Target Percent is dependent on the individual’s position and level (Band) in the organization. The STAR Target
percent for participants at Band 7 or above is set by the C&LD Committee. The STAR Target percent for all other
participants is set by the Chief Executive Officer, with the concurrence of the Chief Human Resources Officer,
pursuant to authority delegated to them by the C&LD Committee. If an individual’s position and/or level changes
during a fiscal year, and that change results in a new STAR Target Percent, the STAR Target Percent is pro-rated
according to the amount of time in each position/level during the fiscal year.
• The Business Unit Performance Factor is weighted at 70% and is based on the fiscal year success for the
appropriate STAR business unit. The STAR business units are defined by the Chief Human Resources Officer and
may consist of business categories, segments, geographies, functions, organizations or a combination of one or
more of these items. The STAR business units will be defined within ninety (90) days of the beginning of the fiscal
year but may be adjusted as necessary to reflect business and/or organizational changes (e.g., reorganization,
acquisition, merger, divestiture, etc.). The Business Unit Performance Factors can range from 0% to 200% with a
target of 100%. In general, a committee consisting of at least two of the Chief Executive Officer, Chief Financial
Officer, Chief Human Resources
-- 100 of 137 --
Officer and/or the Chief Operating Officer (the “STAR Committee”), conducts a comprehensive retrospective
assessment of the fiscal year performance of each STAR business unit against previously established goals and
relative to competition for one or more of the following measures: Operating Total Shareholder Return, After Tax
Profit, Free Cash Flow Productivity, Value Share, Organic Sales, Internal controls, Accounts receivable, Inventory,
Organization Head Self-Assessment, and Cross Organization Assessment. The STAR Committee makes a
recommendation of an appropriate Business Unit Performance Factor to the C&LD Committee. There may also be
other factors significantly affecting STAR business unit results positively or negatively which can be considered by
the STAR Committee when making its recommendation. No member of the STAR Committee makes any
recommendation or determination as to their own STAR award. As a result, there are certain instances in which a
Business Unit Performance Factor recommendation to the C&LD Committee must be made exclusively by the Chief
Executive Officer.
Business Unit leaders may then allocate the approved STAR Business Unit Factors among the divisions of the
Business Unit to more closely align the STAR award with performance, so long as the total expenditure does not
exceed that approved by the STAR Committee and no individual STAR award exceeds 200% of target.
• The Total Company Performance Factor is weighted at 30% and is based on the total Company’s success during
the fiscal year and ranges from 0% to 200%, with a target of 100%. The same Total Company Performance Factor is
applied to all STAR award calculations, regardless of STAR business unit. It is determined using a matrix which
compares results against pre-established goals for fiscal year organic sales growth and core earnings per share
(“EPS”) growth for the fiscal year. For participants who are members of the Global Leadership Council (GLC) at any
time during the fiscal year, an ESG Factor will be applied to the Total Company Performance Factor. The ESG Factor
will be based on an ESG scorecard approved by the C&LD Committee in the August meeting at the start of the fiscal
year. Based on a retrospective assessment of final fiscal year results, a factor in the range of 80% - 120% will be
assigned and multiplied by the Total Company Performance Factor to determine final awards. Application of the ESG
Factor may not cause the final award to exceed the 200% of target maximum.
While the STAR Committee makes recommendations to the C&LD Committee regarding the Business Unit and Total
Company performance factors to be applied to all STAR awards (except those for the STAR Committee members), only
the final award amounts for principal officers are approved specifically by the C&LD Committee. The C&LD Committee
has delegated the approval of STAR awards for other participants to the Chief Executive Officer. The C&LD Committee
has discretion to use, increase or decrease the performance factors recommended by the STAR Committee and/or to
choose not to pay STAR awards during a given year.
III. TIMING AND FORM
STAR awards are determined after the close of the fiscal year and are paid on or about September 15. The award form
choices and relevant considerations are explained to participants annually. Participants receive written notice of their
award detailing the calculation and grant letters for those employees who elect to receive awards in stock options
Generally, STAR awards are paid in cash. However, before the end of the calendar year preceding the award date,
eligible participants can elect to receive their STAR award in forms
-- 101 of 137 --
other than cash. Alternatives to cash include stock options, stock appreciation rights (“SARs”), local deferral programs
(depending on local regulations in some countries) and/or deferred compensation (for employees eligible to participate in
the Executive Deferred Compensation Program). The number of stock options or SARs awarded to each employee will
be determined on grant date by determining the USD value of the award chosen by the employee to be paid in stock
options and dividing that value by the grant date GAAP expense of one stock option. The result will be rounded up to the
nearest whole share. Any STAR award paid in stock options or other form of equity shall be awarded pursuant to this
program and the terms and conditions of the 2019 Plan or any successor stock plan approved in accordance with
applicable listing standards, as they may be revised from time to time. STAR awards paid in stock options or SARs will
have the following terms unless otherwise approved by the C&LD Committee at grant:
Grant date will be the last business day on or before September 15. If the New York Stock Exchange is closed on the
day of the grant, then the C&LD Committee will establish a grant date as soon as practical following the date previously
specified. Provided participants remain in compliance with the terms and conditions set forth in the currently active Stock
Plan and the Regulations, STAR stock options and SARs are not forfeitable, will become exercisable three years after
the grant date, and will expire ten years after the grant date. In the event of death of the participant, the award becomes
exercisable as of the date of death and the award remains exercisable until the Expiration Date. For awards granted in
France or the United Kingdom, the consequences of death are determined by the local plan supplement, if applicable.
The option price used for any STAR Award will be the closing price for a share of Common Stock on the New York Stock
Exchange on the grant date, or such higher price as may be specified in the French Addendum of the Regulations (the
“Grant Price”).
IV. SEPARATION FROM THE COMPANY
• Retirement, Death or Special Separation Agreement: If a participant worked at least 28 days (4 calendar weeks)
during the fiscal year, the STAR award is pro-rated by dividing the number of calendar days the participant was an
“active employee” during the fiscal year by 365.
• Voluntary Resignation or Termination for cause: Separating employees must have been active employees as of
June 30 or the last business day in June (the close of the fiscal year for which the award is payable) to receive an
award.
• Separation due to a Company authorized divestiture: In the case of divestitures the CHRO is authorized to
determine the appropriate STAR payout based on Business Unit factors either at Target or at projected or actual
business results. The CHRO is also authorized to pay awards for the current or following partial fiscal year at time of
divestiture close for administrative convenience.
Eligible participants who have left the Company will receive a cash payment (stock options can only be issued to active
employees) on the same timing as STAR awards or as soon thereafter as possible.
V. CHANGE IN CONTROL
-- 102 of 137 --
Notwithstanding the foregoing, if there is a Change in Control in any fiscal year, STAR awards will be calculated in
accordance with Section II above, but each factor will be calculated for the period from the beginning of the fiscal year in
which a Change in Control occurred up to and including the date of such Change in Control (“CIC Period”). “Change in
Control” shall have the same meaning as defined in the 2019 Plan or any successor stock plan.
VI. GENERAL TERMS AND CONDITIONS
While any STAR award amount received by one individual for any year shall be considered as earned remuneration in
addition to salary paid, it shall be understood that this plan does not give to any officer or employee any contract rights,
express or implied, against any Company for any STAR award or for compensation in addition to the salary paid to him
or her, or any right to question the action of the Board of Directors or the C&LD or STAR Committees.
The Chief Human Resources Officer or the Chief Legal Officer may withhold a STAR award for a separated employee
who is discovered to have engaged in serious misconduct or actions detrimental to the Company’s interests. Each
award to an individual at Band 7 and above, made pursuant to this plan, is subject to the Senior Executive Recoupment
Policy as amended by the C&LD Committee in April 2018.
To the extent applicable, it is intended that STAR comply with the provisions of Section 409A. STAR will be administered
and interpreted in a manner consistent with this intent. Neither a Participant nor any of a Participant’s creditors or
beneficiaries will have the right to subject any deferred compensation (within the meaning of Section 409A) payable
under STAR to any anticipation, alienation, sale, transfer, assignment, pledge, encumbrance, attachment or
garnishment. Except as permitted under Section 409A, any deferred compensation (within the meaning of Section 409A)
payable to a Participant under STAR may not be reduced by, or offset against, any amount owing by a Participant to the
Company.
This program document may be amended at any time by the C&LD Committee.
-- 103 of 137 --
Exhibit (10-12)
Company’s Form of Separation Agreement & Release
-- 104 of 137 --
SEPARATION AGREEMENT AND RELEASE
To: «Employee_Name»
Date: «Actual_Offer_Date»
«Company» (“P&G”) is willing to provide you with certain assistance in connection with your employment separation from the
Company. The following describes the terms under which you are separating from employment. Your receipt of the benefits
described below is conditioned upon your accepting and abiding by the terms of this Agreement.
Last Day of Employment: Your last day of employment will be «Exit_Date», referred to as your “Last
Day of Employment.” You understand and agree that if P&G determines that
you engaged in misconduct during your employment, or if you fail to perform
your work and responsibilities in a satisfactory manner up to and including your
Last Day of Employment, P&G may terminate your employment immediately
and will not provide, nor be obligated to provide, the payment(s) and other
benefits described in this Agreement. Otherwise, unless noted below, your pay
and benefits will cease as of your Last Day of Employment.
Separation Payment: As soon as administratively practical after your Last Day of Employment, P&G
will provide you with a Separation Payment of «Total_Amount», less legally
required withholdings and deductions. In no event will payment be made before
expiration of the seven-day revocation period discussed below or later than the
March 15th of the year following the year which includes your last day of
employment
Amounts you owe to P&G as of your Last Day of Employment, including, but
not limited to, wage and/or benefit overpayments and unpaid loans, will also be
deducted from the Separation Payment.
Payment for Unvested PST: If you are not fully-vested in the Procter & Gamble Profit Sharing Trust and
Employee Stock Ownership Plan (“PST”) as of your Last Day of Employment,
as soon as administratively practical after your Last Day of Employment, but no
later than the March 15 of the year following the year which includes your
Last Day of Employment, you will receive a lump sum payment in an amount
substantially equivalent to the non-vested credits in your account in the PST.
th
-- 105 of 137 --
STAR Awards: As of your Last Day of Employment, if you worked at least 28 days (4 calendar
weeks) during that fiscal year, you will receive a pro-rated STAR award for that
fiscal year. Your STAR award will be pro-rated by dividing the number of
calendar days during the fiscal year from July 1 through your Last Day of
Employment by 365. Your STAR award will be paid in cash in the September
(but no later than September 15th) immediately following the end of the fiscal
year in which you terminate.
Equity Awards Your separation will be treated as a Special Separation for purposes of any
outstanding equity awards granted under the Procter & Gamble 2009 Stock and
Incentive Compensation Plan, the Procter & Gamble 2001 Stock and Incentive
Compensation Plan, the Procter & Gamble 1992 Stock Plan, or the Gillette
Company 2004 Long-Term Incentive Plan and, as a result, you will retain the
awards subject to the original terms and conditions of the awards. You will also
retain awards granted under the Procter & Gamble 2014 Stock and Incentive
Compensation Plan and the Procter & Gamble 2019 Stock and Incentive
Compensation Plan subject to the terms and conditions of those Awards. For
awards granted on or after October 1, 2020, pursuant to the Long-Term
Incentive Program (LTIP) and/or Performance Stock Program (PSP), awards
will be prorated based on the number of days worked in the 12 months
following the October 1 grant date, with a minimum requirement of 28 days
worked beyond October 1.
This agreement does not alter the rights and obligations that you may have
under the Procter & Gamble 2019 Stock and Incentive Compensation Plan, the
Procter & Gamble 2014 Stock and Incentive Compensation Plan, the Procter &
Gamble 2009 Stock and Incentive Compensation Plan, the Procter & Gamble
2001 Stock and Incentive Compensation Plan, the Procter & Gamble 1992
Stock Plan, and the Gillette Company 2004 Long-Term Incentive Plan.
-- 106 of 137 --
Current Medical, Dental, and
Life Insurance Benefits:
If you are enrolled in P&G’s active health (including medical, prescription drug,
and EAP coverage), active dental, and company-paid life insurance coverage,
that coverage will continue under the same terms until «Benefits_End_Date».
If you continue to receive P&G active health coverage during the extension of
benefits period, that coverage will be impacted if you (or your eligible
dependents, including but not limited to your spouse or domestic partner) are or
become eligible for Medicare. For more information on this impact, see the
Coordination With Medicare section in the Summary Plan Description for your
P&G active health coverage.
If you continue to receive P&G active health coverage during the extension of
benefits period, you may be entitled to continue your health and dental coverage
under COBRA when the extension of benefits period ends. If you are entitled to
COBRA continuation coverage, you will receive a notice of your right to elect
COBRA.
Any life insurance coverage other than company-paid life insurance coverage
will not continue during this time.
Retiree Medical and Dental
Benefits:
If you were eligible for P&G retiree healthcare coverage on your Last Day of
Employment, you will be eligible to enroll in P&G’s retiree medical and dental
insurance coverage. You are eligible for P&G retiree healthcare coverage if you
satisfy the regular retiree eligibility rules (i.e., you are a Regular Retiree) as of
your Last Day of Employment. Under the terms of this Agreement, you also are
eligible for P&G retiree healthcare coverage as a Special Retiree by satisfying
the Rule of 70 as of your Last Day of Employment. You satisfy the Rule of 70
when your full years of age plus your full years of service equal 70 . If you are
eligible for P&G’s retiree healthcare coverage as either a Regular Retiree or a
Special Retiree as of your Last Day of Employment, you should contact P&G
Employee Care before your extension of coverage ends to request retiree
healthcare enrollment information. For details regarding the terms and
conditions of your retiree health coverage, please refer to and review the
summary plan descriptions, available at Benefits Online.
Important Note: If you become employed by a direct competitor of P&G (as
determined by P&G’s Chief Human Resources Officer) in any capacity, you
will not be eligible for coverage under P&G’s retiree healthcare coverage as
long as you remain employed by such competitor. If you have questions, please
contact the P&G Employee Care at 1-833-441-4357.
_______________________
Special rules apply to Gille e Heritage Employees with regard to re ree medical eligibility and the re ree medical cost sharing under the re ree medical
plan. If you are a Gille e Heritage Employee, you will receive a separate handout on your re ree medical eligibility.
1
1
-- 107 of 137 --
Outplacement Services: P&G’s preferred third-party provider will provide services to assist you in
managing your transition to a new future, based on your interest. Services
include pre-decision counseling, career transition programs, and job
development opportunities. P&G’s preferred third-party provider will also assist
you in preparing for your job search, including résumé preparation, cover
letters, other written materials and interview and networking training.
After you accept this Agreement, you may begin utilizing outplacement services
on a limited basis prior to your Last Day of Employment, consistent with the
needs of the business and your responsibilities to complete and/or transition
your work. Note that you must begin utilizing outplacement services within 45
days of your Last Day of Employment to be eligible for this benefit.
No Consideration Without
Executing this Agreement:
You affirm that you understand and agree that you would not receive the
separation payment and/or benefits specified in this Agreement without
executing this Agreement and fulfilling the promises contained in it. Except as
provided in this Agreement or under the terms and conditions of an applicable
benefit plan or policy sponsored by P&G, you shall not be due any payments or
benefits from P&G in connection with the termination of your employment.
Continued Employment Through
Your Last Day of Employment:
You agree to perform your work and responsibilities as an employee in a
satisfactory manner up to and including your Last Day of Employment,
including compliance with all provisions of this “Separation Agreement and
Release.” If P&G determines that you have engaged in serious misconduct
during your employment, you understand and agree that P&G may terminate
your employment immediately and will not provide, nor will it be obligated to
provide, you with the Separation Payment, medical benefits, outplacement and
other benefits described above. If you have already received any such pay or
benefits, you agree to repay them to P&G upon demand.
Nonadmission of Wrongdoing: You affirm that you understand and agree that neither this Agreement nor the
furnishing of the consideration for this Agreement, including the Separation
Payment, shall be deemed or construed at any time for any purpose as an
admission by P&G of wrongdoing or evidence of any liability or unlawful
conduct of any kind.
-- 108 of 137 --
Release of Claims – Including
Age Discrimination and
Employment Claims:
In consideration of the Separation Payment and other benefits provided above to
which you would not have been entitled under any existing P&G Policy, you
release P&G from any and all claims you have against P&G. The term “P&G”
includes «Company» and any of its present, former and future owners, parents,
affiliates and subsidiaries, and its and their directors, officers, shareholders,
employees, agents, servants, representatives, predecessors, successors and
assigns and their employee benefit plans and programs and their administrators
and fiduciaries.
This release applies to claims about which you now know or may later discover,
and includes but is not limited to: (1) claims arising under the Age
Discrimination in Employment Act, 29 U.S.C. § 621, et seq.; (2) claims arising
out of or relating in any way to your employment with P&G or the conclusion
of that employment; (3) claims arising under any federal, state and local
employment discrimination laws, regulations or ordinances or other orders that
relate to the employment relationship and/or employee benefits; and (4) any
other federal, state or local law, rule, regulation or ordinance, public policy,
contract, tort or common law.
This release does not apply to claims that may arise after the date you accept
this Agreement or that may not be released under applicable law.
You are not waiving any rights you may have to: (a) your own vested accrued
employee benefits under the P&G health, welfare, or retirement benefit plans as
of the Last Day of Employment; (b) benefits and/or the right to seek benefits
under applicable workers’ compensation and/or unemployment compensation
statutes; (c) pursue claims which by law cannot be waived by signing this
Agreement; (d) enforce this Agreement; and/or (e) challenge the validity of this
Agreement.
You agree that the decision as to what would be your Last Day of Employment
was made prior to your accepting and executing this Agreement, and you agree
that you are releasing any claim in connection with the separation of your
employment.
If any claim is not subject to release, to the extent permitted by law, you agree
that you waive any right or ability to be a class or collective action
representative or to otherwise participate in any putative or certified class,
collective or multi-party action or proceeding based on such a claim in which
P&G is a party.
-- 109 of 137 --
Governmental Agencies: Nothing in this Separation Letter & Release prohibits
or prevents you from filing a charge with or participating, testifying, or assisting
in any investigation, hearing, or other proceeding before the U.S. Equal
Employment Opportunity Commission, the National Labor Relations Board or
a similar agency enforcing federal, state or local anti-discrimination laws.
However, to the maximum extent permitted by law, you agree that if such an
administrative claim is made to such an anti-discrimination agency, you shall
not be entitled to recover any individual monetary relief or other individual
remedies. Nothing in this Separation Letter & Release, including but not limited
to the “Release of Claims – Including Age Discrimination and Employment
Claims” and the “Confidential, Proprietary, Trade Secret Information & Period
of Non-Competition” sections of this Separation Letter & Release, prohibits you
from: (1) reporting possible violations of federal law or regulations, including
any possible securities laws violations, to any governmental agency or entity,
including but not limited to the U.S. Department of Justice, the U.S. Securities
and Exchange Commission, the U.S. Congress, or any agency Inspector
General; (2) making any other disclosures that are protected under the
whistleblower provisions of federal law or regulations; or (3) otherwise fully
participating in any federal whistleblower programs, including but not limited
to any such programs managed by the U.S. Securities and Exchange
Commission and/or the Occupational Safety and Health Administration. You
understand you do not need the prior authorization from the Company to make
any such reports or disclosures, and you are not required to notify the Company
that you have made such reports or disclosures. Moreover, nothing in this
Separation Letter & Release prohibits or prevents you from receiving individual
monetary awards or other individual relief by virtue of participating in such
federal whistleblower programs.
-- 110 of 137 --
Confidential, Proprietary, Trade
Secret Information & Period of
Non-Competition:
Subject to the “Governmental Agencies” portion of the “Release of Claims –
Including Age Discrimination and Employment Claims” above, you agree that
you will not use or share any confidential, proprietary or trade secret
information about any aspect of P&G’s business with any non-P&G employee
or business entity at any time in the future. You further agree that you will not
obtain, transfer or have in your possession any confidential, proprietary or trade
secret information on or after your last day of employment, even information
you may have created yourself or to which you may have contributed as a P&G
employee. Confidential, proprietary or trade secret information includes, but is
not limited to, marketing and advertising plans, pricing information, upstream
plans, specific areas of research and development, project work, product
formulation, processing methods, assignments of individual employees, testing
and evaluation procedures, cost figures, construction plans, and special
techniques or methods of any kind.
Notwithstanding the requirements of confidentiality contained in this section,
the federal Defend Trade Secrets Act of 2016 immunizes you against criminal
and civil liability under federal or state trade secret laws for your disclosure of
trade secrets that is made i) in confidence to a federal, state, or local
government official, either directly or indirectly, or to an attorney solely for the
purpose of reporting or investigating a suspected violation of law; ii) in a
complaint or other document filed in a lawsuit or other proceeding, if such
filing is made under seal; or iii) to your attorney for use in a lawsuit alleging
retaliation for reporting a suspected violation of law, provided that any
document containing the trade secret is filed under seal and you do not
otherwise disclose the trade secret, except pursuant to court order.
You further understand and agree that, unless you have prior written consent
from P&G, you will not engage in any activity or provide any services for a
period of three (3) years following your Last Day of Employment in connection
with the manufacture, development, advertising, promotion or sale of any
product which is the same as, similar to, or competitive with any products of
P&G or its subsidiaries (including both existing products as well as products in
development which are known to you, as a consequence of your employment
with P&G):
1. With respect to which your work has been directly concerned at any
time during the two (2) years preceding your Last Day of Employment;
or
2. With respect to which during that period of time you, as a consequence
of your job performance and duties, acquired knowledge of trade secrets
or other confidential information of P&G.
-- 111 of 137 --
For the purposes of this section, it shall be conclusively presumed that you have
knowledge or information to which you were directly exposed through the
actual receipt of memos or documents containing such information or through
actual attendance at meetings at which such information was discussed or
disclosed. The provisions of this section are not in lieu of, but are in addition to,
your continuing obligation to not use or disclose P&G’s trade secrets and
confidential information known to you until any particular trade secret or
confidential information becomes generally known (through no fault of yours).
Information regarding products in development, in test market or being
marketed or promoted in a discrete geographic region, which information P&G
is considering for a broader use, shall not be deemed generally known until
such broader use is actually commercially implemented. Also, “generally
known” means known throughout the domestic United States industry or, if you
have job responsibilities outside of the United States, the appropriate foreign
country or countries’ industry.
If any restriction in this section is found by any court of competent jurisdiction
or arbitrator to be unenforceable because it extends for too long a period of time
or over too great a range of activities or in too broad a geographic area, it will
be modified and interpreted to extend only over the maximum period of time,
range of activities or geographic area so that it may be enforceable.
As a participant in the 2009 Stock and Incentive Compensation Plan, the 2001
Stock and Incentive Compensation Plan, or the 1992 Stock Plan, you are also
bound by the terms of Article F – Restrictions & Covenants of those plans,
which are incorporated herein by reference.
If you are a participant in the Procter & Gamble 2019 Stock and Incentive
Compensation Plan and the Procter & Gamble 2014 Stock and Incentive
Compensation Plan, you are also bound by the terms of Article 6 – Restrictions
and Covenants of this plan which are incorporated herein by reference.
Non-Solicitation You acknowledge, as a participant in the Procter & Gamble 2019 Stock and
Incentive Compensation Plan, the Procter & Gamble 2014 Stock & Incentive
Compensation Plan, the Procter & Gamble 2009 Stock and Incentive
Compensation Plan, the Procter & Gamble 2001 Stock and Incentive Plan, the
Procter & Gamble 1992 Stock Plan, and/or the Gillette Company 2004 Long-
Term Incentive Plan that you are bound to comply with the Plans’ non-
solicitation obligations. Specifically, you agree that you will not, at any time
following your Employment Separation Date, attempt to directly or indirectly
induce any employee of P&G or its affiliates or subsidiaries to be employed or
perform services elsewhere or attempt directly or indirectly to solicit the trade
or business of any current or prospective customer, supplier or partner of P&G
or its affiliates or subsidiaries.
-- 112 of 137 --
Acknowledgements and
Affirmations:
Subject to the “Governmental Agencies” portion of the “Release of Claims –
Including Age Discrimination and Employment Claims” above, you affirm that
you have not filed, caused to be filed, or presently are a party to any claim
against P&G.
You affirm that you have been paid and/or have received all compensation,
wages, bonuses, commissions, and/or benefits which are due and payable as of
the date you sign this Agreement. To the extent that you are required to report
hours worked, you affirm that you have reported all hours worked as of the date
you sign this Agreement.
You affirm that you have been granted any leave to which you were entitled
under the Family and Medical Leave Act or related state or local leave or
disability accommodation laws.
You further affirm that you have no known workplace injuries or occupational
diseases that have not been reported.
Assignment of Intellectual
Property:
You will promptly and fully disclose, transfer and assign to P&G all inventions
and any other intellectual property (collectively “Intellectual Property”) made
or conceived by you during your employment with P&G. You agree to fully
cooperate in executing any papers required for establishing or protecting the
Intellectual Property and for establishing P&G’s ownership, even if such
cooperation is necessary after your Last Day of Employment.
Return of P&G Property: You agree that on or before your Last Day of Employment, you will return to
P&G in good condition all of its equipment, materials and information that
were in your possession, custody or control (including, but not limited to,
computers, files, documents, credit cards, keys and identification badges). You
further agree that you will provide your manager with all passwords to P&G
electronic communication and data systems before your Last Day of
Employment. You further agree that on or before your Last Day of
Employment, you will return or if directed to do so by your immediate
manager, delete (i.e., destroy all copies of) any and all P&G confidential,
proprietary or trade secret information you have maintained in your possession,
custody, or control in paper, electronic and/or digital formats, including but not
limited to, any such confidential, proprietary, or trade secret information (e.g.,
files, documents, etc.) that you may have electronically or digitally processed or
stored on P&G-issued or on personally-owned or maintained digital devices
and/or service accounts. Such digital devices and/or service accounts may
include, but are not limited to desktop and laptop computers, notebooks, tablets,
iPads, mobile phones, smartphones, personal digital assistants (PDAs), USB
and flash drives, external hard drives, CDs, DVDs, and/or external file
processing or storage provided by cloud service providers such as box.net,
dropbox, Google docs, etc.
-- 113 of 137 --
Ethics Compliance: Subject to the “Governmental Agencies” portion of the “Release of Claims –
Including Age Discrimination and Employment Claims” above, you agree that
you provided P&G all information known to you regarding any violations of the
Procter & Gamble Worldwide Business Conduct Manual and/or any other
violations of P&G policy or the law.
Severability: If any court of competent jurisdiction or arbitrator should later find that any
portion of this Agreement is invalid, that invalidity will not affect the
enforceability of any other portion of this Agreement.
Employment References: You understand that P&G’s historical policy is to not provide employment
references to prospective employers. However, P&G is willing to waive that
policy in your case on the following basis: You authorize your manager or
human resources representative to provide an employment reference upon
written or verbal request. In return, you release any claim against P&G and will
not bring a lawsuit in court against P&G based upon that employment reference
(or lack thereof). You agree that you will refer all reference inquiries to your
manager or human resources representative only.
No Reliance: This Agreement sets forth the entire agreement between you and P&G and fully
supersedes any prior agreements or understanding between the parties except
that if you are a participant in the 2009 Stock and Incentive Compensation Plan,
the 2001 Stock and Incentive Compensation Plan, or the 1992 Stock Plan, the
terms of Article F – Restrictions & Covenants of those plans remain in full
force and effect and are incorporated herein by reference and if you are a
participant in the Procter & Gamble 2019 Stock and Incentive Compensation
Plan or the Procter & Gamble 2014 Stock and Incentive Compensation Plan, the
terms of Article 6 – Restrictions & Covenants of those plans remain in full force
and are in effect and are incorporated herein by reference. In deciding to accept
this Agreement, you agree that you have not relied upon any statements or
promises by P&G, its managers, agents or employees, other than those set forth
in this Agreement. No other promises or agreements concerning the matters
described in this Agreement shall be binding unless in a subsequent document
signed by these parties.
-- 114 of 137 --
Your Attorney: You acknowledge that you have been and hereby are advised to consult with
legal counsel before accepting this Agreement and have either done so or have
voluntarily declined to do so.
Timing for Acceptance or
Revocation:
You have forty-five (45) calendar days in which to consider this Agreement in
which you waive important rights, including those under the Age
Discrimination in Employment Act of 1967. If you choose to sign this
Agreement, please do so by indicating your acceptance of this Agreement with
your electronic signature in P&G’s electronic system. We advise you to consult
with an attorney of your choosing prior to signing this Agreement. Further, you
may within seven (7) calendar days following the date you sign this Agreement,
cancel and terminate it by giving written notice of your intention to revoke the
Agreement to your immediate manager, and by returning to P&G any
remuneration or benefits that have been advanced to you in anticipation of your
not revoking your agreement and to which you are not entitled. If notice of your
revocation is mailed, it must be postmarked within seven (7) calendar days after
you sign this Agreement.
You agree that any modifications, material or otherwise, made to this
Agreement, do not restart or affect in any manner the original up to forty-five
(45) calendar day consideration period.
The benefits described in this Agreement and pursuant to the summary plan description for the Procter & Gamble Basic Separation
Program for U.S. Employees (to be obtained from your HR business partner), are the special benefits you will receive by signing this
Agreement. To the extent this Agreement describes benefits under other benefit plans and policies sponsored by P&G, these special
benefits are also described in the summary plan descriptions for those plans. As such, nothing in this Agreement amends or changes
the terms of any P&G-sponsored employee benefit plan or policy.
After your Last Day of Employment, you will no longer be an active P&G employee, which may affect your coverage under those
plans and policies. For example, plans may require that you enroll in Medicare to be eligible for coverage. For more information on
how not being an active P&G employee may affect your coverage, please refer to and review the summary plan descriptions for each
plan.
-- 115 of 137 --
Exhibit (10-13)
Company’s Form of Separation Letter and Release
-- 116 of 137 --
[ON P&G LETTERHEAD]
[INSERT DATE]
[INSERT EMPLOYEE NAME]
[INSERT EMPLOYEE ADDRESS]
[INSERT EMPLOYEE ADDRESS]
RE: Separation Agreement & Release
Dear [INSERT EMPLOYEE NAME]:
[INSERT PROPER LEGAL ENTITY] (“P&G”) is willing to assist you following your employment separation from P&G in
exchange for your agreement and compliance with the terms set forth below.
Employment Separation Date: Your last day of employment with P&G will be [INSERT DATE], which will be your
“Employment Separation Date” for purposes of this agreement. You understand and agree that if
P&G determines that you engaged in misconduct during your employment, or if you fail to
perform your work and responsibilities in a satisfactory manner up to and including your
Employment Separation Date, P&G may terminate your employment immediately and will not
provide, nor be obligated to provide, the payment(s) and other benefits described in this
agreement.
Vacation: You will receive payment for your accrued but unused vacation as of your Employment
Separation Date, which sum will be paid to you in accordance with P&G policy and applicable
laws. You will not accrue any additional vacation following your Employment Separation Date.
STAR Award
(use this paragraph only if the
employee is eligible for STAR
awards)
As of your Employment Separation Date, if you were otherwise eligible for a STAR award and
you worked at least 28 days (4 calendar weeks) during the fiscal year, you will receive a pro-rated
STAR award for the fiscal year. Your STAR award will be pro-rated by dividing the number of
calendar days during the fiscal year from July 1 through your Employment Separation Date by
365. Your STAR award will be paid in cash in the September (but no later than September 15th)
immediately following the end of the fiscal year in which your employment terminates with P&G.
-- 117 of 137 --
Separation Payment (use this
paragraph only if a separation
payment will be provided):
P&G will, within thirty (30) calendar days after your Employment Separation Date, provide you
with a separation payment in the amount of $[INSERT AMOUNT] (“Separation Payment”)
(representing [INSERT #] weeks of pay at your current salary), less applicable state and federal
withholdings and deductions, which sum will be paid in one lump sum payment. The Separation
Payment will be the only assistance P&G provides upon your separation. Other resources may be
available to you as a participant in general compensation and benefit plans, which it will be your
responsibility to identify and make any necessary arrangements upon separation.
Amounts you owe to P&G as of your Employment Separation Date, including, but not limited to,
wage and/or benefit overpayments and unpaid loans, will also be deducted from the Separation
Payment.
Unemployment Compensation
Benefits (use this paragraph
only if a separation payment is
being provided):
Your Separation Payment will be allocated to the [INSERT #] week period following your
Employment Separation Date.
-- 118 of 137 --
Special Retirement (“Rule of
70”) (use this paragraph only if
the Company has decided to
give access to special retirement
upon separation)
P&G will agree to allow the “Rule of 70” to apply to you, but only for purposes of eligibility for
retiree health care benefits under the Procter & Gamble Retiree Welfare Benefits Plan. The Rule
of 70 is a special eligibility rule for retiree health care coverage (including medical, dental, and
prescription drug benefits) under the Procter & Gamble Retiree Welfare Benefits Plan that only
applies in specific circumstances. The Rule of 70 will apply to you with respect to health care
coverage under the Procter & Gamble Retiree Welfare Benefits Plan as long as that Plan continues
to exist and as long as the Rule of 70 continues as an eligibility rule for coverage under that Plan.
For purposes of this paragraph only, the parties agree that your employment with P&G ended on
[EMPLOYMENT SEPARATION DATE], and that you were not terminated for cause. The parties
also agree that at the time your employment with the Company ended, you were [##] years old
and had [##] years of service with the Company, making your full years of age plus full years of
service [TOTAL], which is greater than 70.
To avoid confusion, other than establishing that the Rule of 70 applies to you for purposes of
retiree health care coverage under the Procter & Gamble Welfare Benefits Plan, you are subject to
the same terms and conditions of the Procter & Gamble Welfare Benefits Plan, including but not
limited to (1) coverage does not begin until you enroll in the Plan, and once enrolled coverage is
only prospective, (2) the monthly premiums required for coverage under the Plan must be paid on
time to avoid coverage from terminating, (3) you will become ineligible for coverage under the
Plan while you are employed by a direct competitor of P&G (as determined by P&G’s Chief
Human Resources Officer) in an officer and/or director capacity (if you were at Band 5 or below
at the time your employment with the Company ended) or in any capacity (if you were at Band 6
or above at the time your employment with the Company ended), and (4) the Company’s
reservation of amendment and termination rights with respect to the Plan.
-- 119 of 137 --
Retention of Vested & Unvested
Equity Awards (use this
paragraph only if the Company
has decided to allow the person
to retain his/her equity and the
proper approvals have been
obtained)
Your separation will be treated as a Special Separation for purposes of any outstanding equity
awards granted under the Procter & Gamble 2009 Stock and Incentive Compensation Plan, the
Procter & Gamble 2001 Stock and Incentive Compensation Plan, the Procter & Gamble 1992
Stock Plan, or the Gillette Company 2004 Long-Term Incentive Plan and, as a result, you will
retain the awards subject to the original terms and conditions of the awards. You will also retain
awards granted under the Procter & Gamble 2014 Stock & Incentive Compensation Plan and the
Procter & Gamble 2019 Stock & Incentive Compensation Plan subject to the terms and conditions
of those Awards. For awards granted on or after October 1, 2020 pursuant to the Long-Term
Incentive Program (LTIP) and/or Performance Stock Program (PSP), awards will be prorated
based on the number of days worked in the 12 months following the October 1 grant date, with a
minimum of 28 days worked beyond October 1.
This Separation Agreement & Release does not alter the rights and obligations that you may have
under the Procter & Gamble 2019 Stock & Incentive Compensation Plan, the Procter & Gamble
2014 Stock & Incentive Compensation Plan, the Procter & Gamble 2009 Stock and Incentive
Compensation Plan, the Procter & Gamble 2001 Stock and Incentive Plan, the Procter & Gamble
1992 Stock Plan, and the Gillette Company 2004 Long-Term Incentive Plan.
-- 120 of 137 --
Release of Claims - Including
Employment Claims:
You hereby release P&G from any, and all claims or rights you may have against P&G. The term
“P&G” includes The Procter & Gamble Company and any of its present, former and future owners,
parents, affiliates and subsidiaries, and its and their directors, officers, shareholders, employees,
agents, benefit plans, trustees, fiduciaries, servants, representatives, predecessors, successors and
assigns. This release applies to claims about which you now know or may later discover, and
includes but is not limited to: (1) claims arising under the Age Discrimination in Employment
Act ("ADEA"), 29 U.S.C. § 621, et seq.; (2) claims arising under any other federal, state or local
law, regulation or ordinance or other order that regulates the employment relationship and/or
employee benefits; and (3) claims arising out of or relating in any way to your employment with
P&G or the conclusion of that employment. This release does not apply to claims that may arise
after the date you sign this agreement or that may not be released under applicable law.
Governmental Agencies: Nothing in this Separation Agreement & Release prohibits or prevents
you from filing a charge with or participating, testifying, or assisting in any investigation, hearing,
or other proceeding before the U.S. Equal Employment Opportunity Commission, the National
Labor Relations Board or a similar agency enforcing federal, state or local anti-discrimination
laws. However, to the maximum extent permitted by law, you agree that if such an administrative
claim is made to such an anti-discrimination agency, you shall not be entitled to recover any
individual monetary relief or other individual remedies. Nothing in this Separation Agreement &
Release prohibits you from: (1) reporting possible violations of federal law or regulations,
including any possible securities laws violations, to any governmental agency or entity, including
but not limited to the U.S. Department of Justice, the U.S. Securities and Exchange Commission,
the U.S. Congress, or any agency Inspector General; (2) making any other disclosures that are
protected under the whistleblower provisions of federal law or regulations; or (3) otherwise fully
participating in any federal whistleblower programs, including but not limited to any such
programs managed by the U.S. Securities and Exchange Commission and/or the Occupational
Safety and Health Administration. You understand you do not need the prior authorization from the
Company to make any such reports or disclosures, and you are not required to notify the Company
that you have made such reports or disclosures. Moreover, nothing in this Separation Agreement &
Release prohibits or prevents you from receiving individual monetary awards or other individual
relief by virtue of participating in such federal whistleblower programs.
-- 121 of 137 --
Return of P&G Property: You agree that by your Employment Separation Date, you will return to P&G in good condition all
of its equipment, materials and information that were in your possession, custody or control
(including, but not limited to, computers, phones, iPads, tablets files, documents, credit cards, keys
and identification badges). You further agree that you will provide your manager with all
passwords to P&G electronic communication and data systems before your Employment
Separation Date.
Confidential Business
Information:
Consistent with the “Information for the Departing Employee” document reviewed with you prior
to your Employment Separation Date, you agree to protect P&G business information. Subject to
the “Government Agencies” paragraph in the above Release of Claims, you agree not to disclose or
transfer to yourself or others any P&G business information, even information you may have
created yourself or to which you may have contributed as a P&G employee. Please refer to the
“Information for the Departing Employee” document for more information.
Continuing Cooperation (this
paragraph should be used for
R&D employees)
Regardless of whether you sign this Agreement and in the event it becomes necessary, following
your Employment Separation Date, you are required to cooperate in executing any and all papers
required for filing and prosecuting any patent applications and establishing P&G’s ownership of all
inventions relating to its business which are made by employees hired to invent or create. You
understand that you will not receive any additional compensation for such cooperation.
No Other Agreements: Except as specifically set forth in this Paragraph (“No Other Agreements”), this agreement
supersedes any prior written or oral agreements between P&G and you concerning the termination
of your employment and any benefits you might receive following that event. This agreement is
neither a Negotiated Separation Agreement under the Procter & Gamble Basic Separation Program
nor an agreement under any other separation program or plan sponsored by The Procter & Gamble
Company or any of its subsidiaries. This agreement does not alter your rights and obligations under
the terms of the P&G Profit Sharing and Employee Stock Ownership Plan, other retirement plans,
the P&G Stock and Incentive Compensation Plan, and other compensation plans.
To accept the terms set forth in this agreement, you can do so by following one of the two options below:
1. To accept electronically via the Global Separation System (“GSS”) according to the terms of the above agreement:
Go back to the e-mail and electronic link you received from GSS and click on the “Accept” button to accept the
electronic signature process. Then you will be taken to the page that you can provide your decision to the above
agreement. By clicking “Accept,” you acknowledge that you have read the entire agreement, that you understand it,
and that you voluntarily accept its terms. You further agree that you understand that it is a
-- 122 of 137 --
legally binding agreement, that you have been advised to consult with an attorney, that you have been given 21 days
to consider this Separation Agreement & Release, and that you can revoke your acceptance within seven days of
accepting the agreement by providing written notification to your immediate manager. Finally, you understand that
(1) this Separation Agreement & Release includes the release of all claims and (2) you are waiving unknown
claims and are doing so intentionally and voluntarily. If you do not wish to accept the terms of this agreement,
click on the “Decline” button.
2. To accept this agreement by manual signature, please sign and date below. By signing below, you acknowledge that
you have read the entire agreement, that you understand it, and that you voluntarily accept its terms. You further agree
that you understand this is a legally binding agreement, that you have been advised to consult with an attorney, that
you have been given 21 days to consider this Separation Agreement & Release and that you can revoke your
acceptance within seven days of your acceptance by providing written notification to your human resources manager.
Finally, you understand that (1) this Separation Agreement & Release includes the release of all claims and (2)
you are waiving unknown claims and are doing so intentionally and voluntarily.
Sincerely,
The Procter & Gamble Company
By: ________________________
Accepted and agreed to this _______ day of ___________, 20__.
_________________________________
[INSERT EMPLOYEE NAME]
-- 123 of 137 --
EXHIBIT (21)
The Procter & Gamble Company and Subsidiaries
Subsidiaries of the Registrant
-- 124 of 137 --
The Procter & Gamble Company and Subsidiaries
The registrant's subsidiaries are listed below, omitting certain entities that have de minimis activity that, if considered in the aggregate as a single subsidiary,
would not constitute a significant subsidiary as of June 30, 2022.
SUBSIDIARIES OF THE PROCTER & GAMBLE COMPANY Jurisdiction
1837, LLC Ohio
Agile Pursuits Franchising, Inc. Ohio
Agile Pursuits, Inc. Ohio
Arbora & Ausonia, S.L.U. Spain
Braun (Shanghai) Co., Ltd. China
Braun GmbH Germany
Celtic Insurance Company, Inc. Vermont
Charlie Banana (USA), LLC Delaware
Detergent Products B.V. Netherlands
Detergent Products Sarl Switzerland
Detergenti S.A. Romania
Farmacy Beauty Japan Kabushiki Kaisha Japan
Farmacy Beauty, LLC New Jersey
Farmacy Korea Co., Ltd. Korea
Fater Central Europe SRL Romania
Fater Eastern Europe LLC Russia
Fater Portugal Unipessoal Lda Portugal
Fater S.p.A. Italy
Fater Temizlik Urunleri Ltd STI Turkey
First Aid Beauty Limited Delaware
Fountain Square Music Publishing Co., Inc. Ohio
FPG Oleochemicals Sdn. Bhd. Malaysia
Gillette (China) Limited China
Gillette (Shanghai) Ltd. China
Gillette Australia Pty. Ltd. Australia
Gillette Commercial Operations North America Massachusetts
Gillette del Uruguay, S.A. Uruguay
Gillette Diversified Operations Pvt. Ltd. India
Gillette Dominicana, S.A.S. Dominican Republic
Gillette Egypt S.A.E. Egypt
Gillette Holding Company LLC Delaware
Gillette Holding GmbH Germany
Gillette India Limited India
Gillette Industries Ltd. U.K.
Gillette Latin America Holding B.V. Netherlands
Gillette Management, LLC Delaware
Gillette Pakistan Limited Pakistan
Gillette Poland International Sp. z.o.o. Poland
Gillette U.K. Limited U.K.
Grooming Ventures - FL LLC Florida
Grooming Ventures LLC Delaware
Hyginett KFT Hungary
iMFLUX Inc. Delaware
Industries Marocaines Modernes SA Morocco
Ismail Abudawood Procter & Gamble - Dammam Saudi Arabia
Laboratoire Mediflor S.A.S. France
Laboratorios Vicks, S.L.U. Spain
Lamberts Healthcare Ltd. U.K.
Liberty Street Music Publishing Company, Inc. Ohio
LLC "Procter & Gamble - Novomoskovsk" Russia
-- 125 of 137 --
LLC 'Procter & Gamble Trading Ukraine' Ukraine
LLC with foreign investments “Procter & Gamble Ukraine” Ukraine
Modern Products Company - Jeddah Saudi Arabia
Nature's Best Health Products Ltd. U.K.
New Chapter Canada Inc. Canada
New Chapter, Inc. Delaware
Oral-B Laboratories Delaware
P&G Consumer Health Germany GmbH Germany
P&G Distribution East Africa Limited Kenya
P&G Distribution Morocco SAS Morocco
P&G Hair Care Holding, Inc. Delaware
P&G Health Austria GmbH & Co. OG Austria
P&G Health Belgium BV Belgium
P&G Health France S.A.S. France
P&G Health Germany GmbH Germany
P&G Healthcare (Zhejiang) Company Limited China
P&G Industrial Peru S.R.L. Peru
P&G Innovation Godo Kaisha Japan
P&G Investment Management Ltd. United Arab Emirates
P&G Israel M.D.O. Ltd. Israel
P&G Japan G.K. Japan
P&G K.K. Japan
P&G Northeast Asia Pte. Ltd. Singapore
P&G Prestige Godo Kaisha Japan
P&G South African Trading (Pty.) Ltd. South Africa
"Petersburg Products International" LLC Russia
PG 13 Launchpad Alpha, Inc. Delaware
PG13 Launchpad Beta, Inc. Delaware
PG13 Launchpad Gamma, Inc. Delaware
Phase II Holdings Corporation Philippines
Principle Forsaking AB Sweden
Procter & Gamble (Chengdu) Ltd. China
Procter & Gamble (China) Ltd. China
Procter & Gamble (China) Sales Co., Ltd. China
Procter & Gamble (Guangzhou) Consumer Products Co., Ltd. China
Procter & Gamble (Guangzhou) Enterprise Management Service Company Limited China
Procter & Gamble (Guangzhou) Ltd. China
Procter & Gamble (Guangzhou) Technology Innovation Co., LTD. China
Procter & Gamble (Guangzhour) Commerce Co. Ltd. China
Procter & Gamble (Health & Beauty Care) Limited U.K.
Procter & Gamble (Jiangsu) Ltd. China
Procter & Gamble (L&CP) Limited U.K.
Procter & Gamble (Malaysia) Sdn Bhd Malaysia
Procter & Gamble (Manufacturing) Ireland Limited Ireland
Procter & Gamble (Singapore) Pte. Ltd. Singapore
Procter & Gamble Algeria EURL Algeria
Procter & Gamble Amiens S.A.S. France
Procter & Gamble Arabia L.L.C. United Arab Emirates
Procter & Gamble Argentina SRL Argentina
Procter & Gamble Asia Pte. Ltd. Philippines
Procter & Gamble Australia Proprietary Limited Australia
Procter & Gamble Azerbaijan Services LLC Azerbaijan
Procter & Gamble Bangladesh Private Ltd. Bangladesh
Procter & Gamble Blois S.A.S. France
Procter & Gamble Brazil Holdings B.V. Netherlands
-- 126 of 137 --
Procter & Gamble Bulgaria EOOD Bulgaria
Procter & Gamble Business Services Canada Company Canada
Procter & Gamble Canada Holding B.V. Netherlands
Procter & Gamble Chile Limitada Chile
Procter & Gamble Colombia Ltda. Colombia
Procter & Gamble Commercial LLC Puerto Rico
Procter & Gamble Czech Republic s.r.o. Czech Republic
Procter & Gamble d.o.o. za trgovinu Croatia
Procter & Gamble Danmark ApS Denmark
Procter & Gamble de Venezuela, S.C.A. Venezuela
Procter & Gamble de Venezuela, S.R.L. Venezuela
Procter & Gamble Detergent (Beijing) Ltd. China
Procter & Gamble Deutschland GmbH Germany
Procter & Gamble Distributing (Philippines) Inc. Philippines
Procter & Gamble Distribution Company (Europe) BV Belgium
Procter & Gamble Distribution S.R.L. Romania
Procter & Gamble Distributorskaya Compania LLC Russia
Procter & Gamble do Brasil Ltda. Brazil
Procter & Gamble do Brazil, LLC Delaware
Procter & Gamble doo Beograd Serbia and Montenegro
Procter & Gamble DS Polska Sp. z o.o. Poland
Procter & Gamble Eastern Europe, LLC Ohio
Procter & Gamble Ecuador Cia. Ltda. Ecuador
Procter & Gamble Egypt Egypt
Procter & Gamble Egypt Distribution Egypt
Procter & Gamble Egypt Holding Egypt
Procter & Gamble Egypt Supplies Egypt
Procter & Gamble Energy Company LLC Ohio
Procter & Gamble España, S.A.U. Spain
Procter & Gamble Far East, Inc. Ohio
Procter & Gamble Finance Holding Ltd. U.K.
Procter & Gamble Finance Management S.a.r.l. Luxembourg
Procter & Gamble Financial Investments LLP U.K.
Procter & Gamble Financial Services Ltd. U.K.
Procter & Gamble Finland OY Finland
Procter & Gamble France S.A.S. France
Procter & Gamble Germany GmbH Germany
Procter & Gamble Germany GmbH & Co. Operations oHG Germany
Procter & Gamble Ghana Trading Limited Ghana
Procter & Gamble GmbH Germany
Procter & Gamble Grundstucks-und Vermogensverwaltungs GmbH & Co. KG Germany
Procter & Gamble Gulf FZE United Arab Emirates
Procter & Gamble Hair Care, LLC Delaware
Procter & Gamble Health Limited India
Procter & Gamble Health Ltd. U.K.
Procter & Gamble Health Poland Sp. z o.o. Poland
Procter & Gamble Hellas Single Member Ltd. Greece
Procter & Gamble Holding (Thailand) Limited Thailand
Procter & Gamble Holding France S.A.S. France
Procter & Gamble Holding GmbH Germany
Procter & Gamble Holding S.r.l. Italy
Procter & Gamble Home Products Private Limited India
Procter & Gamble Honduras S de RL Honduras
Procter & Gamble Hong Kong Limited Hong Kong
Procter & Gamble Hungary Wholesale Trading Partnership (KKT) Hungary
-- 127 of 137 --
Procter & Gamble Hygiene & Health Care Limited India
Procter & Gamble Inc. Canada
Procter & Gamble India Holdings, Inc. Ohio
Procter & Gamble Indochina Company Limited Vietnam
Procter & Gamble Industrial - 2012 C.A. Venezuela
Procter & Gamble Industrial e Comercial Ltda. Brazil
Procter & Gamble Industrial S.C.A. Venezuela
Procter & Gamble Interamericas de Costa Rica, Limitada Costa Rica
Procter & Gamble Interamericas de El Salvador, Limitada de Capital Variable El Salvador
Procter & Gamble Interamericas de Guatemala, Limitada Guatemala
Procter & Gamble Interamericas de Panama, S. de R.L. Panama
Procter & Gamble International Operations SA Switzerland
Procter & Gamble International Operations SA-ROHQ Philippines
Procter & Gamble International Sarl Switzerland
Procter & Gamble Italia, S.p.A. Italy
Procter & Gamble Kazakhstan Distribution LLP Kazakhstan
Procter & Gamble Korea S&D Co. Korea
Procter & Gamble Korea, Inc. Korea
Procter & Gamble Leasing LLC Ohio
Procter & Gamble Levant S.A.L. Lebanon
Procter & Gamble Limited U.K.
Procter & Gamble LLC Russia
Procter & Gamble Manufacturing (Thailand) Limited Thailand
Procter & Gamble Manufacturing (Tianjin) Co. Ltd. China
Procter & Gamble Manufacturing Belgium N.V. Belgium
Procter & Gamble Manufacturing Berlin GmbH Germany
Procter & Gamble Manufacturing GmbH Germany
Procter & Gamble Manufacturing Mexico S. de R.L. de C.V. Mexico
Procter & Gamble Manufacturing SA (Pty) Ltd South Africa
Procter & Gamble Marketing Romania SRL Romania
Procter & Gamble Mataro, S.L.U. Spain
Procter & Gamble Mexico (US) LLC Delaware
Procter & Gamble Mexico S. de R.L. de C.V. Mexico
Procter & Gamble Middle East FZE United Arab Emirates
Procter & Gamble Nederland B.V. Netherlands
Procter & Gamble Netherlands Services B.V. Netherlands
Procter & Gamble Nigeria Limited Nigeria
Procter & Gamble Norge AS Norway
Procter & Gamble Operations Polska Sp. z o.o. Poland
Procter & Gamble Overseas India B.V. Netherlands
Procter & Gamble Pakistan (Private) Limited Pakistan
Procter & Gamble Peru S.R.L. Peru
Procter & Gamble Philippines Business Services Inc. Philippines
Procter & Gamble Philippines, Inc. Philippines
Procter & Gamble Polska Sp. z o.o Poland
Procter & Gamble Portugal - Produtos De Consumo, Higiene e Saúde S.A. Portugal
Procter & Gamble Product Supply (U.K.) Limited U.K.
Procter & Gamble Productions, Inc. Ohio
Procter & Gamble Retail Services Sarl Switzerland
Procter & Gamble RHD, Inc. Ohio
Procter & Gamble RSC Regional Service Company Ltd. Hungary
Procter & Gamble S.r.l. Italy
Procter & Gamble Service, GmbH Germany
Procter & Gamble Services Company N.V. Belgium
Procter & Gamble Sverige AB Sweden
-- 128 of 137 --
Procter & Gamble Taiwan Limited Taiwan
Procter & Gamble Taiwan Sales Company Limited Taiwan
Procter & Gamble Technical Centres Limited U.K.
Procter & Gamble Technology (Beijing) Co., Ltd. China
Procter & Gamble Trading (Thailand) Limited Thailand
Procter & Gamble Tuketim Mallari Sanayii A.S. Turkey
Procter & Gamble UK U.K.
Procter & Gamble UK Group Holdings Ltd U.K.
Procter & Gamble Vietnam Company Limited Vietnam
Procter & Gamble West Africa Sarl Switzerland
Procter & Gamble, Spol. s.r.o. (Ltd.) Slovak Republic
Procter & Gamble-Rakona s.r.o. Czech Republic
Procter and Gamble Lanka (Private) Limited Sri Lanka
Progam Realty & Development Corporation Philippines
PT Procter & Gamble Home Products Indonesia Indonesia
PT Procter & Gamble Operations Indonesia Indonesia
Redmond Products, Inc. Minnesota
Richardson-Vicks Real Estate Inc. Ohio
Riverfront Music Publishing Co., Inc. Ohio
Rosemount LLC Delaware
Series Acquisition B.V. Netherlands
Seven Seas Limited U.K.
Shulton, Inc. New Jersey
Snowberry New Zealand Limited New Zealand
SPD Development Company Limited U.K.
SPD Swiss Precision Diagnostics GmbH Switzerland
Sunflower Distributing LLC Delaware
Tambrands Inc. Delaware
TAOS - FL, LLC Florida
Temple Trees Impex & Investment Private Limited India
The Dover Wipes Company Ohio
The Gillette Company LLC Delaware
The Procter & Gamble Distributing LLC Delaware
The Procter & Gamble Global Finance Company, LLC Ohio
The Procter & Gamble Manufacturing Company Ohio
The Procter & Gamble Paper Products Company Ohio
The Procter & Gamble U.S. Business Services Company Ohio
This is L. Inc. Delaware
TULA Life, Inc. Delaware
United Beauty Brands, LLC California
US CD LLC Delaware
Vidal Sassoon (Shanghai) Academy China
VitaminHaus Pty Ltd Australia
VitaminHaus Pty Ltd U.K.
Walker & Co. Brands, Inc. Delaware
Zenlen, Inc. Delaware
ZeroBrush, Inc. Delaware
-- 129 of 137 --
EXHIBIT (23)
Consent of Independent Registered Public Accounting Firm
-- 130 of 137 --
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the following registration statements of our reports dated August 5, 2022, relating to
the consolidated financial statements of The Procter & Gamble Company and the effectiveness of The Procter & Gamble Company’s
internal control over financial reporting, appearing in this Annual Report on Form 10-K for the year ended June 30, 2022:
Form S-8 Form S-8 Form S-3
No. 33-49289 No. 333-108997 No. 333-249543
No. 33-47656 No. 333-108998 No. 333-249545
No. 33-50273 No. 333-108999 No. 333-249546
No. 33-51469 No. 333-111304
No. 333-14381 No. 333-128859
No. 333-21783 No. 333-143801
No. 333-37905 No. 333-155046
No. 333-51213 No. 333-161725
No. 333-51219 No. 333-164612
No. 333-51221 No. 333-192841
No. 333-34606 No. 333-208407
No. 333-44034 No. 333-208408
No. 333-47132 No. 333-208409
No. 333-75030 No. 333-208410
No. 333-100561 No. 333-208411
No. 333-108991 No. 333-208412
No. 333-108993 No. 333-234131
No. 333-108994 No. 333-199592
No. 333-108995
/s/ Deloitte & Touche LLP
Cincinnati, Ohio
August 5, 2022
-- 131 of 137 --
EXHIBIT (31)
Rule 13a-14(a)/15d-14(a) Certifications
I, Jon R. Moeller, certify that:
(1) I have reviewed this Form 10-K of The Procter & Gamble Company;
(2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to
make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the
period covered by this report;
(3) Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
(4) The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as
defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules
13a-15(f) and 15d-15(f)) for the registrant and have:
i) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known
to us by others within those entities, particularly during the period in which this report is being prepared;
ii) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed
under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with generally accepted accounting principles;
iii) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such
evaluation;
iv) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's
most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is
reasonably likely to materially affect, the registrant's internal control over financial reporting; and
(5) The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial
reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent
functions):
a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which
are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information;
and
b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's
internal control over financial reporting.
/s/ JON R. MOELLER
(Jon R. Moeller)
Chairman of the Board, President and Chief Executive Officer
August 5, 2022
Date
-- 132 of 137 --
EXHIBIT (31)
Rule 13a-14(a)/15d-14(a) Certifications
I, Andre Schulten, certify that:
(1) I have reviewed this Form 10-K of The Procter & Gamble Company;
(2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to
make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the
period covered by this report;
(3) Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
(4) The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as
defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules
13a-15(f) and 15d-15(f)) for the registrant and have:
i) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known
to us by others within those entities, particularly during the period in which this report is being prepared;
ii) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed
under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with generally accepted accounting principles;
iii) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such
evaluation;
iv) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's
most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is
reasonably likely to materially affect, the registrant's internal control over financial reporting; and
(5) The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial
reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent
functions):
a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which
are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information;
and
b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's
internal control over financial reporting.
/s/ ANDRE SCHULTEN
(Andre Schulten)
Chief Financial Officer
August 5, 2022
Date
-- 133 of 137 --
EXHIBIT (32)
Section 1350 Certifications
Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of The Procter &
Gamble Company (the “Company”) certifies to his knowledge that:
(1) Form 10-K of the Company for the year ended June 30, 2022 fully complies with the requirements of Section 13(a) or 15(d) of the
Securities Exchange Act of 1934; and
(2) The information contained in that Form 10-K fairly presents, in all material respects, the financial conditions and results of
operations of the Company.
/s/ JON R. MOELLER
(Jon R. Moeller)
Chairman of the Board, President and Chief Executive Officer
August 5, 2022
Date
A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that
appears in typed form within the electronic version of this written statement required by Section 906, has been provided to The Procter & Gamble Company
and will be retained by The Procter & Gamble Company and furnished to the Securities and Exchange Commission or its staff upon request.
-- 134 of 137 --
EXHIBIT (32)
Section 1350 Certifications
Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of The Procter &
Gamble Company (the “Company”) certifies to his knowledge that:
(1) Form 10-K of the Company for the year ended June 30, 2022 fully complies with the requirements of Section 13(a) or 15(d) of the
Securities Exchange Act of 1934; and
(2) The information contained in that Form 10-K fairly presents, in all material respects, the financial conditions and results of
operations of the Company.
/s/ ANDRE SCHULTEN
(Andre Schulten)
Chief Financial Officer
August 5, 2022
Date
A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that
appears in typed form within the electronic version of this written statement required by Section 906, has been provided to The Procter & Gamble Company
and will be retained by The Procter & Gamble Company and furnished to the Securities and Exchange Commission or its staff upon request.
-- 135 of 137 --
EXHIBIT (99-1)
Summary of Directors and Officers Insurance Program
-- 136 of 137 --
The Procter & Gamble Company purchases Directors and Officers Liability insurance from various insurance carriers. The policy limits for the period from
June 30, 2021 to June 30, 2022 were $300 million.
-- 137 of 137 --